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SELF-ASSEMBLED MONOLAYERS TO CREATE NOVEL SURFACES UTILISING 
PEPTIDES IDENTIFIED BY PHAGE DISPLAY FOR IN VITRO STUDY OF CANCER 
STEM CELLS 
Abstract 
Systematic analyses of global cancer rates suggest the annual number of head and neck 
cancer (HNC) cases is approaching 1 million and in England 5-year survival rates are 
remain around 50%. This is due to metastasis and recurrence which are thought to be 
driven by a subset of cells within the tumour with stem cell-like properties, so-called 
cancer stem cells (CSCs). Within HNC further sub-populations of CSCs with a 
mesenchymal phenotype have been identified. To better understand the role of these 
epithelial-to-mesenchymal transition (EMT) cells in cancer progression in vitro models are 
used. One rapid way of creating a system with a controlled surface environment for 
studying cell behaviour is to use self-assembled monolayers (SAMs). Here we use a 
peptide-based SAM to immobilise hyaluronic acid (HA), which plays a role in HNC 
progression, to create and characterise a model surface for studying the interaction with 
cells in vitro. This surface can support the culture of cancer cells and, when compared to 
existing methods of HA immobilisation, has different properties, including roughness and 
hydrophobicity and was seen to influence cell migration. In vitro use of HA-inspired 
glycopolymers was also assessed for their ability to mimic HA’s effects on cancer cell 
behaviour, with a view to reducing the use of animal-derived HA. In parallel studies phage 
display was used to identify a peptide which showed enhanced binding to the EMT subset 
of CSCs. This peptide can then be used in the previously established SAM system to create 
a surface with the potential to probe cancer cell behaviour in a well-defined surface. 
Looking ahead this surface could be used for crude enrichment of the EMT fraction and 
determining the peptide’s cell surface binding partner could provide an additional marker 
for FACS-based isolation of this population. 
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Background 
The study of cancers in vitro has provided a plethora of insights on the initiation, growth, 
progression, response to treatment, and recurrence which had led to vast improvements 
in cancer treatment and overall survival rates. However, there are still significant gaps in 
our understanding of cancer and how environmental cues are transduced to affect a 
response, such as altered gene transcription, migration, or proliferation. To effectively 
probe the response of cells to individual stimuli it is essential to have a well-defined 
culture environment. The use of self-assembled monolayers (SAMs) for controlling tissue 
culture conditions has been highly effective. Their benefits are manifold, spontaneous 
assembly, a rapid and simple fabrication process, and modification of the free end to 
display a range of functionalities. These factors make SAMs an accessible, highly tuneable 
tool for in vitro cell culture studies. 
Functionalisation of surfaces through incorporation of peptides into SAMs provides a 
platform for studying the interactions of cell surface proteins and functional protein 
domains, such as those from extracellular matrix proteins. Through manipulation of the 
assembly process, surfaces can also be formed which exhibit dual functionality for 
creating more complex systems. The overall benefit of utilising SAMs in this way is the 
production of customizable cell culture environments in a controlled and defined 
manner. 
Identification of peptide sequences which are biologically important and that play a key 
role in progression or modulation of disease can be a challenging and time consuming 
process. Phage display is a technique which provides a platform for the high-throughput 
screening of many interactions, for the purpose of this work the focus will be protein-
protein interactions. The physical linkage between the modified phage genome and the 
encoded fusion protein displayed on the viral coat enables isolation of the DNA sequence 
based on the binding properties of the peptide. The technique has successfully been used 
to select peptide-binders to recombinant proteins as well as to more complex targets 
such as cancer cells. An additional desirable feature of phage display is the ability to pan 
against complex mixtures of biological samples or cells to select for binders without the 
need to isolate and purify a precise target. 
The advent of automated peptide synthesis now means that isolated binding peptides 
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can now be synthesised, for a comparatively lower cost over a much shorter time frame, 
a matter of hours for sequences with less than 20 amino acids. Synthesised peptides can 
then be characterised further in vitro and developed for downstream applications, 
including cell-targeting, drug delivery, or as in vitro reagents. 
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Research objectives 
The overall aims of this PhD work were: 
i. To develop a simple platform for studying in vitro the interactions of phage 
display-derived peptides with relevant biomacromolecules and cells. 
ii. To then apply this platform for the immobilisation of extracellular matrix 
components) to create model surfaces for investigating the response of head and neck 
cancer cells. 
iii. To investigate in vitro the potential of hyaluronic acid-based glycopolymers to 
influence stem behaviours on head and neck cancer cells. 
iv. To establish a whole-cell phage display protocol to identify a novel peptide 
sequence that is able to specifically bind to head and neck cancer stem cells. 
 
 The work within chapter IV sets out the development of a self-assembled monolayer 
system and demonstration of its ability to immobilise hyaluronic acid. It also begins to 
investigate the application of the platform in the in vitro cell culture of head and neck 
cancer stem cells. 
Chapter V deals with the development of a phage display protocol to select for peptide 
sequences that could be modified in the same way as the Pep-1 peptide used in chapter 
IV to create a self-assembling peptide surface. 
The investigation of the effects of hyaluronic acid-inspired glycopolymers on head and 
neck cancer cells is contained within chapter VI. Here initial studies are performed which 
lay the ground work for exploring the option of using synthetic glycopolymers in place of 
natural glycosaminoglycans in the platform outlined in chapter IV.  
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Chapter I - Introduction 
1. Head and neck cancer 
Over the past decade, the incidence of head and neck cancer (HNC) has been steadily 
increasing, from 600,000 cases worldwide in the year 2000 to almost 1 million in 2012.1 
The average 5-year survival rate is still only 58%.2 Current treatment of HNC involves 
surgical intervention, radiotherapy, or chemotherapy, or combinations of all three.3  
1.1. Cancer stem cells  
Many solid tumours have been shown to contain a subpopulation of cells with stem cell-
like qualities.4 These so-called cancer stem cells (CSCs) can both self-renew and display a 
plasticity which enables them to differentiate into each of the cell types found within a 
tumour, thus generating heterogeneity.5 For head and neck squamous cell carcinoma 
(HNSCC) a tumour stem-like cell population was first identified by Prince et al.,6 who 
found that Cluster of Differentiation 44 positive (CD44+) cells, isolated from human head 
and neck tumours, had significantly higher rates of tumour formation when implanted 
into immunocompromised mice when compared with CD44- cells from the same tumour. 
When analysed by flow cytometry, the tumours that grew gave rise to cell with a range 
of CD44 expression, indicating that tumour heterogeneity was restored.  
1.1.1. In vitro culture of head and neck squamous cell carcinoma (HNSCC) cell lines  
Maintenance of adult stem cells relies on asymmetrical division where the stem cell gives 
rise to an identical stem cell, as well as a transit amplifying cell which will ultimately 
differentiate. This same hierarchy is also seen within cancer stem cells, and, as with 
epidermal cells, when HNSCC cell lines are cultured in vitro distinct colony morphologies 
are seen.7 There are three colony morphologies, paraclone, holoclone, and meroclone. 
Paraclone colonies are irregular in shape and cells are loosely packed; holoclone colonies 
are round with tightly packed cells and meroclones have features in-between the two.8 
In HNSCC cell lines, holoclone-derived cells can give rise to all colony types and show 
higher levels of proliferation and clonogenicity compared to paraclone-derived cells. 
Looking at stem cell-related markers, holoclone colonies exhibited greater staining for 
stem cell-related markers whereas paraclone colonies showed positive staining for early 
markers of differentiation.7 Thus holoclone formation can be used as an indicator of 
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stem-ness. 
1.1.2. Cancer stem cells and treatment 
Several studies have demonstrated that CSCs, like normal adult stem cells, have an 
increased resistance to conventional cancer treatments when compared to the bulk 
tumour.9 Reduced sensitivity of CSCs to current treatments may contribute to the low 5-
year survival rate still seen in HNCs. While standard treatments, radiotherapy, 
chemotherapy and surgery, or a combination of these, can drastically reduce the size of 
the tumour, any remaining CSCs, are able, through self-renewal and differentiation to 
repopulate the tumour and re-establish heterogeneity. This also occurs where CSCs have 
metastasised and initiated secondary tumours at distal sites.10 In HNSCC specifically, it 
has been shown that the CSC population exhibits reduced apoptosis in response to 
chemotherapy drugs, such as cisplatin and etopiside, as well as to radiation treatment 
when compared to cells which did not express high levels CD44.11,12 It is also seen that 
cells which exhibit cisplatin resistance have higher expression levels of stem cell markers 
Oct4 and Nanog, alongside greater migration capacity and clonogenicity, again 
suggesting a link between stem properties and chemo-resistance.13 They may also be 
more effective at evading anti-tumour immunity, as experiments demonstrate CD44+ 
cells have greater ability to inhibit T cell proliferation and to induce Treg production when 
compared to CD44- cells from the same human HNSCC cell line Gun-1.14 With these 
characteristics in mind, the current school of thought implicates CSCs as drivers of tumour 
growth, reoccurrence, and metastasis.15 
1.1.3. Targeted therapeutics 
Having an important role in disease progression, CSCs have been considered as an 
interesting option for targeted therapies to help to meet the current need in HNSCC 
treatment. Traditional treatment of cancer by radiotherapy and chemotherapy has 
several unwanted and unpleasant side effects, which are due to the broad-brush nature 
of their mechanisms. Radiotherapy is applied as a highly-focused beam to minimise 
exposure and damage to healthy cells. Chemotherapy is administered 
either intravenously or in tablet form and because of the systemic nature of these 
delivery methods; off-target side effects are seen in healthy fast-dividing tissues. 
Reducing the number of chemotherapy or radiotherapy treatment cycles needed 
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through adjuvant therapies, especially those that are targeted, is expected to improve 
patient quality of life during and after treatment.4,5 In addition, the rate of recurrence 
would also be reduced due to a greater elimination of CSCs.  
Targeted cancer therapy is a rapidly expanding field and through coupling a 
chemotherapeutic agent to a cancer-specific targeting molecule, such as an antibody or 
a peptide, improvements in drug delivery have been seen in vivo. For example, in mouse 
xenograft models of breast cancer, coupling doxorubicin to peptides known to specifically 
bind tumour vasculature resulted in increased survival and reduced tumour volume, 
compared with free drug alone.16 The first antibody-targeted chemotherapeutic 
approved for clinical use was gemtuzumab ozogamicin (GO), a humanised anti-CD33 
antibody. Despite initial concerns over levels of toxicity, subsequent and ongoing clinical 
trials have demonstrated that in conjunction with other treatments GO can improve 
relapse rates and event-free survival in patients with acute myeloid leukaemia (AML), and 
has since be approved Food and Drug Administration (FDA) for use in the United States.17–
20 
To develop targeted therapies, identification of a cell surface marker unique to the cells 
of interest is required. In the case of HNC, CD44v6 has been used as a target, in a phase 
1 clinical trial. Riechelmann et al.21 used a monoclonal antibody, conjugated to a 
chemotherapeutic, against CD44v6 to direct the drug to the CD44v6 expressing HNSCCs. 
On binding to CD44v6, receptor internalization is triggered and the drug is metabolised 
and activated within the cell. The use of a therapy that is only active when inside the 
target cell allows for a systemic delivery system, where all tissues are exposed to the 
drug, while only those expressing the target marker are affected. While this trial 
demonstrated that it was possible to accurately deliver treatment to cells based on their 
expression of CD44v6, several side effects were seen, particularly within normal epithelia, 
due to their expression of CD44v6.22 The complexity of the expression profile of CD44 
and its variant isoforms, coupled with the off-target side effects seen in the above 
trial, leaves room for the identification of an additional specific marker of HNSCC CSCs.  
1.2. Epithelial to mesenchymal transition  
Epithelial-to-mesenchymal transition (EMT) is a process that has been implicated in 
cancer migration and metastasis, as well as in therapeutic resistance.10 During 
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development, EMT is a vital process in formation of the mesoderm, where epithelial cells 
undergo a change in gene expression, acquire a mesenchymal phenotype and migrate 
away from the epithelial layer from which they originated.23 It is also an important 
process in wound healing, where the EMT programme can be triggered by inflammation 
at the site of injury, and enables keratinocytes at the edge of the wound to become motile 
and advance into the wound and initiate re-epithelialisation through the reverse process 
of mesenchymal-to-epithelial transition (MET).24 Characteristically, epithelial cells 
show cell polarity, cell-cell adhesions and low motility. These characteristics are lost 
during EMT and cells acquire a mesenchymal phenotype defined by increased motility, 
invasion and resistance to apoptosis.25  
These processes are also associated with the progression of cancer, and within HNC, a 
subset of CSCs has been identified, which appears to have undergone EMT and have a 
more mesenchymal phenotype. The so-called EMT subpopulation in HNSCC can be 
isolated using fluorescence activated cell sorting (FACS) by looking at cell surface 
expression of CD44 and Epithelial Cell Adhesion molecule (EpCAM, also known as 
epithelial specific antigen, ESA). EMT cells are CD44high/EpCAMlow compared to epithelial 
(Epi) CSCs which show a CD44high/EpCAMhigh expression profile (Figure 1).26 EpCAM is a 
transmembrane protein with a primary role in epithelial cell-cell adhesion, and mRNA 
levels are elevated in HNSCC and EpCAM expression is used as a marker of cancer 
cells.27,28    
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Figure 1: Flow cytometry scatter plot, showing the distinct CD44/EpCAM expression profile of 
EMT and Epi populations within the LuC4 cell line, which are used in the experiments throughout 
the thesis. 
These CD44high/ESAlow cells have a morphology and behaviours distinct from 
CD44high/ESAhigh cells, they have higher expression of EMT-related genes, such as Twist, 
Snail and Vimentin, as well as lower expression of epithelial-specific genes, including E 
Cadherin, Involucrin, and Calgranulin B.26 Some EMT cells can switch between 
mesenchymal and epithelial phenotypes, and supports the hypothesis that these CSCs 
are involved in tumour metastasis, when they undergo EMT, migrate out of the tumour 
and to reach secondary sites where they return to an epithelial phenotype, via MET, and 
generate secondary tumours with the same heterogeneity as primary tumour.29  
Combinations of therapies can be used to increase the effect of a single therapy, for 
example radiation therapy can be enhanced by co-treatment with cetuximab. However, 
in HNSCC cell lines, which upregulate EMT-associated genes, this effect is negated.30 This 
association of a more migratory and treatment-resistant phenotype, with the 
upregulation of EMT-related genes and down regulation of epithelial specific genes, has 
been observed in several tumour types,31,32 corroborating the hypothesis that cells which 
have undergone EMT may play a pivotal role in understanding and improving the 
treatment of cancers.  
Identification of additional specific markers of the EMT subpopulation of cancer cells 
would provide useful tools to improve effective isolation of EMT cells, either alone or in 
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combination with the existing marker panel. This would allow more extensive in vivo 
studies to further characterise these cells and to elucidate fully their role in cancer 
progression, resistance to treatment, and recurrence. Such markers and specific cell-
binding molecules, would also have a potential to be translated into a clinical setting for 
in vivo detection, as a diagnostic device, or as a targeting molecule for therapy.  
1.3. CD44 
As mentioned previously, CD44 is used as a marker of CSCs and is a potential therapeutic 
target. CD44 is a widely expressed transmembrane receptor encoded by a single gene, 
consisting of 20 exons (Figure 2). Exons 6 to 15 (or v1- v10) can be alternatively spliced to 
give rise to multiple CD44 isoforms.33,34 The standard isoform (CD44s) is the smallest and 
does not contain any of the variable exons. CD44 gene products that contain the 
alternately spliced exons are referred to as ‘variant’ isoforms (CD44v). Variant exons are 
found in the extracellular portion of the CD44 molecule, between the plasma membrane 
and the amino-terminal domain (Figure 2). 
 
Figure 2: CD44 exons and structure. (A) The 20 exons which make up the CD44 protein, those 
present in all CD44 isoforms are depicted in orange and those subject to alternative splicing in 
either green, blue, or purple. Below are known variant isoforms. (B) A comparison of the structure 
of the standard isoform and the largest isoform containing all variant exons. The presence of 
variant exons extends the stem region, while the hyaluronic acid binding site containing amino-
terminal domain remains unaffected (Adapted from Ponta et al. 2003). [208] 
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1.3.1. Variant isoform expression 
Distinct patterns of CD44 isoform expression are seen across tissue and cell types,35 these 
alternatively spliced exons are susceptible to a range of post translational modifications, 
which can influence its downstream function through interactions with other receptors 
of signalling molecules.36 For example, v3 –containing CD44 receptors contain the Ser-
Gly-X-Gly motif, proposed as a glycosaminoglycan (GAG) attachment site, and are 
modified with heparin sulfate which facilitates specific growth factor binding.37,38 
Furthermore CD44 splice variants, including v10, contain an additional HA-binding motif 
B-(X7)-B where B is either R or K and X7 contains no acidic residues and at least one basic 
amino acid. This has been shown to enhance chondroitin sulfate (CS) dependent cell-cell 
adhesion.39 
When CD44-expressing epithelial cells are induced to undergo EMT, a switch in isoform 
expression can be seen, from CD44v to CD44s. In addition, knock down of CD44 by shRNA 
prevented cells from going through EMT, which was recovered by the introduction of 
CD44s but not CD44v isoforms.40 This demonstrated a requirement for CD44s expression 
for epithelial cells to transition to a mesenchymal phenotype. CD44s is also seen to 
protect against cell death which supports the role for EMT cancer cells in tumour 
recurrence.40 Additionally, there is experimental evidence that variant isoforms of CD44 
have an additional role in tumour progression and metastasis.41–43 
In HNSCC cell lines, the fraction of CSCs which have undergone EMT show preferential 
expression of CD44s, compared to the CSCs with an epithelial phenotype which 
predominantly express CD44v isoforms.44  
1.3.2. CD44 and role in HNSCC 
Current literature looking at the role CD44 plays in HNSCC specifically, demonstrates the 
relevance of CD44 as a prognostic marker, as well as its active role in several cell-signalling 
pathways through which it exerts its effects on tumour behaviour. 
In terms of CD44 expression status, and its use as an indicator of disease prognosis, a 
retrospective analysis of CD44 expression in biopsies of early stage cancers, taken prior 
to treatment, showed that higher levels of both CD44 mRNA and general protein, was 
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correlated with recurrence following radiotherapy.45 Initial studies have also suggested 
that levels of CD44 present in patient saliva can be used as a predictor of HNSCC when 
used in combination with total saliva protein levels and clinical factors.46 Taken together, 
these results indicate that higher levels of CD44 are seen in HNSCC, and yet higher levels 
seem to be associated with cancer and its progression. 
FACS sorted CD44high cells show increased resistance to treatment with cisplatin and 
docetaxel, with the CD44high/EpCAMlow population having an even greater resistance. 
Induction of the CD44high/EpCAMlow phenotype through the upregulation of transcription 
factor Snail also resulted in reduced sensitivity to cisplatin and docetaxel, as well as 
increased ATP-binding cassette (ABC) drug transporter expression.47 Further to this, 
knockdown of CD44 results in increased cisplatin sensitivity, again corroborating the 
functional role of CD44 in HNSCC treatment resistance.42  
Additionally, it has been demonstrated that chemical and siRNA-mediated down 
regulation of CD44 results in reduced proliferation and expression of stem-cell markers 
Oct4, Nanog, and Sox2, as well as a loss of clonogenicity, sphere forming ability, and an 
upregulation of markers of epithelial differentiation.48,49 These results indicate that CD44 
is required for maintenance of stem cell properties. Correlation has also been observed 
between expression of stem cell-markers and resistance to cisplatin.50 
1.3.3. CD44 and HA 
The majority of CD44s functions within HNSCC, such as proliferation, migration, and gene 
expression, have been linked with its interaction with hyaluronan, a component of the 
extracellular matrix (ECM) discussed in more detail below.51 Hyaluronan, also known as 
hyaluronic acid (HA), binds to CD44 at its amino-terminal domain through interactions 
with 8 key amino acids.52 HA binding can induce interaction with or stabilisation of 
signalling complexes to affect downstream responses.51 
HA’s ability to increase cell migration is consistently reported and this effect is abrogated 
when CD44-HA interactions are disrupted, either by anti-CD44 antibodies which 
physically inhibit binding,53 or by knockdown of CD44 by siRNA.42 Further investigation of 
CD44-dependent cell migration in HNSCC highlights a role for CD44 association with 
epidermal growth factor receptor (EGFR), immunoblots of cell lysates obtained following 
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treatment with HA show co-immunoprecipitation of CD44 with EGFR. This physical 
linkage between the two receptors,53 is mediated by leukemia-associated RhoGEF 
(LARG).54 EGFR-mediated signalling is also increased on HA binding to CD44 and use of 
EGFR inhibitors stops cell migration,53 and this effect on cell motility has been shown to 
be mediated by protein kinase C, phospholipase C (PLC) and RhoA signalling.55–57 
Signalling pathways and interactions of CD44-HA with EGFR have been implicated in drug 
resistance. Cisplatin resistance of HNSCC cells was abolished by treatment with both  
EGFR and ERK inhibitors independently,53 inhibition of PLC was also able to reduce CD44-
HA induced cisplatin resistance,56 as did Rho and PI-3 kinase inhibitors.57 In addition to 
these signalling cascades, CD44-HA binding is implicated in cancer therapy resistance 
through regulation of ABC drug transporters, where HA depletion is seen to correlate 
with reduced drug transporter expression.58,59 
A potential way to exploit the CD44-HA interaction would be to use HA as a targeting 
molecule to deliver payloads. HA has been used to deliver metal nanoparticles to CD44-
expressing cells, which when exposed to an alternating magnetic field generated an 
increase in temperature that induced apoptosis.60 
From these results, it is clear that CD44-HA interactions have an important role in 
initiating a range of signalling pathways that are able to increase HNSCC cells motility and 
therapy resistance, thus supporting tumour progression. 
2. Hyaluronic Acid 
Hyaluronic acid is a GAG comprised of two alternating sugars, D-glucuronic acid and N-
acetyl-D-glucosamine. These sugars contain several hydrophilic carboxyl, hydroxyl and 
acetamido groups which are responsible for HA’s high water solubility.61 Additionally, 
axial hydrogen atoms create hydrophobic patch domains along the molecule which play 
an important role in the way HA chains interact with each other in solution.62 
2.1. Biological importance 
HA is widely expressed throughout the body making up a large component of the ECM in 
many tissues. Unlike other members of the GAG family, such as chondroitin sulphate or 
heparin sulphate, HA is non-sulphated and has a unique set of viscoelastic properties. The 
presence of hydrophilic and hydrophobic regions, allows HA to form a mesh-like network 
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when in water, where the hydrophobic domains interact with each other. As part of the 
ECM, this behaviour and mesh formation confers resilience to tissues. When external 
pressure is applied to the HA network an internal swelling pressure is created through 
mutual repulsion between carboxyl groups and this allows the HA to spring back into its 
original shape once the pressure is released.63 These viscoelastic properties are 
responsible for HA’s function in the vitreous humour,64 and within synovial fluid and 
articular cartilage.65  
Since its isolation from bovine vitreous humour,66 HA has been widely studied and applied 
to both translational and basic science perspectives. It has been successfully applied in 
the clinic, as a treatment for osteoarthritis,67 in ophthalmic surgeries and in augmentation 
procedures as dermal fillers.68 HA levels are also being investigated as potential 
biomarkers; its serum levels can help to monitor disease progression in cases of liver 
fibrosis 69 and is also used as a biomarker for cancers of the including bladder,70 
prostate,71 breast,72 and head and neck.73 
There is extensive evidence for the role of HA in many biological processes which are 
executed through interactions with its main receptors, receptor for hyaluronan-mediated 
motility (RHAMM, also known as CD168),74 lymphatic vessel endothelial hyaluronan 
receptor (LYVE-1),75 intracellular hyaluronan-binding protein 4 (IHBP4),76 and CD44 
(discussed in the context of HNSCC above). In addition to its contribution to migration 
and drug resistance, HA is seen to be involved in angiogenesis,77 inflammation,78 and 
would healing.79    
2.2. Molecular weight 
As a result of its polysaccharide nature HA exists within a range of molecular weights 
(MWs), but HA chains are typically of high molecular weight, usually 1000 kDa and 
above.80 However, enzymatic digestion by hyaluronidases results in the production of low 
MW HA, 20 kDa to 800 Da,81 which can have remarkably different effects both in vitro 
and in vivo. The size of HA chains is broadly divided into 4 categories; high MW (HMW) 
>1000 kDa, medium MW (MMW) 250-1000 kDa, low MW (LMW) 10-250 kDa, and oligo-
HA <10 kDa.80 
A review of research papers which have investigated the MW of HA present in different 
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tissues determined that HMW HA tends to be found in healthy tissues and LMW HA is 
broadly seen in disease.80 Oligo-HA is angiogenic in endothelial cells (ECs), whereas HMW 
HA inhibits EC proliferation and migration, and therefore angiogenesis.79 Broadly 
speaking, LMW HA is a pro-inflammatory molecule and HMW HA can be 
immunosuppressive,78 this effect is particularly evident in rheumatoid arthritis. 82,83 
However, in the current literature, there are still conflicting opinions as to the exact role 
of varying MWs of HA (comprehensively reviewed by Monslow et al).80 
2.3. Immobilisation on surfaces 
Due to the pivotal role of HA in many cellular processes, especially cancer progression, 
numerous strategies have been developed to immobilise HA on surfaces, aiming to study 
its effects in a 2D in vitro environment. These approaches often require the chemical 
modification of native HA with several different molecules, and can include biotinylation 
to allow immobilisation by streptavidin,84,85 conjugation to dopamine for co-
immobilisation,86,87 thiolation to enable tethering to gold,88 and azidation to allow 
crosslinking and stabilisation of HA films formed by spin-coating.89 Functionalisation of 
surfaces with epoxy, amine, or hydroxyl groups is required to allow covalent attachment 
of HA.90–93 For example, 11-mercapto-1-undecanol can be used to form self-assembled 
monolayers (SAMs) which bind to gold through S-Au interaction resulting in the display 
of hydroxyl groups. These can be modified further with epoxy groups which can undergo 
ring opening to covalently bind HA via its hydroxyl groups.90  
Such modifications can be problematic as chemicals used for crosslinking, such as 
glutaraldehyde, can be toxic to cells.94 The degree of crosslinking can also be detrimental 
to cell survival and influence cell functions.95 They may also interfere with the native 
properties of HA. For example, both thiolation and biotinylation have been shown to 
inhibit HA degradation by hyaluronidases, and influence its conformation once 
immobilised.85,96 Altered presentation of macromolecules has been shown to affect cell 
adhesion and highlights the sensitivity of mammalian cells to their culture environment 
and the importance of creating well-defined surfaces for in vitro studies of cell 
behaviour.97,98 
Combining SAMs with phage display is a useful tool for fabrication of functionalised 
culture surfaces with precise properties and the ability to interact with cells to influence 
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their behaviour. 
3. Phage display 
Phage display is a technique involving rounds of affinity selection of large libraries of 
genetically modified bacteriophage displaying a fusion protein on its surface against a 
target. Since being developed by Smith in 1985,99 it has undergone continuous 
optimisation to become a valuable platform across a range of fields, including consensus 
sequence identification for drug development,100 selecting sequences to maintain stem 
cells in culture for tissue engineering and regenerative medicine,101 and isolation of 
antibodies to use as blood-typing reagents.102 Phage display takes advantage of the 
relatively straightforward genetic modification of bacteriophage (phage) such that a 
fusion protein, or peptide, is expressed and displayed on the surface of the mature phage. 
This leaves the inserted protein free to interact with its environment. Libraries of 
modified phage can then be screened for binders against a whole range of different 
target molecules, including proteins,103 DNA,104 cell surface receptors,105 whole cells,106 
and in vivo targets.107 The technique has successfully been used to identify numerous 
high affinity, target-specific antibodies, antibody fragments and peptides, as well as short 
binding motifs, such as Lys-Pro-Pro (LPP) and Thr/Ser-Ala-Arg (T/SAR).100 The way in which 
libraries are constructed, and an attractive feature of phage display, is the physical linkage 
between the genotype of the phage and its phenotype, with the encoded molecule 
displayed on its surface.  
3.1. Applications of phage display 
Phage display has a diverse range of applications and, depending on the experimental set 
up, can be used to answer many research questions, including identifying novel ligands 
for known receptors, determining the sequence of an epitope, or selecting specific cell-
targeting molecules. The use of phage display has evolved from being a technique 
primarily used in biological sciences to one that is now used across materials sciences and 
beyond. The success of the technique lies in part, with the creativeness of the researchers 
developing the protocols. Most applications of phage display fall into the category of 
epitope mapping or identification of novel target-binders and these applications are 
discussed below. However, for the most part this review will focus on the use of phage 
display for the discovery of novel binders. 
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3.1.1. Epitope mapping 
Epitope mapping enables the identification of the critical binding regions of proteins and 
antibodies, as well as the minimal sequence required for their functionality. There are 
many strategies which use phage display to achieve this, using either gene fragment, 
cDNA or genomic expression libraries.108 
Phage libraries with restricted diversity, such as gene-fragment libraries, are useful tools 
where binding sites or epitopes are to be characterised within a particular protein or 
antibody. Gene fragment libraries take the cDNA of the target protein and, through 
random digestion of the sequence using DNase 1, phage libraries consisting of peptides 
covering the whole amino acid sequence of the protein can be generated. This strategy 
has been successfully used to map additional epitopes of the bluetongue virus outer 
capsid protein VP5109 and to identify novel epitopes in the sp100 nuclear PBC 
autoantigen.110 
Entire cDNA or genomic libraries can also be used to construct genomic expression phage 
libraries and identify epitopes within the genome. These libraries are, by nature, larger 
than gene-fragment libraries and are a useful tool in identifying the most immunogenic 
epitopes and for vaccine development. Libraries constructed from the genome of 
Staphylococcus epidermidis have also been utilised to isolate the bacterial protein 
responsible for fibrinogen-binding and the location of the binding site within the 
protein.111 Such libraries can be screened against complex mixtures, such as patent sera, 
and peptides which bind to clinically relevant components of the sera will be selected 
for.112 
Crucially, methods using cDNA allow the identification of functional proteins that are 
encoded by genomic material and therefore sequences identified exist in vivo and are not 
simply mimics. The use of random peptide libraries for epitope mapping has reported 
several useful mimotopes, such as those mimicking house dust mite-specific antibodies 
113 and an antibody-binding region of HIV-1 protein gp120.114 Both the linear B-cell 
epitope of the Classical swine fever virus’ E2 protein and a linear epitope of the anthrax 
toxin lethal factor were also mapped using a commercially available random peptide 
library and the sequences identified used to determine the role of each residue in epitope 
function.115,116 These examples have utilised monoclonal antibodies (mAb) in the panning 
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steps, but polyclonal antibodies have also been able to identify epitopes within a random 
peptide libraries.117,118 
Further to this, random peptide libraries have been successfully used to determine key 
amino acids within an antibody-binding domain of the glycoprotein D of herpes simplex 
virus type 1 and, when synthesised, the selected peptide could be used to immunise mice 
against the herpes simplex virus type 1.119 
For comparing genomic or gene-fragment libraries with random peptide libraries for 
epitope mapping, gene-based libraries have the benefit of selecting sequences which are 
present in vivo while random peptide libraries may only identify similar consensus 
sequences. Additionally, random peptide libraries are limited when investigating larger 
epitopes, as libraries of 6 or 7 amino acids might not be long enough to cover the minimal 
binding sequence. Conversely, larger 12-, or 15-mer fusions may not have all amino acid 
sequence combinations represented due to limitations on how many phages can be 
contained within a library.120 
However, with the emergence of commercially available random peptide libraries and 
the need to generate a new fragment library for each target, while random libraries can 
be screened against multiple unrelated targets, random libraries may provide the 
simplest way for researchers to carry out epitope mapping using phage display.  
3.1.2. Protein-protein interactions  
Both peptide and antibody phage libraries have demonstrated usefulness in screening for 
novel target-binders and identifying important protein-protein interactions (PPIs) playing 
essential roles in signal transduction and many cellular functions and behaviours. There 
is a wide interest in identifying new peptide sequences and antibodies or antibody 
fragments which bind to target molecules. Whether it is for targeted drug delivery, to 
form reagents for molecular biology, for in vitro characterisation of cell populations, or 
to induce the directed differentiation of stem cells for regenerative medicine. 
Antibody libraries, constructed from either Ig isotopes, antigen-binding (Fab) fragments, 
single-chain variable fragments (scFv) or single domain antibodies (sdAb) display large 
exogenous sequences providing ample surface area for interacting with the target being 
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panned against. Peptide libraries tend to display a much shorter sequence and successful 
panning has been done with libraries between 6 and 43 amino acid peptides. Commercial 
libraries are commonly between 7 and 12 amino acids, which obviously presents a smaller 
surface to interact with the target. It is known that the number of amino acids required 
for specific binding varies across different interactions. Typically, antibodies require a 
grouping of 6 amino acids to recognise and bind antigens.121 Major histocompatibility 
complex proteins recognize sequences of 12 -16 residues.122 In the case of fibronectin, 
only 3 amino acids, arginine-glycine-aspartic acid (RGD), are required for integrin 
binding.123 The ability of binding to be mediated by such a small number of amino acids 
suggests that phage display libraries constructed from short, 7-12 amino acid fusions, are 
of sufficient size to identify sequences capable of specific target binding. 
Highly specific binders have been found using recombinant or purified target molecules. 
However, for some targets, recombinant versions are of limited value. For example, 
membrane bound proteins or transmembrane receptors contain hydrophobic domains 
which, in vivo, are inserted into the lipid bilayer. When recombinantly expressed, some 
proteins form aggregates or fold incorrectly, this presents a problem when trying to 
identify functional ligands where conformation is key for binding. The flexibility of phage 
display means that this problem can be avoided by panning against cells modified to 
stably express a known target protein. For example, the successful transfection of CHO 
cells with a human recombinant VPAC1 was used to select binders from a peptide 
library.105 It is also possible to select phage clones against cell targets without a known 
marker on the cell surface. These ‘fishing’ experiments have been used to find peptide 
sequences that can specifically target hepatocarcinoma and breast cancer cells.124,125 This 
highlights the potential of phage display in cell identification and targeted therapeutics.  
3.1.3. Protein-target interactions 
In addition to probing PPIs, phage display has also been applied to investigating the 
interaction of the displayed fusion proteins with non-protein targets, such as inorganic 
(metals, minerals), biological (tissues, proteins, and polysaccharides) and synthetic 
materials (tissue culture surfaces). 
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Matsubara et al. (1999)126 identified 3 phage clones which could bind to their target 
ganglioside monosialoganglioside galactose, a glycolipid that is present on the cell surface 
and a known receptor of cholera toxin. Sequences which can bind camptothecin (CPT), a 
small molecule inhibitor of topoismerase, have been successfully identified,127  and 
protein-DNA interactions have also been probed through the expression of zinc-fingers 
as a fusion protein on the phage surface. Random mutation of the amino acid sequence 
followed by panning on the DNA target resulted in the identification of the crucial 
residues involved in making protein-DNA contacts.104 
Further to non-protein cellular targets, several groups have used phage display to identify 
clones which bind to surfaces of materials. Metal surfaces that have been used as targets 
include silver, platinum, titanium, aluminum, and gold, and sequences identified have 
been used to initiate nucleation of metal crystals or to guide the growth of nanowires.128 
These studies provide a useful insight into how proteins interact with surfaces and 
information gained can potentially be used to optimize experimental systems where 
metal surfaces are used as substrates for the attachment of peptides, proteins, or cells.  
Polymers have also been targeted to isolate binding sequences. This is of interest as a 
significant number of panning experiments are carried out in plastic dishes, wells, or 
tubes. Knowledge of known plastic-binders enables researches to identify any such 
selected sequences in their experiments and exclude them from subsequent experiments 
and analysis. Submission of the identified sequences to databases such as SAROTUP 
provides a searchable tool to determine which clones may be target-unrelated. Plastic 
binding sequences can also be used to immobilise molecules on a plastic surface.129,130 
3.2. Panning strategy  
The basic phage display protocol for identification of target-binding clones involves 
immobilisation of the target, purified protein or cell type, followed by incubation with a 
diverse phage library. Any unbound phages are removed by washing and bound phages 
can then be eluted, either non-specifically using a high or low pH, or by using a known 
ligand for the target. This process, known as biopanning or affinity selection, is followed 
by amplification of eluted phages using an appropriate bacterial strain and once purified 
these phages can then be used in further rounds of panning. Typically, biopanning is 
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carried out 3 or 4 times and is combined with rounds of negative selection to reduce the 
number of non-specific phages from the pool, such as those binding the plastic of the 
dish. 
There have been several iterations of this basic method each tailored to the type of 
target. Below the key features and some of the binders identified by the most common 
panning strategies are described. 
3.2.1. Recombinant target immobilisation 
When using a specific protein, virus, or toxin, which can be recombinantly expressed, the 
simplest way of immobilising the target is to allow it to adsorb onto a 96-well plate by 
incubation of the purified target in an appropriate buffer. This protocol has been used to 
find peptides that bind to HA.131 The peptide identified, named Pep-1, has been used for 
several downstream applications. Through biotinylation of Pep-1 and detection by FITC-
labelled streptavidin it has been utilised as a reagent for in situ staining of HA in tissue 
sections of human foreskin.132 It has also been used to immobilise HA on the surface of 
contact lenses and improve longevity of lens hydration. 133 Pep-1 can further be used as 
an in vitro reagent to inhibit HA-receptor binding to elucidate a role for HA in T cell 
proliferation.134 
Another strategy for panning is to use target molecules with affinity tags to immobilize 
the target, or to allow the library to be incubated with the target in solution before 
capture onto a solid matrix. Using a tag reduces any changes in conformation induced by 
adsorption to a surface and enables all faces, and therefore epitopes, of the target to be 
accessible to the phages, maximising the probability of identifying a binder.  
The strong and specific interaction between biotin and streptavidin can be exploited. 
Biotinylation of the target molecule enables immobilisation on a streptavidin-coated 
plate or beads. This method has been successful in isolating peptides which bind Troponin 
I, a biomarker for heart disease, with nano-molar affinity.103 However, biotinylation of 
recombinant proteins is a multi-step process and can denature the protein, meaning it is 
not suitable for use with all potential targets. Additionally, using this technique, elution 
of bound phage is achieved using a low pH or bacteria can be added directly to wells 
containing the phage-target complexes. Both these methods use non-specific elution, 
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and there are likely to be a larger number of non-specific background phage clones taken 
into future rounds of panning.108 To eliminate this problem, Koide et al. (2009)135 
developed a system which allows eversible affinity capture on a streptavidin-coated 
surface.  
Several alternative reagents can be used for affinity capture protocols including maltose-
binding protein (MBP) and amylose, glutathione S-transferase (GST) and glutathione, or 
polyhistidine with chelated nickel beads. Antibody targets can be captured by protein A 
or protein G beads,136 and His-tagging of EphB receptors has been used to select peptides 
which can discriminate between the different classes of receptor and, in some cases, 
block ephrin binding.137 
3.2.2. Whole cell panning  
Panning on membrane bound proteins and cell-surface receptors can be challenging, 
because hydrophobic domains within the protein can aggregate when not inserted in the 
cell membrane, or complex tertiary or quaternary structures may not be formed 
correctly. In these situations, phages that are isolated as binders by panning experiments 
may not interact with the native target in the same way. In the case of transmembrane 
proteins, phages recognising intracellular domains not accessible in situ will have limited 
use for targeted treatments or cell staining without permeabilising the cells.  
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Figure 3: Whole cell panning schematic. A potential workflow of biopanning, including rounds of 
positive and negative selection, on target and non-target cells respectively, with subsequent 
sequencing of identified phages. 
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Panning libraries against whole cells, either in suspension or as a monolayer, can 
circumvent these limitations. However, the sheer number of potential binding sites, 
either lipids, proteins or carbohydrates, on the cell surface can lead to large numbers of 
different phage clones being selected as a result of either specific or non-specific binding. 
If the chosen target has a known ligand, this can be used for the elution of phages which 
are bound to an overlapping region on the target, ensuring the majority of recovered 
phages were target-associated. Where there is no known ligand, or to select a phage with 
high binding affinity, rounds of negative selection can be used to deplete the phage pool 
of sequences which do not bind the target.138 For example, incubating the library with a 
cell type that does not express the target to sequester phages which bind to ubiquitous 
cell surface molecules before carrying out positive selection (Figure 3). This strategy had 
been used to identify antibodies which bind human blood group antigens as well as 
human autoantibodies against the thyroid.139,140 
There are still limitations associated with this approach using whole cells for affinity 
selection. Each round of negative selection removes only a fraction of the non-specific 
phages and can also remove target-binding phages from the pool, as well as reducing 
library diversity. Combining positive and negative selection is another approach which 
can be used. The library is incubated with both target-positive and target-negative cells 
at the same time, where the negative cells are in an excess to absorb non-target-specific 
phages. To isolate the target cell-bound phages, the cell types need to be separated. This 
can be done by fluorescence activated cell sorting (FACS), which requires and existing 
marker for the target cell population. Alternatively, magnetically activated cell sorting can 
be used where target cells are labelled with magnetic beads before mixing with negative 
cells. A magnetic field can then be applied to a column to pull out the labelled cells.102 
3.2.3. Biopanning and rapid analysis of selective interactive ligands 
Biopanning and rapid analysis of selective interactive ligands (BRASIL) was pioneered by 
Giordano et al., (2001)141 and uses differential centrifugation and organic phase 
separation to isolate phages bound to cell targets. Briefly, cells are incubated with a 
phage library in suspension and this suspension is then transferred onto the surface of an 
organic phase consisting of a mixture phthalates. Following centrifugation of these two 
layers, to pellet the cells and any bound phages, the tube is snap-frozen and the tube cut 
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to recover the cells which are transferred to a fresh tube. Removing the pellet by cutting 
the tube reduces the risk of unbound phages in the aqueous layer cross-contaminating 
recovered phages. Amplification and purification of cell-binding phages can then be 
carried out in an appropriate bacterial strain in the same manner as other biopanning 
methods. To date, there are 98 original research articles citing the used of the BRASIL 
method for separation of target-binding phages. 
The AWYPLPPA peptide was isolated from random peptide library as a sequence which 
specifically binds hepatocellular carcinoma (HCC) cell line with a high metastatic potential 
compared to a cell line which exhibits low levels of migration. In the first round, the library 
was incubated with cells of low metastatic potential to preclear the library and the 
unbound phages remaining in the aqueous layer were then used to pan against the HCC 
cells to isolate cell-binding peptides.142 Combining this method with traditional cell-
bound phage isolation as a more stringent final washing step, Derda et al., (2010)101 were 
able to isolate peptides which support the growth of embryonal carcinoma cells and 
maintain their pluripotent state. Further examples of cell-binding peptide sequences can 
be found in the comprehensive review of using peptide libraries to select for cell-binding 
peptides by Gray & Brown.143 
3.2.4. In vivo panning 
The principle behind conducting phage display in vivo involves injecting the library into a 
host animal and allowing phages to circulate before washing the cardiovascular system, 
harvesting the tissue or organ of interest and collecting the clones which have 
accumulated locally. Using this simple strategy, and allowing the injected peptide library 
to circulate for 6 minutes across 3 rounds of selection, Yao et al. (2005)144 were able to 
identify 2 peptides which targeted the vasculature of the pancreas. Enriched libraries can 
also aid selection. For example, using a mouse model of islet cell carcinoma Joyce et al. 
(2003)145 identified three peptides which home to the tumour vasculature. They 
conducted initial rounds of panning ex vivo on cells isolated form the mouse model, to 
enrich for target cell-binding clones, before in vivo selection was carried out.  
Most in vivo studies have used animal models where the animal is sacrificed following 
selection. While this method has generated many useful peptides and antibody 
fragments, the quality of these molecules will be limited by how good the model is or by 
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interspecies differences. The first study conducted in humans146 used a cyclic peptide 
library injected intravenously which was allowed to circulate for 15 minutes. Biopsies 
were then taken from multiple sites including the skin, bone marrow, fat and skeletal 
muscle. Analysis of the recovered phages and their inserts revealed several peptides 
containing a three amino acid motif within each tissue type. Using online databases, it 
was seen that some of the sequences identified are found in human proteins, 
demonstrating the potential for this method to select for biologically relevant sequences. 
Further to this, a peptide mimic of interleukin-11 (IL-11) isolated from the prostate 
sample was shown to display the same staining pattern as an antibody against the IL-11 
receptor on tissue sections and in vitro experiments showed that peptide binding to the 
IL-11 receptor was inhibited by addition of the natural ligand, demonstrating the 
specificity of the interaction. 
Panning in living human cancer patients with both peptide and scFv libraries has also been 
conducted, where following intravenous infusion of libraries and circulation for 30 
minutes superficial tumour nodules were removed and phages recovered. Again, 
sequences collected contained motifs that are present in human proteins, and binding 
studies suggested that the presence of phages in the tumour was not due to random 
accumulation. Importantly, this study also demonstrated no allergic response to the 
infusion of the phage libraries in patients which means in vivo phage display in humans 
may be a viable option for the selection of patient specific tumour-targeting peptides and 
antibody fragments.147 
3.3. Limitations 
Biopanning provides a platform for high throughput screening of phage libraries for 
interaction with a target of choice, be it DNA, proteins, or cells. However there some 
inherent limitations that must be considered when designing a protocol.  
3.3.1. Selection bias  
One consideration is loss of library diversity through the amplification process. While 
reduced library diversity is a desired outcome from the rounds of panning, as only target-
binding phages are selected to enter the next round, amplification of phages in bacteria 
imposes another selection pressure on the pool. As a result, phage clones with no specific 
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interaction with the target, but which have a replicative advantage, such as increased 
growth rate or infectivity, will be overrepresented in the library following amplification 
(Reviewed Derda et al., 2011).148  
To eliminate the binding-independent reduction of diversity, it is possible to select for 
target-binders without including an amplification step. Combining differential 
centrifugation with a single round of panning on colorectal cancer cells with a Fab phage 
library, generated by immunizing mice with three colorectal cancer cell lines, resulted in 
51-90% of recovered clones giving a positive result in the enzyme-linked immunosorbent 
assay (ELISA).149 A similar method was also used for selecting polyclonal Fab fragments 
against either Cryptosporidium parvum glycoproteins or a C. parvum oocyst/sporozoite 
preparation where 50-73% of the recovered phages were specific for the antigen.150 
Combining phage display with next generation sequencing also appears to provide a 
promising method for reducing panning and amplification rounds while still identifying 
high affinity clones.151 
Amplifying each recovered phage clone in isolation would also minimise selection bias, as 
this would remove the competition between different clones during the amplification 
process. In practice this can be challenging, however, Derda et al. (2010)152 used a 
microfluidic system to generate consistent sized droplets in which individual phage clones 
could be amplified uniformly, thus removing amplification-induced selection bias. 
3.3.2. Clone Specificity 
For both antibody and peptide phage display, not all identified phage clones are true 
binders of their target. Clones which bind non-specifically to the target or the plastic of 
tubes or wells used to carry out each round of selection will be eluted with specific phages 
when a low pH elution is used or when panning against cells unbound phages can become 
trapped with the pellet during washing steps. 
There are several ways to assess target-specificity. The use of online databases is a quick 
way to determine if potential binders contain known plastic-binding motifs or have been 
previously identified as conferring a replicative advantage to the phage (reviewed Vodnik 
et al., 2011).153 It is also possible to see if sequences obtained from panning experiments 
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have been found as binders for other targets within the literature or if they correspond 
to portions of human proteins. However, such online data bases are reliant on 
researchers continually submitting their sequences and updating the catalogue as more 
work is done. 
The use of online databases, outlined in Table 1, to check if identified binders contain 
target-unrelated binding motifs, or if they have been identified in other studies, requires 
the sequence of the DNA insert of selected phages to be known. While extracting and 
sequencing the phage DNA is not particularly difficult, it can be time-consuming and 
expensive, depending on the number of clones being investigated. A phage-binding ELISA 
allows the specificity of individual clones or clone pools to be assessed without the 
sequence needing to be known. If an antibody against the target molecule is available 
plates can be coated with selected phage clones and incubated with a solution of the 
target, the appropriate enzyme-linked antibody can then be used to determine binding. 
If there is no available antibody for the target, or the exact molecule is unknown, a phage 
capture ELISA can be used. The target is immobilised and then incubated with phage 
clones. An antibody which recognises the bacteriophage can then be used to indicate 
binding. It is often beneficial to test the entire phage pool that is recovered from panning 
to ensure that there is some binding capacity before clones are amplified and tested by 
ELISA individually. 
Where individual clones are used, those that give a positive signal can be analysed further 
and their binding assessed more quantitatively using, for example, competition assays.   
3.4. Library Construction   
Phage display libraries can be constructed using many different bacteriophage strains 
with a range of fusion sites available for the insertion of DNA sequences. The most 
commonly used phages include M13 and fd filamentous phages, the T4 and T7 lytic 
phages as well as λ phage.  
The exact structure of a bacteriophage differs between types, however, they all possess 
a coat or capsid protein which can display the fusion product in a way which does not 
interfere with the normal phage life cycle. It is possible for the fusion proteins to be 
displayed at different sites depending on where the DNA fragments are ligated, the 
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location of the fusion can also influence the number of times the fusion is expressed, as 
well as impose constraints on the peptide or antibody being displayed. In the case of 
filamentous bacteriophage, they have an elongated shape consisting of different coat 
proteins, encasing the single stranded DNA (Figure 4). The most common sites for display 
are as fusions to the amino terminal of pIII or pVIII coat proteins. There are approximately 
2700 copies of the pVIII protein on each phage, which means inserting new genetic 
material at the pVIII gene site can result in a level of high display.154 However fusions of 
large sequences at this site are not well tolerated.59 The pIII site is compatible with larger 
fusions and can support both multivalent and monovalent display. 
 
Figure 4: Diagram of M13 bacteriophage structure.  Showing the distribution of coat proteins pIII, 
pVI, pVII, pVIII, and pIX. The fusion protein, encoded by the inserted DNA sequence, is displayed 
at the N-terminal of the pIII coat protein. In this diagram multivalent display is shown. 
Several phage libraries also incorporate antibiotic resistance and screening mechanisms, 
such as α-complementation of β-galactosidase for blue/white screening, to help prevent 
and identify cross-contamination or enrichment of wild-type phage. 
Random peptide libraries, including 7-mer, 12-mer and cyclic libraries are commercially 
available from New England Biolabs, making peptide phage display accessible to a wider 
range of researchers. Bio-Rad also offers commercially available Fab fragment libraries 
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such as Human Combinatorial Antibody Libraries (HuCAL) which represent over 95% of 
human antibody diversity. Customised libraries can also be purchased from companies, 
such as Creative Biolabs or Antibody Design Laboratories, which allows scientists to use 
more specific antibody or cDNA libraries without having to construct their own.   
3.4.1. Phage vs phagemid 
When using filamentous phage to construct a library, either a phage or phagemid system 
can be used. In a phage system, the cDNA comprising the library is incorporated into the 
bacteriophage genome using restriction enzymes and ligases to ensure the DNA fragment 
is inserted at the required location. The first use of bacteriophage to display a polypeptide 
as a fusion protein on its surface was reported by Smith, et al. in 1985,99 where BamHI 
was used to generate a fragment of Eco R1 endonuclease for insertion into the genome 
of a f1 phage.  
A phagemid system uses a Ff-phage-derived expression vector, the so called phagemid 
and this plasmid consists of the DNA sequence of the protein to be displayed, the 
required sequences for bacterial replication and the origin of replication and packaging 
signal of the strain of bacteriophage being used. The phagemid alone is unable to 
complete the full phage lifecycle and requires co-infection with helper phage to do so. 
The helper phage provides the bacteriophage proteins missing from the phagemid and 
allows packaging of the fusion protein into complete phage which can then be secreted 
by the bacterium.  
Two key differences between using phagemids or phages are the ability of the phagemid 
to accommodate larger inserts and the control over the number of times the fusion 
protein is displayed. Monovalent display of antibody libraries in a M13 phagemid system 
has assisted the selection of high affinity binders, where a multivalent system may also 
select for binders with a lower affinity, but which interact with the multiple targets on 
display.155 A comparison using the two library types, phage an phagemid, demonstrates 
the specific benefits of each system; multivalent display by a scFv phage library yields a 
higher number of different binding clones being identified in each round of panning, 
while the same library in a phagemid system identified fewer antigen-binding antibodies 
with higher affinity binding.156 
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3.4.2. Antibody libraries  
Antibody libraries can be generated from the cDNA isolated from either naïve or 
immunised donor antibody producing cells, while large naïve libraries can be used to 
identify target-binding antibodies.157 There are benefits to using immune libraries. 
Immunisation of animals with the target antigen, or using human donors who have 
already been exposed to the antigen of interest, allows for the enrichment of antibodies 
which are target related within the library and can lead to the selection of high affinity 
antibodies, for even complex targets such as human cancer cells.149 One drawback of 
immune libraries is the requirement to generate a new library for each new target antigen 
to be investigated. 
An additional consideration is the use of scFv or Fab libraries. Fab fragments demonstrate 
higher stability and a reduced tendency to form multimers compared to scFv molecules, 
but broadly have lower expression levels in E. Coli. On the other hand, scFv are smaller 
and may be a more useful tool in downstream applications. Additionally, their library 
production can be simpler than that of Fab fragments.108 
Semi-synthetic antibody libraries offer another method of generating a library with high 
diversity and sequences not found in vivo. Using polymerase chain reaction (PCR) 
techniques, amino acid substitutions or sequence insertions can be made in the 
complimentary determining region (CDR) of an antibody.158 Typically, these changes are 
made in the heavy chain of CDR3 as it contributes substantially to antigen binding and its 
function is not dependent on conformation.159 
3.4.3. Sub-libraries  
Once target binding clones have been identified and the sequences determined, it is 
possible to construct a sub-library to enhance its affinity for the target. For example, 
semi-synthetic antibody libraries can also be generated based on antigen-binding 
antibody fragments previously identified by phage display.  
With random peptide libraries, this can be done by the random mutation of the identified 
sequence through error prone PCR or site directed mutagenesis. It has been used to gain 
a more accurate picture of the consensus sequence which recognises the human Mab 
b12.160 
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Caloxin 1b1, a peptide inhibitor of a Ca+ pump found in the coronary artery was modified 
by random mutagenesis to generate a new peptide phage display library. Further panning 
lead to the identification of a more selective secondary peptide with a 20-fold increase in 
affinity. This new peptide, caloxin 1c2, was also seen to elicit physiological effects in 
vitro.161 Peptide sub-libraries have also been generated based on biologically important 
in vivo sequences to select peptides with the capacity to bind to multiple receptor 
targets,162 demonstrating their use in combination with rational design. 
3.5. Properties of ligands (peptides or antibodies) from phage display libraries 
3.5.1. Size 
Peptide libraries display smaller fusion products compared to antibody display libraries, 
but both are of sufficient size to identify specific binders. The size of the displayed protein 
can influence experimental set up and, to an extent, may limit the sequences identified; 
it also has important implications for use of target-binders in downstream applications.  
Smaller molecules can diffuse further and, in the context of drug delivery, peptides could 
provide improved tissue penetration when compared to antibodies or antibody 
fragments. The average molecular weight of an amino acid is 110 Da and a peptide 
identified through phage display using a 12-mer library would have a molecular weight 
around 1300 Da whereas antibody fragments have molecular weights ranging from 12 to 
160 kDa for single antibody domain to a normal antibody, respectively (Figure 5).  
 
Figure 5: Relative sizes of ligands generated from phage display libraries. Ranging from an antibody, 
typically the largest, to short peptide sequences. 
The iRGD peptide identified as tumour homing peptide by panning of ex vivo tumours 
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with one round of in vivo selection with a cyclic 7-mer library on the T7 phage, is seen to 
travel out of the tumour vasculature and into the tumour tissue when injected 
intravenously and allowed to circulate.163 The consensus sequence R/K-X-X-R/K has been 
observed in many phage display-derived peptides and is a requirement at the C-terminal 
for these peptides to penetrate the targeted tissue.164 
The use of Fab fragments compared to intact monoclonal antibodies has also been shown 
to enhance penetration into tumour spheroids and the smaller Fab molecules are able to 
give a more homogeneous coverage,165 although other factors such as binding affinity 
and kinetics may have a greater influence on targeted tissue penetration. 
3.5.2. Binding affinity 
Antibody-antigen interactions are known to exhibit high affinity and specificity in vivo. 
This is demonstrated through their use as in vitro reagents for cell staining and in vivo as 
therapeutics but there are still limitations. Experimental observations showed that 
antibody distribution within a tumour is heterogeneous when administered intravenously 
and this leads to the binding-site barrier hypothesis.166 Modeling antibody-antigen 
binding suggests that, along with size, one important factor in the binding-site barrier 
hypothesis is the affinity with which the antibody binds to the antigen. A higher affinity 
slows the diffusion into the center of the tumour.166,167 Utilising Fab fragments, which 
bind though monovalent interactions, in place of monoclonal antibodies, can reduce 
binding affinity therefore improving infiltration. Good tissue penetration is particularly 
important when antibodies, their fragments or peptides, are being used as targeting 
molecules for drug delivery to ensure that cells throughout the target tissue receive the 
payload. 
Cyclisation of peptides has been seen to alter peptide characteristics, resulting in 
increased stability, cell penetration and reduced systemic clearance across a range of 
applications (Reviewed Cardote & Ciulli, 2016).168 Studies which manipulate the 
conformation of displayed peptides to form cyclic libraries have shown that higher affinity 
binders can be selected.169 Cyclic peptides can be achieved by including pairs of cysteines 
for the formation of disulfide bridges, or through chemical modification of the library. A 
comparison of peptide libraries containing sequences with either a single leading cysteine 
or a pair of flanking cysteines found that the cyclic peptide library identified higher affinity 
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binders.170 
3.5.3. In vivo properties 
When choosing between using an antibody or peptide based phage library, an important 
consideration is how the purified binder will behave in its intended downstream 
application. For example, if the antibody, antibody fragment or peptide, is to be 
conjugated to a drug or an imaging agent and used to target specific tissues in vivo then 
non-specific uptake and half-life will influence success.  
Panning strategies which include at least one in vivo round can enrich for clones which 
bind the target while also identifying, and eliminating, those which accumulate in non-
target organs. This can be done by recovering phages from organs where high levels of 
drug would cause off-target toxicity, such as the liver, kidneys or bone marrow, and 
comparing these sequences to those retrieved from the target organ. Any sequences 
which feature highly in phages isolated from off-target organs can then be discounted 
from the target organ phage pool.171 
A potential drawback of using small peptides, Fab or scFv fragments with molecular 
weights below ~50 kDa, is that they often exhibit a short half-life in vivo due to rapid 
clearance from the blood by the kidneys. A short half-life can be seen as a limitation as it 
can mean low levels of accumulation at the target site. However, longer half-lives can 
also increase unwanted toxicity. For applications in imaging, where probes such as 
fluorophores, contrast agents, are coupled to the targeting ligand, half-lives which are 
too long can result in reduced contrast images.172 In the case of both peptides and 
antibody fragments, half-life can be modulated through chemical modification. 
PEGylation of antibody fragments can be used to increase half-life due, in part, to 
increased molecular weight as the complexes are not filtered out of circulation by the 
kidney.173 
When using antibodies and their fragments as diagnostic tools or therapies, there is a risk 
of immune-related adverse events, where non-human phage libraries have been used, 
but the resulting binders can be humanized to reduce their immunogenicity. However, 
doing this, by CDR grafting, framework fine tuning or other methods, can reduce antigen 
binding affinity.108 Owing to their smaller size, synthesized peptides identified by phage 
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display tend to have a lower level of immunogenicity and higher concentrations may be 
required to elicit an immune response.122 
3.5.4. Internalisation 
For use in targeted drug delivery, or as a therapeutic agent themselves, internalisation of 
peptides and antibodies can either be required for their function or enhance their 
effect.174 Around 10% of FDA approved drugs require metabolism by the body to be 
converted into the active form.175 In the context of targeted therapeutics, it is beneficial 
for any homing molecule to be easily internalised by target cells. 
Whole cell panning experiments can be set up to maximise the proportion of phage 
clones isolated which can undergo cell internalisation. After incubation with the library, 
phages bound to the surface can be eluted using a non-specific elution buffer, intact cells 
can then be dissociated, pelleted and lysed to free any internalised clones. Further 
modification of the phage genome has also been used to identify internalised clones, 
insertion of a reporter gene, such as green fluorescence protein (GFP), allows cells 
containing phage can be visualised and separated from those which have not taken up 
phage.176 
Using a library designed around the Tat transduction domain, peptides which could cross 
the cell membrane were identified. Panning was carried out on a human epidermoid 
carcinoma cell line where cell surface-bound clones were removed by repeated washes 
and internalised phages were recovered from cell lysates. Synthesis of the isolated 
peptide sequences and labelling with fluorescein isothiocyanate (FITC) allowed 
assessment of the amount of cellular uptake when compared to the parent peptide 
sequence.177 
3.5.5. Production and modifications 
Recent advances in peptide synthesis technologies enable the synthesis of identified 
target-binding peptides at a relatively low cost and with a short turnaround time. They 
can be purified by reverse-phase high performance liquid chromatography (HPLC) 
methods. To generate desired Fab and scFv molecules, expression can be carried out in 
either bacteria or yeast systems and purified using optimised conditions for the fragment. 
For example, Fab fragments can be purified using Protein G affinity chromatography or 
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other protocols using protein G due to the presence of a constant region.108 
Once antibody fragments or peptides have been made, there are multiple options for 
chemical modifications to enhance their function in their downstream applications. Both 
antibodies and peptides can be conjugated to fluorophores for use in imaging or as in 
vitro reagents as well as to drugs, such as chemotherapeutics, while preserving their 
target-binding homing function 178–180 Doxorubicin coupling to tumour-targeting peptides 
using carbodiimide chemistry saw improved survival compared with doxorubicin 
treatment alone in mouse models of breast cancer.16 
To further increase the suitability of peptides for use as therapeutics, a number of 
modifications can be made. Improved cellular uptake can be achieved by conjugation to 
known cell penetrating peptides, 181 while incorporation of D- and non-natural amino 
acids into peptide sequences has the potential to reduce susceptibility to cleavage by 
proteases in vivo resulting in an increased half-life.182 
3.6. Successes of phage display 
Utilising combinations of panning strategies, modification and conjugations such as 
cyclisation, fluorescent labelling, biotinylation, or PEGylation highlighted above, phage 
display has produced several successful approved therapies and reagents with even more 
in the pipeline. 
The first fully humanized antibody approved by the FDA, adalimumab, was identified by 
phage display with panning against tumour necrosis factor alpha (TNFα), with a binding 
affinity of 15 nM.183 Since its initial licensing for the treatment of rheumatoid arthritis, it 
has also been approved for treating Crohn’s disease, psoriasis and several other 
inflammatory diseases. Its success is highlighted by its position as the bestselling drug of 
2016.184  
There are many phage display-derived antibodies currently in clinical development, as 
therapies in their own right or as conjugates. An example of an antibody drug conjugate 
(ADC) currently in phase 1 clinical trials is BAY 1129980, which consists of an auristatin 
(an inhibitor of cell division) derivative coupled to a monoclonal antibody against the cell 
surface protein C4.4A, which serves as an indicator of metastatic potential in cancers. The 
antibody was generated from a recombinant antibody gene library panned against 
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biotinylated C4.4A which was then captured on magnetic streptavidin-coated beads. In 
vivo studies treating non-small cell lung carcinoma models demonstrate that BAY 
1129980 is able to inhibit tumour growth, indicating its potential for use in the clinic.180  
Screening of a scFv library against interleukin-12 (Il-12) and subsequent targeted 
mutagenesis of the identified fragment to improve binding resulted in the isolation and 
development of briakinumab. There have been several clinical trials assessing its use to 
treat multiple sclerosis, Crohn’s disease and psoriasis.185 However, development has 
since been discontinued for all three indications. This demonstrates that while phage 
display is an excellent tool for identifying candidates for therapy they are still at risk of 
the same stumbling blocks as any other new therapeutic.  
In comparison to the use of antibodies, peptide based therapeutics is much younger, but 
rapidly expanding field, with a number of exciting candidates undergoing clinical trials. 
Bicycle Therapeutics is a biotechnology company which uses phage display based 
platforms to identify target-binding peptides and these can then be converted to bicyclic 
peptides using chemical scaffolds. Using this strategy, several drug candidates have been 
identified and are at various stages of development, from discovery through to clinical 
trials. BT1718, a Membrane Type 1 Matrix Metalloproteinase-targeting bicyclic peptide 
coupled to the MD1 toxin, has entered first time in human phase I/IIa trial following its 
success in xenograft models which is due to be completed in 2022 (ClinicalTrials.gov, 
2018).  
Wu et al. (2015)186 provide an elegant example of how in vitro panning on a colorectal 
cancer cell line using a random peptide library was able to identify several phage clones 
which specifically home to tumour tissue in xenograft models. They identified the best 
target-binder and coupled it to polyethylene glycol- 1,2-Distearoyl-sn-glycero-3-
phosphoethanolamine (DSPE) to incorporate it into lipid nano-particles encasing 
anticancer drugs. Inclusion of the peptide resulted in enhanced cellular uptake of the 
nano-particles accompanied by increased cytotoxicity in target cells in vitro and in in vivo 
xenografts treatment reduced tumour size beyond the reduction seen with non-targeted 
liposomes. While these results present a potential candidate for enhanced treatment of 
colorectal cancer in humans, Wu and colleagues were also able to identify the binding 
partner of the pHCT74 peptide on the cell surface as α-enolase, which could be a useful 
58 
 
marker to further characterise cell properties in vitro. The pattern of 
immunohistochemistry staining of tumour and non-target organ sections also 
demonstrated the potential of these peptides for use as diagnostic reagents. 
Peptide phage display has also proven to be a useful tool for identifying ligands for 
difficult to target intracellular signaling molecules, such as β-catenin, an intracellular 
protein involved in both cell adhesion and regulation of gene transcription, where 
dysregulated β-catenin function is associated with several cancers. Due to its multiple 
roles, finding an inhibitor which only acts to interfere with disease function has been 
challenging. Through the use of chemically constrained peptide phage display libraries, 
several potential candidates for inhibitors have been identified, although studies to 
investigate in vitro function are still required.187 
4. Self-assembled Monolayers (SAMs) 
Self-assembled monolayers are an organised arrangement of molecules that are able to 
form spontaneously on solid surfaces via chemisorption 188 Most commonly SAMs are 
formed using alkanethiols, where the HS- group has an affinity for metals, such as gold 
and silver. 189 Typically, Au is the chosen surface for alkanethiol SAM formation for cell 
based studies and this interaction has been well characterised, with molecule spacing 
seen to be 0.5 nm and aligned molecules assemble at a 30° angle which give the optimal 
van der Waals forces between each chain.188 SAM formation can also be applied to a 
range of substrates utilising different functional groups, many of which have uses in cell 
culture or important clinical applications. For example stainless steel (reviewed 190) 
titanium,191 silicon,192and glass193 have all been used as surfaces for SAM formation, and 
in the case of glass used successfully to create mixed peptides SAMs which induced the 
expression of chondrogenic markers by human articular chondrocytes when used as a 
culture surface.  
4.1. Functionalisation of SAMs 
Another advantage to using alkanethiols for SAM formation is the ability to functionalise 
the alkyl chain at its opposite end. This allows control over, and optimisation of, the 
properties of the SAM for use in its intended application. At the most basic level, 
functionalisation can alter the charge or hydrophobicity of a surface (Figure 6),194,195 
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present a range of chemical groups which can be used to further modify the SAM,87 or to 
create more complex systems using molecules such as peptides. 
 
 
Figure 6: Self-assembled monolayers with different surface properties as a result of the terminal 
group. Hydrophobic surface created by alkanethiols containing groups such as CH3 (A) and more 
hydrophilic surfaces formed by alkanethiols with functional groups including OH, COOH, and 
NH2(B). 
 
4.1.1. Functionalised surfaces for cell culture 
SAMs provide a simple way to fabricate well-defined substrates to control and investigate 
cell behaviour. These surface modifications can be made in a way which is nontoxic to 
cells, making them a particularly attractive option as a research tool for in vitro cell 
culture. The effect of changing surface hydrophobicity has been studied by several groups 
and it is generally accepted that hydrophilic surfaces tend to promote cell binding while 
a hydrophobic surface will reduce cell adhesion.  
As mentioned, the terminal group on a SAM can be altered and the effects of a range of 
functional groups on cells in culture can then be investigated. The most commonly 
studied groups, in terms of cell culture, are hydroxyl (-OH), carboxyl acid (-COOH), amino 
(-NH2), methyl (-CH3) and mercapto (-SH). Increased proliferation and cell migration has 
been documented with -NH2 and -COOH modifications, while the opposite was seen 
when -OH and -SH terminal groups were used.194,196,197  
Functionalisation of alkanethiols with peptides provides a platform to study the effects 
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of peptide sequences, which may be derived from known binding sites from ligands or by 
phage display, on cell behaviour. This strategy has been successfully employed to 
influence cell adhesion, support proliferation, and direct differentiation or even maintain 
pluripotency of stem cells.194–196,198,199 Using the cell-binding amino acid motif, arginine - 
glycine - aspartate (RGD), initially identified in fibronectin (Fn) and subsequently in 
additional ECM proteins, Roberts et al.200 were able to assess the function of the RGD 
sequence and demonstrate that it is sufficient to mediate cellular attachment to the SAM 
substrate. 
Due to the ease and speed with which they can be created, SAMs can also be applied to 
high-throughput screening of peptide-cell interactions to identify surfaces able to elicit 
the desired effect on cells in culture.201 Using this approach, in combination with phage 
display to identify candidate peptides binding embryonic stem cells (ESCs), Derda et al.202 
were able to fabricate two peptide-SAMs to which ESCs adhered and which supported 
their proliferation and maintained pluripotency. 
The ability to fabricate well defined and ordered surfaces is increasingly important for the 
regulated production of in vitro-expanded pluripotent, multipotent, or differentiated 
cells for cell-based therapies. SAMs can provide a rapid and simple method to achieve 
this and can eliminate the need for animal-derived products, or feeder cells,203 to support 
cell proliferation or differentiation.  
4.1.2. SAMs for adsorption of biological molecules 
Manipulation of surface properties through the application of SAMs can also be used to 
alter the adsorption of macromolecules. In the case of Fn, an ECM protein involved in 
integrin binding, conformational changes in the way the protein is displayed can be 
induced by using SAMs with different functional groups. Alkanethiol SAMs displaying -
OH, -COOH and -NH2 groups caused a significant difference in the binding between Fn 
adsorbed and an anti-Fn antibody.97 Subsequent studies revealed that culture on 
adsorbed Fn caused an upregulation of osteoblast specific genes, matrix mineralisation 
and increased enzyme activity on -OH and -NH2, whereas -COOH functionalised SAMs did 
not, demonstrating that surface chemistry can influence complex cellular functions.198 
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In addition to the chemical modification and covalent immobilisation of HA, thiol reactive 
surfaces have been reacted with a cysteine-containing HA-binding peptide, termed 
HABpep, which is then able to bind and immobilise unmodified HA.133 This strategy has 
been applied to immobilise HA both on contact lenses and cartilage, while the use of 
covalent bonds required for the peptide immobilisation exclude this method from being 
considered self-assembly. It does demonstrate, however, that HA-binding peptides can 
be used to immobilise native HA. It opens the possibility of functionalising alkanethiols, 
or other self-assembling molecules, with HA-binding peptides as a means of non-
covalently modifying a surface with HA. 
4.2. Patterning of self-assembled monolayers 
Another useful property of SAMs is the ability to restrict their formation to discreet areas. 
Selectively covering a surface with a SAM, or multiple SAMs, with differential cell-binding 
properties, can be used to restrict cell growth on desired areas. Being able to spatially 
control the binding of proteins and cells is particularly useful in several fields including, 
biosensors, tissue engineering and in the automatisation of cell screening studies.  
There are several methods for creating patterned surfaces with SAMs; once a monolayer 
is formed micromachining can be used to remove the gold and therefore creating 
channels or areas where the SAM is no longer present. However, there are limitations to 
using this technique, mainly that it is a slow process.204 A method which is now more 
commonly used for substrate patterning is micro-contact printing (µCP), where a 
polydimethylsiloxane (PDMS) stamp can be ‘inked’ with the required alkanethiolates to 
form the SAM and then these transferred onto the gold surface.204 In the case of 
alkanethiolates on a gold surface, this happens within seconds, meaning the complete 
process is much quicker and the amount of SAM spreading seen is minimal.205 
More complex patterned substrates can be created by using micro-contact printing to 
deposit a SAM functionalised with one peptide or chemical terminal group and then 
immerse the surface in a solution with a different functionalisation. The result is distinct 
areas of the substrate with different surface chemistries and properties, such as SAMs 
resistant to protein binding and those which promote it.206 This can then be applied to a 
range of cell studies to define areas of cell growth,205 and can aid the use of automated 
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microscopes for medium to high-throughput screening. Alternatively, creating channels 
of cell permissive surfaces can be used to model complex cell structures for potential use 
in organ-on-chip platforms.207 
4.3. SAM stability 
When engineering a surface for cell-based applications, as described above, an important 
consideration is the environment in which the SAM will be used and how they will 
interact. By modifying the sequence or components of the molecules used to create a 
SAM the half-life of resulting monolayers can be tuned. As an example, µCP of glycol-
terminated alkane thiols have been developed which have a substantially increased 
lifespan of at least 35 days, during which time they are able to support the culture of cells 
in vitro.208 Systems have also been established where SAM-surfaces can be regenerated 
following their initial use. SAMs used to create a biosensing surface show retained 
function and sensitivity for anywhere between 25 and 50 cycles of use and 
restoration.209,210 Re-use of such surfaces allows preservation of reagents and will 
ultimately reduce the cost of these materials. Similarly, SAMs with applications in cell 
culture can also be utilised repeatedly for cell culture.  By employing a simple 
regeneration step, following removal of cells using trypsin, the surfaces can retain their 
integrity to be used for up to 15 rounds of subsequent culture.211 These works highlight 
the capability of SAMs to function as a stable surface and an increasingly affordable 
technology for cell culture applications.  
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SECTION 2: EXPERIMENTAL 
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Chapter II - Materials and Methods 
1. HA-binding peptide identified by phage display (Pep-1) 
Pep-1 is a 12-amino acid peptide which was identified by Mummert et al.131 as a HA-
binder through phage display using the New England Biolabs random peptide library. 
Since first being published, several studies have demonstrated the utility of Pep-1 for 
blocking HA-cell interactions via the cell surface receptor CD44,131 and inhibiting the 
downstream function of HA212 as well as in situ detection of HA.132,213 Pep-1’s sequence 
is GAHWQFNALTVR (Figure 7).   
 
Figure 7: Structure of Pep-1. Created with ChemDraw. 
The Pep-1 used in this work was synthesised, modified and purified, by Mr Dominic Collis 
from MHAtricel group, as described below. 
1.1. Peptide synthesis 
Peptide synthesis, either in a liquid- or solid-phase format, enables the production of 
useful biological molecules ranging in size from a few amino acids to much larger 
proteins. Chemical synthesis avoids the need for genetic modification of host organisms, 
such as bacteria to produce recombinant proteins, which is beneficial for peptides to be 
used in vivo. The Pep-1 peptide used for this thesis was synthesised on the Liberty Blue 
automated microwave peptide synthesiser (CEM, UK), using solid-phase peptide 
synthesis with 9-fluorenylmethoxycarbonyl (Fmoc) chemistry.214 In this method, 4-
methylbenzhydrylamine (MBHA) rink amide resin is used to tether the first amino acid at 
its C-terminal, subsequent protected amino acids are added to its N-terminal via their C-
terminal through a condensation reaction forming an amide bond (Figure 8). The Fmoc 
group protecting the N-terminal is base-labile and when used in combination with acid-
labile protecting groups on amino acid side chains allows effective orthogonal growth of 
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the peptide. The deprotection of the N-terminal under basic conditions, using 20% 
piperidine in dimethylformamide (DMF), does not affect protection of the R groups and 
ensures the newly free amine group is the only available site for the carboxyl group of 
the next amino acid to react with. As the growing peptide is attached to a solid support, 
and is insoluble, it is possible to wash and filter excess reagents and unwanted by-
products out after each round of deprotection and coupling. Once the desired peptide 
sequence is achieved and the final N-terminal deprotection is complete, the peptide can 
be capped or coupled to another molecule, such as an alkyl tail or a fluorophore, before 
being cleaved from the resin. The acidic cleavage conditions for the resin also allow the 
simultaneous deprotection of amino acid side-chains.  
 
Figure 8: Schematic for solid phase peptide synthesis. 
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For peptide synthesis using the Liberty Blue automated microwave peptide synthesiser, 
Fmoc amino acids (Novabiochem, USA) were coupled to a MBHA rink amide resin 
(Novabiochem), amino acid couplings were performed in 4 times excess of 1-
hydroxybenzotriazole hydrate (HOBt), N,N′-diisopropylcarbodiimide (DIC) (both Sigma-
Aldrich). Fmoc deprotection was carried out in 20% piperidine in DMF (v/v) and the resin 
was washed with DMF then dichloromethane (DCM) after each round of coupling and 
deprotection. The peptide was removed from the synthesiser and Pep-1 was manually 
capped with either an acetyl group or 3-(((4-methoxyphenyl) 
diphenylmethyl)thio)propanoic acid. Peptides were cleaved, and side groups 
deprotected, using a solution of trifluoroacetic acid (TFA, Sigma-Aldrich), 
triisopropylsilane (Alfa Aesar, US) and water (95:2:5:2.5), or TFA, thioanisole (Sigma-
Aldrich), anisole (Sigma-Aldrich) and ethylenediaminetetraacetic acid (EDTA, Sigma-
Aldrich) (90:5:2.5:2.5) for 3 hours at room temperature for acetylated or thiolated 
peptides, respectively. The cleaved peptide solution was collected and excess TFA was 
removed by rotary evaporation. The peptide was precipitated by the addition of cold 
diethyl ether (Sigma-Aldrich) and the mixture centrifuged to pellet the peptide. The 
supernatant was discarded and the peptide was lyophilised. 
1.2. Pep-1 capping 
1.2.1. Thiol tail capping 
The incorporation of a thiol group into a molecule is often used to induce the formation 
of self-assembled monolayers on a gold surface, as it is known that a strong sulphur-gold 
bond is formed.215 To enable Pep-1 to assemble on a gold substrate, it was capped with 
a 3-(((4-methoxyphenyl) diphenylmethyl)thio)propanoic acid (Acros Organics, Belgium) 
tail (Figure 9).  
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Figure 9: Reaction scheme for the coupling of Pep-1 to the thiol group. 
 
Pep-1 was coupled manually to 3-(((4-methoxyphenyl) diphenylmethyl)thio)propanoic 
acid using 4 times excess of HOBt and DIC, by shaking for 2 hours at room temperature 
(Figure 10). The resin was washed with DMF then DCM before a Kaiser test (Sigma-
Aldrich) was performed according to manufacturer’s instructions, to confirm the success 
of the coupling. Briefly, a few resin beads were removed and 3 drops of 80% phenol in 
ethanol, KCN in H2O/ pyridine and 6% ninhydrin in ethanol were each added. The sample 
was heated to 120 °C for 5 minutes. The beads and solution remaining yellow indicates a 
successful capping, whereas if the coupling is incomplete the presence of a primary amine 
causes a colour change to blue. 
 
Figure 10: Structure of thiolated Pep-1, HS-Pep-1. Created with ChemDraw. 
1.2.2. Acetyl capping  
To confirm that the thiol group is responsible for the HS-Pep-1 forming a SAM, rather 
than it simply adsorbing on the gold surface through electrostatic interactions, acetylated 
Pep-1 (Ac-Pep-1) was used as a control (Figure 11). While still attached to the resin, Pep-
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1 was capped at the N-terminal with an acetyl group, by shaking for 20 minutes at room 
temperature with acetic acid (Sigma Aldrich) and 10% DMF (w/v). Once the capping was 
done, the resin was washed with DMF then DCM. To confirm the success of the capping, 
a Kaiser test (Sigma-Aldrich) was performed according to manufacturer’s instructions. 
 
Figure 11: Structure of acetylated Pep-1, Ac-Pep-1. Created with ChemDraw. 
1.3. Purification 
1.3.1. Preparative high performance liquid chromatography 
The purification of crude peptides was achieved by using high performance liquid 
chromatography (HPLC). This technique separates molecules in solution based on their 
interaction with a solid support, or column, where greater interaction with the column 
will result in a slower elution. Reverse-phase HPLC employs a non-polar solid phase and 
an aqueous mobile phase, where hydrophobic molecules have a greater retention time 
and hydrophilic molecules are eluted much more quickly. In the case of peptide 
purification, an aqueous solution containing the peptide is initially injected into the 
column and eluted over time using a gradient of aqueous/organic solvent which results 
in the separation and elution of the desired peptide. The more hydrophilic molecules are 
eluted first followed by increasingly hydrophobic ones.  
As compounds are eluted from the column they pass through a detector which can 
monitor the absorbance at 220 nm, the wavelength at which a peptide bond has its peak 
absorbance, this allows analysis of the elution time. 
To purify the Pep-1 peptides, preparative reverse-phase liquid chromatography using a 
C18 XBridge column (Waters, UK) was used with a gradient of 98% H2O to 100% 
acetonitrile (Sigma-Aldrich) supplemented with 0.1 % TFA. The exchange was run over 30 
minutes using a flow rate of 20 mL/min. The purified product was collected based on the 
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peptide mass, as detected by the SQ Mass Detector (Waters) and acetonitrile was 
removed by rotary evaporation followed by lyophilisation to obtain peptides as powders. 
 
1.4. Peptide characterisation 
1.4.1. Electrospray ionisation mass spectrometry 
Electrospray ionisation mass spectrometry is an analytical technique for both the 
structural and quantitative measurement of biological molecules. Samples are 
aerosolised by subjecting the sample solution to an electric current, ionised samples then 
travel through a magnetic field and depending on their mass/charge (m/z) ration are 
detected by different areas of the detector. The abundance of ions at each m/z ratio can 
then be used to determine quantitative information about the sample.216 In this work 
samples were dissolved in methanol, the mass of the peptides used in chapter III was 
determined by LC-MS using the 1100 LC/MSD Trap (Agilent, US), as shown in Figure 12A 
and B.  
 
Figure 12: Characterisation of peptides. Electrospray Ionisation Mass Spectrometry of (A) HS-Pep-
1-CONH2 (Found 1486.6 [M+H]+, 744.0 [M+2H]2+. Expected 1486.7) and (B) Ac-Pep-1-CONH2 
(Found 1440.8 [M+H]+, 720.9 [M+2H]2+. Expected 1440.6) High Performance Liquid 
Chromatography trace of (C) HS-Pep-1-CONH2 and (D) Ac-Pep-1-CONH2 showing a single peak. 
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1.4.2. High performance liquid chromatography 
To assess the purity of the peptides synthesised for use in this work HPLC was used (Figure 
12C, D). Samples were analysed on the Alliance HPLC System (Waters, UK) with an X-
bridge column (C18, 3.5 μm, 4.6 × 150 mm) with a water/acetonitrile gradient (from 98/2 
to 0/100), and a flow rate of 1 mL/min. The absorbance of the peptide bond at 220 nm 
was monitored by 2489 UV/visible detector (Waters).  
 
2. Hyaluronic acid 
Hyaluronic acid (HA), which can also be called hyaluronate or hyaluronan, is a non-
sulfated glycosaminoglycan that has numerous essential roles within the body. It 
comprises a large part of the extracellular matrix (ECM) as well as the tumour micro-
environment. It is made up of repeating disaccharides, N-acetyl-glucosamine and D-
glucuronic acid (Figure 13), and in vivo HA can be found with a range of molecular weights 
(MWs) which has been shown to influence its biological function. To investigate the role 
MW might play, a range of molecular weights, 20 kDa, 200 kDa or 1.5 MDa sourced from 
Lifecore Biomedical Inc. (Chaska, USA), was used in the experiments ofsubsequent 
chapters. 
 
Figure 13: Structure of hyaluronic acid repeating disaccharide. Created with ChemDraw. 
2.1. Sterilisation 
To prevent contamination in cell-based assays, HA was filter-sterilised. HA was dissolved 
in distilled water and passed through a 0.22 µm filter in a cell culture hood, the filtered 
solution was then transferred to a 50-mL TubeSpin® Bioreactor tube (TPP, Switzerland) 
and lyophilised. 
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2.2. Texas Red tagging 
To visualise the immobilisation of HA following micro-contact printing of HS-Pep-1 by 
fluorescence microscopy, a Texas red tagged HA (HA-TxRd) was synthesised. (Figure 14) 
 
Figure 14: Structure of Texas red- conjugated hyaluronic acid repeating unit. Created with 
ChemDraw. 
Texas red (Thermo Fisher Scientific) was conjugated to HA using a previously described 
method.217 Briefly, 1.5 MDa HA (Lifecore Biomedical, USA) was dissolved in 20 mM MES 
(Sigma) pH 4.5, 30% ethanol (Sigma-Aldrich), and 3 times excess N-(3-
Dimethylaminopropyl)-N′-ethylcarbodiimide hydrochloride (EDCI) (Sigma-Aldrich) 
compared to the number of HA disaccharide units. Texas Red hydrazide (Molecular 
Probes, Invitrogen, UK) was dissolved in DMF and added to the HA mixture at a molar 
ratio of fluorophore to disaccharide number of 1:10 and incubated at room temperature 
with shaking, overnight in the dark. The solution was dialysed against 75 mM NaCl (Fisher 
Scientific), in 40% ethanol, using regenerated cellulose membranes (10,000 molecular 
weight cut-off, Spectra/Por, USA), in the dark for 4 days then lyophilised and stored at -
20 C.  
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3. Poly-D-Lysine 
Poly-lysine is a positively charged polymer which can be synthesised from the L or D forms 
of lysine to yield either poly-L-lysine (PLL) or poly-D-lysine (PDL). Both polymers are highly 
hydrophilic and at a physiological pH have a pKa~ 10.5.218 In cell culture, poly-lysine is 
often used as a surface coating to enhance cell adhesion. PLL is susceptible to degradation 
by proteolytic enzymes expressed by cells whereas PDL is more resistant which can be 
beneficial to insure poly-lysine integrity throughout cell-based assays.219 Due to their 
positive charge, both PLL and PDL can immobilise HA through strong ionic interactions 
and can be exploited for layer-by-layer assembly studies.220 In this work HA was 
immobilised by poly-lysine as a comparison for Pep-1 immobilisation of HA in vitro. PDL 
was selected to minimise cell-dependent degradation. For all experiments, a solution of 
0.1 mg/mL Poly-D-lysine homobromide (Sigma-Aldrich), with an average molecular 
weight of 70 – 150 kDa, was used. 
4. HA glycopolymers 
Chemically synthesised mimics of biological molecules, such as HA, can provide useful 
tools in cell biology. To be able to replicate the effects of biological molecules with a 
synthetic alternative would help to eliminate the use of animal derived products from 
tissue culture, which is especially advantageous for translational applications. 
Additionally, chemical synthesis has the potential to enhance the existing properties of 
the native molecule, allowing properties to be tailored towards a specific application. 
Using the two HA sugars, N-acetyl-glucosamine and D-glucuronic acid, the HA 
glycopolymers were synthesised by Mr Dominic Collis.221 Homo-polymers, consisting 
entirely of either N-acetyl-glucosamine or D-glucuronic acid, an alternating co-polymer, 
synthesised under conditions which ensured subunits were added alternately, and a 
statistical co-polymer which contains both monomers in an undefined order and ratio, 
were synthesised by Reversible Addition Fragmentation Chain-Transfer (RAFT) 
polymerisation (Table 1). The Formation of these polymers was monitored by Fourier-
transformation infrared spectroscopy (FT-IR), gel permeation chromatography (GPC), and 
nuclear magnetic resonance (NMR). 
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Table 1: Structure of the HA glycopolymers as used in Chapter V, shown as individual repeating 
units. Created with ChemDraw. 
Polymer Structure 
PVB-GlcNAc 
 
PVB-GlcA 
 
PVB-GlcNAc-alt-PMI-GlcA 
(Alternating) 
 
PVB-GlcA-co-VB-GlcNAc 
(Statistical) 
 
 
5. Formation of self-assembling monolayers and HA binding 
5.1. Au substrate preparation  
Gold (Au) surfaces were used for the self-assembly of Pep-1 monolayers and the 
adsorption of PDL for the immobilisation of HA. In addition to its ability to form gold-
sulphur bonds for SAM assembly, Au is a noble metal that is widely used in vitro and in 
vivo without any notable side effects or toxicities.222  
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5.1.1. Coating 
The gold surfaces used in this thesis for SAM formation, with the exception of the quartz 
crystal microbalance crystals, were produced by Mr Jotham Selvarajah from the School 
of Physics and Astronomy, Queen Mary University of London. Glass microscope slides 
were cleaned with a mixture of sulphuric acid (Sigma-Aldrich) and 30% hydrogen peroxide 
(Sigma-Aldrich) in a 3:1 ratio, rinsed with DI water, dried under N2 then rinsed with 
acetone (Sigma-Aldrich), dried under N2 and finally rinsed in chloroform (Sigma-Aldrich) 
and dried under N2. Slides were then evaporation coated with a 3 nm chromium adhesion 
layer, then a 100 Å layer of gold. Thickness of the coating was measured by a quartz 
crystal oscillating monitor. 
5.1.2. Cleaning 
Prior to use, all Au surfaces, including QCM-D crystals, were cleaned using the following 
protocol. Gold substrates were submerged in hot (60 C) cleaning solution (30% 
ammonium hydroxide (Sigma-Aldrich), 30% H2O2 (Sigma-Aldrich), and DI water in a 1:1:3 
ratio), for between 2-5 minutes, rinsed with DI water and dried under N2. This cleaning 
protocol is based on the RAC clean and removes organic residues from the surface, and 
is recommended by the manufacturers as the preferred cleaning procedure for the gold-
coated QCM-D sensors,223 this method is also routinely used to remove SAMs224 and as 
such this method has been applied to cleaning of all the Au substrates used. 
5.2. Building of SAM-HA layers/surfaces 
5.2.1. HS-Pep-1 self-assembled monolayers 
The formation of HS-Pep-1 SAMs was achieved by incubating pre-cleaned Au substrates 
with a 1 mM solution of HS-Pep-1 in 99.9% ethanol (Sigma-Aldrich) at room temperature 
for at least 24 hours. Samples were then rinsed with ethanol to remove any excess 
peptide followed by ultra-pure water and dried under N2.  
5.2.2. Poly-D-lysine coating 
Coating of Au substrates was done by incubating pre-cleaned surfaces with 100 µg/mL 
PDL in sterile ultra-pure water at room temperature for at least 24 hours. Samples were 
then rinsed with ultra-pure water to remove any excess PDL and dried under N2.  
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5.2.3. HA immobilisation 
To investigate HA immobilisation on each of the prepared surfaces, PDL, HS-Pep-1 or on 
bare Au, samples were incubated with 0.05 % (w/v) HA for at least 48 hours at room 
temperature. They were then rinsed with ultra-pure water to remove any unbound HA 
and dried under N2.  
A range of molecular weights of HA were used, 20 kDa, 200 kDa and, 1.5 MDa, and for 
each the same percentage concentration was used.  
Surfaces prepared for use in tissue culture studies were made as described under sterile 
conditions, using filter-sterilised HA and sterile ultra-pure water for washes. 
5.3. Micro-contact printing 
Micro-contact printing is a quick and simple method for creating patterns on surfaces, 
which is routinely used in combination with SAMs. To investigate the spatial localisation 
of HA by HS-Pep-1, polydimethylsiloxane (PDMS) stamps, gifted by Dr 
Kseniya Shuturminska, were used to transfer HS-Pep-1 onto the Au surface. A 1 mM 
ethanolic solution of HS-Pep-1 was applied to the PDMS stamp and dried under N2, the 
stamp was brought into contact with the cleaned Au surface. Care was taken to ensure 
the entire surface of the stamp made equal contact, and to avoid air bubbles becoming 
trapped. The stamp was lifted after ~10 seconds, making sure the stamp was not moved 
across the surface causing the pattern to be distorted. Patterned surfaces were then 
washed with ethanol and dried under N2, followed by rinsing with ultra-pure water.225 
Once the surfaces were patterned they were incubated with the fluorescent Texas Red-
labelled HA, as described in 2.2.   
6. Characterisation of self-assembled layers (SAMs) 
To confirm the successful coating, or patterning, of Au surfaces with PDL and HS-Pep-1 
and subsequent immobilisation of HA several characterisation techniques were 
employed. 
6.1. Quartz crystal microbalance with dissipation monitoring  
Quartz crystal microbalance with dissipation monitoring (QCM-D) is a technique which 
has been developed from the original QCM system, which typically uses an AT-cut circular 
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piece of quartz with a metal electrode on each side and exploits the inherent piezoelectric 
properties of quartz to calculate changes in mass on a quartz crystal surface. Application 
of an alternating electric current causes detectable oscillations in the quartz. QCM-D 
enables real-time monitoring of both the adsorption of material onto a surface, by 
observing the change in frequency (∆f) of the crystals oscillation, as well as the 
viscoelastic properties of the adsorbed layer, using the change in dissipation (∆D). When 
mass is added to the surface of the crystal, the frequency of its oscillations is decreased, 
and conversely, when mass is removed from the surface the frequency increases. The 
Sauerbrey relationship equates the change in mass (∆m) with ∆f using Equation 1.226 
Equation 1: The Sauerbrey equation 
𝑚 = −
𝐶 × 𝑓𝑛
𝑛
          
Where Δm is the Sauerbrey areal mass density of the adsorbed layers (mass per unit 
area), C is the mass sensitivity constant of the quartz crystal (17.7 ng cm-2 s for 5 MHz 
quartz crystals), n is the overtone number and f is the resonant frequency. 
However, the Sauerbrey equation makes several assumptions, which means that if the 
film deposited onto the surface is soft or has viscoelastic properties then the ∆m value 
will be underestimated. Dampening of the crystals oscillation is characteristic of soft 
films, this energy dissipation (D), defined by Equation 2, can be used to model further 
information regarding properties of the film. 
Equation 2: Energy dissipation 
𝐷 =  
𝐸𝑙𝑜𝑠𝑡
2𝜋𝐸𝑠𝑡𝑜𝑟𝑒𝑑
 
 
Where Elost is the energy lost during one oscillation cycle and Estored is the energy stored. 
The ∆f and ∆D from multiple overtones can be used in the Voigt-based viscoelastic film 
model to provide information on the adsorbed mass, film thickness, viscosity and shear 
elastic modulus. 
In this thesis, QCM-D was used to confirm and quantify the binding of HS-Pep-1 or PDL to 
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a gold surface using the gold-coated QSX301 sensor (Biolin Scientific, Sweden) and 
subsequent binding of 3 molecular weights of HA (20 kDa, 200 kDa, and 1.5 MDa). 
Measurements were carried out in a liquid environment using either the QS100 or Q-
Sense Pro (both Biolin Scientific) at 37 °C or 25 °C, respectively. Before use, sensors were 
UV/Ozone treated (UVOCS T10X10 OES/E, Ultraviolet Ozone Cleaning Systems, USA or 
UV/Ozone ProCleaner 220, BioForce Nanosciences, Inc., USA) for 10 minutes then 
cleaned as described in 5.1.2. Following cleaning unmodified sensors were then 
UV/Ozone treated for a further 10 minutes.  
The QS100 instrument uses a static system whereas the Q-Sense Pro measures 
adsorption under flow, at a rate of 50 µL/min. For both systems readings were collected 
according to the following general protocol; the baseline frequency and dissipation of the 
crystal was established in 0.15 mM NaCl, a solution of either HS-Pep-1, PDL, or HA in 0.15 
M NaCl was then injected into the crystal chamber. Once a stable frequency was seen, 
the sensor was washed with NaCl to remove weakly associated molecules. A solution of 
0.05 % HA (MW of 20 kDa, 200 kDa or 1.5 MDa) in 0.15 mM NaCl was then injected into 
the crystal chamber. Again, once a stable frequency was acquired the system was washed 
to remove weakly associated molecules. 
For data gathered using the Q-Sense Pro, the thickness of layers was estimated using the 
Voigt-based viscoelastic model implemented in the Q-Sense Dfind software (version 
1.1.2672.53037), assuming a fluid PDL layer density of 1000 kg/m3, a hydrated HA sugar 
density of 1050 kg/m3, and a fluid viscosity of 1 mPa s.  
Assuming the adsorbed film has a uniform thickness and density, f and D can be shown 
as functions of overtone, thickness, density, elasticity, and viscosity.  
Equation 3: Modelling the change in frequency of crystal oscillation 
Δ𝑓 ≈ −
1
2𝜋𝜌𝑞𝑡𝑞
𝑡𝑙𝜌𝑙𝜔 (1 +
2𝑡2𝑋
3𝛿2(1 + 𝑋2)
)   
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Equation 4: Voigt calculation of change in energy dissipation 
Δ𝐷 ≈
2𝑡3𝜌𝑙𝑓𝑚
3𝜋𝑓𝜌𝑞𝑡𝑞
 
1
𝛿2(1 + 𝑋2)
   
Where ρq and tq are the density and thickness of the quartz crystal, ρl and tl are the 
density and thickness of the adsorbed layer, fm is the measured frequency, X the inverse 
of the mechanical loss tangent (tan δ) and is the ratio of the storage modulus (µf) and the 
loss modulus (ηf) as defined in Equation 5. 
Equation 5: Mechanical loss tangent 
tan 𝛿 =  
1
𝑋
=  
2𝜋𝑓𝑚𝜂𝑓
𝜇𝑓
 
 δ is the viscous penetration depth of the shear wave of the bulk liquid (Equation 6) which 
describes the rate of decay of the oscillating wave.  
Equation 6: Viscous penetration depth 
𝛿 =  √
2𝜂𝑓
𝜌𝑓𝑓𝑚
 
Using these equations, the measured f and D values at each overtone can be entered 
along with the assumed density and viscosity so the unknown thickness and density of 
the film can be extracted.  
 
6.2. Contact angle 
For assessing wettability of the surfaces at each stage, contact angle (CA) was measured 
using the static sessile drop method on the Drop Shape Analyser (Model DSA100, Krüss, 
Germany). Each surface was prepared as previously described and 1 L of distilled water 
was dropped onto the sample; an image was acquired and the contact angle, between 
the liquid-solid and the liquid-vapour interface, was calculated using the Circle fit method 
in the Drop Shape Analyser inbuilt software. For all experiments, 3 independent repeats 
were done and contact angle was measured at 3 different locations on each sample. 
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6.3. Atomic force microscopy 
Atomic force microscopy (AFM) enables the nanoscale imaging of a surface and for this 
thesis was used to investigate surface topography and to calculate the average surface 
roughness. AFM uses a rigid tip mounted on a cantilever which scans the sample surface, 
by having a laser trained to the end of the cantilever, above the tip, a detector can be 
used to monitor the deflection of the cantilever. Imaging can be conducted in contact, 
intermittent contact, or non-contact mode, for the studies carried out in chapter III 
intermittent contact was used in Quantitative Imaging (QI) mode using the JPK 
NanoWizard 4 (JPK Instruments AG, Germany). When intermittent contact modes are 
used, the cantilever oscillation is driven at a frequency close to that of its resonance 
frequency and the forces exerted on the cantilever during cycles of sample approach and 
retraction are measured to produce the image. 
To acquire images, samples of bare Au, PDL, HS-Pep-1, PDL-HA and HS-Pep-1-HA were 
prepared as described above and an area of 10 m x 10 m was scanned at a resolution 
of 256x256 pixels, using silicon nitride AFM tips, MSNL-10, with a spring constant of 0.01-
0.06 N/m, and a resonance frequency of 10-20 kHz were used (Bruker AFM Probes, USA). 
From each sample, 3 distinct regions were imaged and 3 independent experiments were 
performed. 
An advantage of using AFM to look at the surface topography of the surfaces is the ability 
to conduct imaging in both hydrated and dried states. Samples to be scanned when 
hydrated were prepared as before and submerged in ultra-pure water prior to imaging. 
Raw images were processed by subtracting the polynomial fit from each scan line 
independently using the JPK Data Processing software. 
6.4. Fluorescence imaging  
To visualise the localisation of Texas Red-labelled HA on surfaces micro-contact printed 
with the HS-Pep-1 SAM, fluorescence microscopy was used. Fluorescence imaging uses 
the ability of fluorophores to emit light of a greater wavelength than the light it was 
excited by. In the case of Texas Red, its peak excitation is at 596 nm and peak emission is 
at 613 nm. 
HS-Pep1 was stamped onto Au substrates and incubated with Texas Red-HA as described 
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previously; images were then acquired using the Leica DMI4000B Epifluorescence 
microscope (Leica, Germany). 
7. Tissue culture 
All the cell studies were performed using either LuC4 or LuC4-GFP human oral squamous 
cell carcinoma-derived immortalised cell lines. Cells were cultured in Dulbecco's Modified 
Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) media (Gibco, Life Technologies Ltd., 
UK), 10% Foetal Calf Serum (FCS), 100 Units/ml penicillin (Sigma), 100 g/ml 
streptomycin (Sigma), and RM+ (Table 2).  
LuC4-GFP cells were generated from LuC4 cells which were transduced with a 
constitutively expressed green fluorescence protein (GFP) plasmid. 227 
Cells were passaged when 85-90% confluent, they were washed with phosphate buffered 
saline (PBS) and incubated at 37 °C with 0.25% trypsin-EDTA (Sigma Aldrich) or cell 
dissociation buffer, enzyme-free PBS-based (Gibco, Life Technologies) until detached. 
Cells were reseeded into new flasks at approximately 250 cells/cm2.  
Table 2: RM+ components, showing final concentration prior to addition to culture medium. 
  COMPONENT FINAL CONCENTRATION COMPANY 
RM+ 
Transferrin 5 µg/ml Sigma 
Hydrocortisone 0.4 µg/ml Sigma 
Cholera toxin 10-10 M Sigma 
EGF 10 ng/ml Serotec 
Insulin 5 µg/ml Sigma 
Liothyronine 2x10-11 M Sigma 
 
7.1. Flow cytometry 
Flow cytometry is a cell analysis technique where cells in suspension are passed by a 
fluidics system, as a stream of single cells, through a laser beam. When a cell is illuminated 
by the laser, features within the cell will deflect light or fluorophores associated with the 
cell are excited and emit fluorescence. The direction in which deflected light is scattered 
is measured and used to determine characteristics of the cell. Forward scattered light 
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(FSC) provides information about the size of the cell, whereas side-scattered light (SSC), 
collected at a 90-degree angle to the laser beam, relates to the granularity or internal 
complexity of the cell. 
When fluorophores are illuminated by the laser, they absorb light and an electron within 
the molecule is elevated to a higher energy state. As the electron returns to its ground 
state, this excess energy is emitted as fluorescence. This is collected by a photomultiplier 
tube (a type of photo detector), converted to an electrical signal and transmitted to the 
computer where it will be displayed on a data plot.  
Fluorophore-conjugated antibodies are used to stain cell samples to determine the 
expression level of each marker protein. As the signal strength is proportional to the 
number of excited electrons, and therefore the number of fluorophores, a stronger signal 
indicates a greater level of expression of the target protein.  
7.1.1. Sample preparation 
For assessment of the expression of cell surface markers CD44 and EpCAM LuC4 cells 
were harvested, as before, with trypsin-EDTA and 5 mL of serum-containing medium was 
added to the cells to stop the action of the trypsin. Cells were centrifuged for at 300g for 
5 minutes at 4 °C and washed with PBS. Cells were re-suspended in PBS and incubated 
for 15 minutes with directly conjugated antibodies, CD44-allophycocyanin (APC, Becton 
Dickinson, US) or EpCAM-phycoerythrin (PE, Miltenyi Biotec Ltd., Germany) diluted 1:100. 
Cells were washed with 5 mL PBS and resuspended in 1 mL of PBS with 200 ng/mL 4′,6-
diamidino-2-phenylindole (DAPI). 
7.1.2. Data acquisition and analysis  
Data were acquired using the BD FACSCanto II (Becton Dickenson). Cells were initially 
gated based on side and forward scatter, to exclude cell debris. DAPI signal was then used 
to exclude dead cells, DAPI is only able to enter the cell if the cell membrane is damaged 
and DAPI positivity identifies cells that are not viable. The DAPI negative cells were plotted 
based on CD44-FITC and EpCAM-APC signal, and a quadrant marker was applied, using 
single-stained and unstained cells to determine the cut-off for negative signals. 
Analysis was performed using FlowJo® version 10.5. 
82 
 
7.2. Fluorescence activated cell sorting 
In addition to looking at the marker profile of cells, flow cytometry can also be used to 
then sort cells based on this information, isolating sub populations of interest for 
downstream applications. This is referred to as fluorescence activated cell sorting (FACS), 
once the cells have passed through the laser and the fluorescence has been detected the 
electronics component can identify if the cell is a target cell, based on the gating strategy 
used. The stream passes through a sort block where positively and negatively charged 
deflection plates deflect each cell into either the specified collection tube or into the 
waste. 
7.2.1. Sample preparation  
For isolation of the EMT (CD44high/EpCAMlow) and Epi (CD44high/EpCAMhigh) populations 
from the LuC4 cell line, for experiments in chapter IV, cells were harvested with trypsin-
EDTA, as before. Cells were centrifuged at 300g for 5 minutes at 4 °C and washed with 
PBS. Cells were resuspended in PBS and incubated with directly conjugated antibodies; 
CD44-FITC (Becton Dickinson, US) and EpCAM-APC (Miltenyi Biotec Ltd., Germany) for 
experiments not including GFP-cells, or CD44-APC and EpCAM-PE for experiments using 
LuC4-GFP. All antibodies were diluted 1:100 and samples incubated for 15 minutes. Cells 
were washed with 5 mL PBS and resuspended in 1 mL of PBS with 200 ng/mL 4′,6-
diamidino-2-phenylindole (DAPI). 
7.2.2. Sample sorting 
Sorted populations were collected using the Aria IIIu Cell Sorter with the assistance of Dr 
Gary Warnes. 
8. Effect of SAM-HA surfaces on human cancer cells 
8.1. AlamarBlue 
To investigate the viability of cells cultured on the fabricated surfaces, their reductive 
capacity was measured using alamarBlue cell viability reagent (Thermo Fisher Scientific, 
US). This is a colourimetric assay where resazurin, the active component in the 
alamarBlue reagent, in its unreduced state is blue and is non-fluorescent. Resazurin is a 
cell permeable compound which, when added to cell medium, enters the cell where it is 
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reduced to resorufin, a red molecule which is highly fluorescent with a peak excitation of 
570 nm and emission of 585 nm (Figure 15). This colour change can be quantified using 
a plate reader to read the fluorescence with an excitation wavelength between 540-570 
nm and monitor the emission wavelength between 580-610 nm. An increase in 
fluorescence should be observed where cells are viable. 
 
Figure 15: Emission spectra of resorufin, shaded curve represents the emission and hollow curve 
represents the excitation spectra. Spectra generated using the fluorescence SpectraViewer 
(Thermo Fisher Scientific).228 
For experiments in chapter III, LuC4 cells were harvested using cell dissociation buffer, 
enzyme free, PBS-based and seeded onto the prepared gold surfaces described in 5.2 at 
a density of 5,000 cells/cm2 in serum-free medium. AlamarBlue cell viability reagent was 
added after 8 hours of culture at a 1:10 dilution and samples were incubated at 37 °C, 5% 
CO2 for 16 hours. To quantify the colour change 100 µL of medium was transferred to a 
96-well plate (Costar, Corning, US) and the fluorescence was measured on the Synergy 
HT plate reader (BioTek, US) at excitation wavelength 530/25 and emission wavelength 
590/35. 
8.2. Scratch assay 
To assess any changes in migration brought by culture on the modified surfaces, LuC4 
cells were detached using cell dissociation buffer and seeded onto the prepared gold 
surfaces described in 3.2 at a density of 10,000 cells/cm2 in serum-free medium. Cells 
were grown to confluency at 37 °C, 5% CO2 and a scratch was made using a 200 µL pipette 
tip. The cell monolayer was washed with PBS to remove any cell debris and images of the 
scratch were captured at 0, 4, 8, 12, 24, and 48 hours using a Nikon Eclipse TE200-S 
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(Nikon, UK). The area of the wound was calculated using ImageJ 1.52a software (National 
Institutes of Health, US).  
8.3. Adhesion assay 
To investigate cell adhesion to the coated Au surfaces, Luc4 cells were harvested using 
cell dissociation buffer and seeded at 10,000 cells/cm2 onto gold surfaces prepared as 
described in 3.2. Samples were incubated for either 6 or 24 hours at 37 °C, 5% CO2. 
Surfaces were then washed with PBS to remove any cells not attached and images were 
taken using a Nikon Eclipse TE200-S and cells counted in ImageJ 1.52a. 
9. Phage display 
In this work, presented in chapter IV, phage display is used as a tool for screening a 
random 12-amino acid peptide library to identify novel sequences which bind to the EMT 
fraction of the LuC4 cell line. The Ph.D-12 Phage Display Peptide Library, purchased from 
New England BioLabs (NEB, US), uses M13 bacteriophage displaying the N-terminal fusion 
protein on the minor coat protein pIII. The library, with a complexity of 109 independent 
clones, is generated by using the M13KE cloning vector to insert DNA sequences into the 
phage genome which will then be expressed on the surface. This method provides a direct 
linkage between the displayed peptide and the encoding genetic information, so 
selection and recovery of phages based on peptide binding affinity to the target will also 
recover the DNA encoding it. 
The M13 bacteriophage is a non-lytic phage, when it infects host bacteria turbid plaques 
are formed due to a reduction of bacterial cell growth. 
Maintenance of M13 phages, bacterial culture, and phage titering were carried out 
according to the Ph.D. Phage Display Libraries Instruction Manual. Panning experiments 
used this manual as a starting point.  
9.1. Media and solutions 
9.1.1. Luria Broth medium 
To make 1 L of LB 20 g of LB Broth (Lennox) powder microbial growth medium (Sigma 
Aldrich) was dissolved in water and autoclaved. The Lennox formulation contains 10 g/L 
tryptone, 5 g/L yeast extract, and 5 g/L NaCl. 
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9.1.2. Tetracycline stock 
A 100x stock solution of Tet was made by dissolving 20 mg of tetracycline (Sigma Aldrich) 
in 1 mL ethanol and water at a 1:1 ratio. Stock was stored at -20 °C and vortexed before 
use. 
9.1.3. IPTG and Xgal stock 
A 100x stock of IPTG/Xgal was made by dissolving 1.25 g IPTG (Sigma Aldrich) and 1 g Xgal 
(Sigma Aldrich) in 25 mL DMF. Stock was stored at -20 °C and vortexed before use. 
9.1.4. Luria Broth and tetracycline agar plates 
LB medium was made as described in 9.1.1 and 15 g/L agar (Sigma Aldrich) was added 
before autoclaving. Subsequently medium was cooled to < 70 °C and Tet stock was added 
at a 1:100 dilution and plates were poured. Once poured plates were stored in the dark 
at 4 °C. 
9.1.5. Luria Broth, IPTG, and Xgal plates 
LB agar was made as described in 9.1.4 and cooled to < 70 °C. IPTG/Xgal stock was then 
added at a 1:100 dilution and plates were poured. Once poured plates were stored in the 
dark at 4 °C. 
9.1.6. Top agar 
LB medium was made as described in 9.1.1, before autoclaving 7 g/L Bacto-agar (Sigma 
Aldrich) was added. Aliquots of 50 mL were stored as a solid at room temperature. Top 
agar was melted in the microwave before use. 
9.1.7. Blocking buffers 
Dulbecco's Modified Eagle Medium: Nutrient Mixture F-12 (DMEM/F-12) media, 100 
Units/ ml penicillin, 100 g/ml streptomycin, RM+ (Table 2), and 1 % (w/v) bovine serum 
albumin (BSA). 
9.1.8. Wash buffer 
Wash buffer was PBS-Tween (PBST, Sigma Aldrich) 0.05 % (v/v) supplemented with 1 % 
(w/v) BSA. 
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9.1.9. Elution buffer 
Non-specific low pH elution was carried out with 0.1 M glycine with 1 mg/mL BSA, pH 2.2. 
9.1.10. Cell lysis buffer 
Lysis buffer was 2 % (w/v) sodium deoxycholate (Sigma Aldrich), 10 mM Tris-HCl, 2 mM 
EDTA, pH8. 
9.1.11. Tris-buffered saline 
Tris-buffered saline (TBS) was made by dissolving Tris-HCl (50 mM, pH 7.5, Sigma Aldrich) 
and NaCl (150 mM) in water and autoclaving. Solution was stored at room temperature. 
9.1.12. Polyethylene glycol sodium chloride  
Polyethlene glycol-8000 (PEG-8000, 20% w/v) was dissolved in 2.5 M NaCl, autoclaved, 
and stored at room temperature. 
9.1.13. Iodide buffer 
Sodium iodide (4 M) was dissolved in 10 mM Tris-HCl (pH 8.0) and 1 mM EDTA and stored 
in the dark at room temperature.  
9.2. Strain maintenance  
9.2.1. Bacterial culture 
The host bacterial strain used for the amplification of M13 bacteriophage was ER2738 
(New England BioLabs). This Escherichia coli (E. coli) strain contains the following plasmid; 
F´ proA+ B+ lacIq Δ(lacZ)M15 zzf::Tn10(TetR) which confers several useful features. Firstly, 
as the M13 phage is male-specific, presence of tetracycline resistance (TetR) in a mini-
transposon within the F-factor (F’) allows selection of F-factor positive cells by using 
media supplemented with tetracycline (Tet). Secondly, the mutation in the lacZ gene 
(Δ(lacZ)M15) which enable blue/white screening. 
The lacZ gene encodes β-galactosidase, an enzyme which cleaves lactose, the gene 
product of the Δ(lacZ)M15 mutation present in the ER2738 strain is the ω-peptide. This 
truncated β-galactosidase is inactive; however, function can be rescued by the co-
expression of the deleted residues called the α-peptide. The M13KE bacteriophage 
genome contains the gene encoding the α-peptide, so only when a ER2738 cell is infected 
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with a phage is a functional β-galactosidase produced. This α-complementation can be 
used for blue/white screening, where M13KE-infected E. coli are propagated on media 
containing isopropyl-β-D-thiogalactopyranoside (IPTG) and 5-bromo-4-chloro-3-indolyl-
β-D-galactopyranoside (Xgal). IPTG induces the expression of the lac operon and Xgal in 
an analogue of lactose which when cleaved by β-galactosidase forms a blue insoluble 
precipitate. Therefore, blue plaques indicate colonies of E. coli which have been infected 
by M13KE phage and white plaques indicate infection by wild-type (WT) phage. 
ER2738 glycerol (Sigma Aldrich) stocks were stored at -80 °C, for used ER2738 was plated 
on a LB+Tet plate and incubated overnight at 37 °C. The plate was stored wrapped in 
parafilm at 4 °C for up to a month and used to start liquid cultures detailed below. 
9.2.2. Phage titering 
To determine the concentration in plaque forming units (pfu), phages were titred by 
infection of ER2739 and plating on LB+Tet plates. 
A mid-log phase, defined by an ocular density at 600 nm (OD600) of around 0.5, culture of 
ER2738 was prepared by inoculation of LB medium and incubation with shaking at 37 °C 
for 6 hours. The phage sample to be titred was serially diluted in LB medium and 10 µL 
was added to 200 µL of the mid-log phase ER2738 culture. Samples were vortexed then 
incubated at room temperature for 5 minutes. Infected bacterial cells were then 
transferred to 3 mL aliquots of top agar, held at 45 °C, samples were vortexed and then 
poured onto pre-warmed LB/IPTG/Xgal plates. Plates were incubated overnight at 37 °C. 
To calculate the titre blue plaques were counted at pfu/10 µL determined by multiplying 
the number of plaques by the dilution factor of each plate. 
9.2.3. Bacteriophage amplification  
9.2.3.1. Amplification of phage pools 
To amplify M13 bacteriophage an overnight culture of ER2738 was diluted 1:100 into 20 
mL of LB medium in a 250 mL Erlenmeyer flask. The culture was then inoculated with the 
phage sample to be amplified and incubated with vigorous shaking at 37 °C for 4 and a 
half hours. 
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9.2.3.2. Plaque amplification of individual clones 
Following titering of phage eluted from the final round of panning, clones were amplified 
separately, so DNA could be extracted and sequenced. An overnight culture of ER2738 
was diluted 1:100 in 1 mL of LB medium. Individual clones were picked, using a pipetted 
tip, to inoculate the culture. Cultures were incubated with vigorous shaking at 37 °C for 4 
and a half hours. Cultures were transferred to a microfuge tube and centrifuged 16,000g 
for 30 seconds, 500 µL was transferred into a fresh tube for DNA extraction (see section 
9.4), 400 µL was transferred to a separate fresh tube and mixed with an equal volume of 
sterile glycerol (VWR, US) for storage at -20°. 
9.2.3.3. Purification of amplified phage pools 
To isolate and purify the amplified phage, the culture was transferred into a centrifuge 
tube and spun at 12,000 g, 4 °C, for 10 minutes to pellet the bacteria. The supernatant 
was transferred to a fresh tube and centrifuged again at 12,000 g, 4 °C, for 10 minutes. 
The upper 80% of the supernatant was transferred to a falcon tube and 1/6 of the volume 
of PEG-NaCl was added. Phages were precipitated overnight at 4 °C. 
The phage/PEG/NaCl mixture was centrifuged at 12,000 g, 4 °C, for 15 minutes, the 
supernatant was discarded and the sample was re-spun. The remaining supernatant was 
carefully removed using a pipette. The pellet was re-suspended in 1 mL TBS and 
transferred to a microfuge tube and the sample was spun at 16,000 g, 4 °C, for 5 minutes. 
The supernatant was transferred to a fresh tube, 1/6 of the volume of PEG-NaCl was 
added and incubated in ice for 1 hour. Samples were centrifuged at 16,000 g, 4 °C, for 10 
minutes, the supernatant was discarded and the sample was re-spun, any remaining 
supernatant was carefully removed using a pipette. The pellet was resuspended in 200 
µL TBS, microfuged for 1 minute at 16,000 g 4 °C and transferred to a fresh tube.  
This purified, amplified eluate can then be titred as described in 7.3. For long-term 
storage at -20 °C, an equal volume of sterile glycerol was added. 
9.3. Cell panning 
To identify phage clones which specifically bind to the target EMT cells, two panning 
strategies were employed. In the first, positive selection was carried out on cell 
monolayers of unsorted LuC4 cells or EMT cells isolated by FACS with a negative selection 
89 
 
carried out on Epi cells also isolated by FACS. The second protocol used a mixture of EMT 
and GFP-Epi cells, isolated by FACS, in suspension. 
9.3.1. Phage display on cell monolayers 
9.3.1.1. Positive selection 
Unsorted LuC4 cells used in were harvested as described in section 5 while EMT and Epi 
CSCs used were isolated by FACS as described in 7.2.  
For all populations, affinity selection was used following the protocol: 1x106 cells were 
seeded into a T25 flask (Corning) and incubated at 37 °C for 24 hours. Before the first 
round of positive selection, ~ 2 x 1011 pfu of the naïve library was diluted in 2 mL of 
blocking buffer and incubated for 1 hour at 37 °C in a fresh T25 flask. This was to deplete 
the phage library of plastic binders. 
Following 24 hours in culture, the target cell population was blocked for 1 hour at 37 °C 
with blocking buffer. Phage library-containing supernatant from the empty T25 flask was 
then transferred to a flask containing the target cell population and incubated for 1 hour 
at 37 °C. Cell monolayers were washed 3 times with wash buffer and bound phages were 
eluted by incubation with the low-pH elution buffer for 20 minutes. The supernatant was 
transferred to an eppendorf and neutralised with 1 M Tris-HCl (pH 9.1). The cell 
monolayer was washed twice with wash buffer, medium was added and cells were 
scraped from the surface. Cells were pelleted by centrifugation at 200 g for 10 minutes 
at 4 °C, cell pellets were lysed with cell lysis buffer.  
After each round of selection, an aliquot of eluted phage was taken for titring as 
described in 9.2.2. Following the first and second rounds of panning, the remaining 
sample was amplified and purified as described in 9.2.3, the titre was then determined 
(see section 9.2.2) 
After the third and final round of positive selection, individual clones were picked, 
amplified, and DNA was isolated for sequencing (see sections 9.2.3.2 and 9.4 
respectively).  
9.3.1.2. Negative selection 
To deplete the phage pool of clones which bind to widely expressed cell surface 
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molecules, panning carried out in chapter IV, a round of negative selection was employed. 
Before the second round of positive selection, ~ 2 x 1011 pfu of the amplified output phage 
of round one were incubated with 1x106 Epi cells, which had been in culture for 24 hours 
and pre-blocked with blocking buffer. Following incubation at 37 °C for 1 hour, the 
supernatant was removed and incubated with the target, EMT, cell population and 
positive selection was carried out as above. 
9.3.2. Suspension panning 
The selection of EMT cell-binding phage clones in suspension used the dilution of target 
cell with non-target cells which act as a ‘sink’ for phage to bind to general cell surface 
markers. To distinguish between target EMT cells and non-target Epi cells, a stably 
expressing LuC4-GFP line was used in addition to the Luc4 cell line used for previous 
selections.  
Cells were dissociated using cell dissociation buffer and cell populations were isolated by 
FACS as described in 7.2. The use of a GFP cell line required a different fluorophore panel 
was used; CD44-APC and EpCAM-PE. EMT cells (CD44high/EpCAMlow) were isolated from 
the non-fluorescent LuC4 line and Epi (CD44high/EpCAMhigh) cells were isolated from the 
LuC4-GFP line.  
For the first round of panning, 1 x 106 LuC4 cells were mixed with 1 x 106 Epi cells in pre-
blocked polypropylene FACS tube in DMEM/F-12 media 10 % FCS, 100 Units/ ml penicillin, 
100 g/ml streptomycin, and RM+. 2 x 1011 pfu of the naïve library was added and cells 
were incubated for 1 hour at 37 °C. Cells were washed 3 times with PBS and resuspended 
in PBS plus DAPI, FACS was used to isolate the GFP-negative target EMT cells. Sorted cells 
were centrifuged at 300g for 5 minutes at 4 °C then lysed with lysis buffer. An aliquot was 
taken to titre the eluted phage as described in 9.2.2. Following the first and second 
rounds of panning the remaining eluate was amplified as described in 9.2.3.1. 
The second round of panning used a 10-fold excess of GFP-Epi cells compared to the EMT 
cells, and was carried out as above.  
The third round of panning used 6-times the number of GFP-Epi cells compared to the 
EMT cells, and was carried out as above. Individual clones were picked and amplified as 
described in 9.2.3.2. 
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9.4. DNA extraction and sequencing 
Once individual phage clones from the third round of panning were picked and amplified, 
individually extraction and sequencing of the M13 phage DNA allows identification of the 
peptide sequence responsible for binding. 
To the 500 µL set aside, following clone amplification as in 9.2.3.2, 200 µL PEG-NaCl was 
added, mixed, and incubated at room temperature for 20 minutes. Samples were 
microfuged at 16,000g for 10 minutes at 4 °C and the supernatant was discarded. Tubes 
were re-spun briefly and residual supernatant was removed with a pipette. The pellet 
was resuspended in 100 µL of iodide buffer, 250 µL of ethanol was added and samples 
were incubated for 20 minutes at room temperature to precipitate the single stranded 
DNA. Samples were microfuged at 16,000g for 10 minutes at 4 °C and the supernatant 
was discarded. Pellets were washed with 500 µL ice-cold 70 % ethanol, re-pelleted and 
the supernatant was removed with a pipette. Pellets were dried for 5 minutes under a 
vacuum (Eppendorf® centrifugal vacuum concentrator, Germany). Pellets were re-
suspended in TE buffer (10 mM Tris-HCl, 1 mM EDTA) and stored at -20 °C. 
DNA was quantified using the Nanodrop ND-100 spectrophotometer (Labtech, UK) and 
aliquots were sent to Source Bioscience for Sanger sequencing using the -96 gIII 
sequencing primer 5´- HOCCC TCA TAG TTA GCG TAA CG –3´. 
DNA sequences were processed using CLC Sequence Viewer version 8. 
9.5. Assessment of phage binding 
9.5.1. Enzyme-linked immunosorbent assay 
To determine the ability of isolated clones to bind to the target cells, an enzyme-linked 
immunosorbent assay (ELISA) was used. The page binding ELISA uses a horseradish 
peroxidase (HRP)-conjugated mouse antibody, α-M13-HRP (GE Healthcare, US), which 
recognises the VIII coat protein on M13 bacteriophage.  
The ELISA works based on the principle that, the α-M13-HRP will bind to M13 phages, 
which are bound to target molecules on the LuC4 cells. On addition of a substrate for 
HRP, a colour change is seen that is proportional to the amount of antibody binding and 
therefore the amount of M13 bound to the target. 
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There are several HRP substrates which can be used in ELISAs, 3,3′,5,5′-
Tetramethylbenzidine (TMB, Sigma Aldrich) is oxidised by HRP (Figure 16) to produce 
3,3',5,5'-tetramethylbenzidine diimine which has a blue colour. When the reaction is 
stopped using sulfuric acid, the colour changes to yellow which can be measured at 450 
nm. TMB was selected for use in these studies as it is very sensitive to HRP so can produce 
a colour change more rapidly than other substrates. 
 
Figure 16: Oxidation of 3,3',5,5'-tetramethylbenzidine, by horseradish peroxidase to 3,3',5,5'-
tetramethylbenzidine diamine. Image modified from product information (Sigma Aldrich).229  
9.5.1.1. Cell monolayer 
During optimisation of the method, detailed in chapter IV, and subsequent applications 
of the technique, all experiments used the following general protocol. Cells were 
harvested with trypsin-EDTA and seeded into a 96-well plate at a density of between 
5,000 and 20,000 cells/well. Cells were incubated for 48 hours at 37 °C, 5% CO2, medium 
was removed and blocked in PBS 3% BSA (or as described) for 1 hour at 37 °C. 
Approximately 1x109 pfu of individual amplified phage clones was added to each well in 
blocking buffer and incubated for 1 hour at 37 °C. Cells were washed 3 times with PBST 
(0.05%) and HRP-conjugated anti-M13 antibody was added in block buffer diluted 1:5000 
and plates were incubated for 1 hour at 37 °C. Cells were washed 3 times with PBST 
(0.05%) and TMB, the HRP substrate solution, was added. Plates were incubated at room 
temperature for 45 minutes and the reaction was stopped by addition of 1 M H2SO4. 
Absorbance values were measured on the Synergy HT plate reader at 450 nm and 540 
nm.  
9.5.2. Cell suspension 
To assess the binding of the clone selected by FACS-assisted panning, the ELISA detailed 
93 
 
in 6.6.1.1 was modified so phage binding could be carried out on cells in suspension. EMT 
and Epi cell populations were isolated by FACS, described in 4.2, seeded into tissue 
culture flask and incubated for 48 hours at 37 °C, 5% CO2. Cells were dissociated using 
cell dissociation buffer and washed with PBS. ~ 1 x 105 cells were transferred into 
polypropylene FACS tubes. Approximately 5x109 pfu were added to the cells, in block 
buffer (9.1.7), and incubated for 1 hour on ice. Cells were washed with PBS anti-M13-HRP 
was added (1:5000) in block buffer and incubated for 1 hour on ice. Cells were washed 
and were transferred to a fresh tube. TMB the HRP substrate was added and tubes were 
incubated for 20 minutes at room temperature. Reaction was stopped by addition of 1 M 
H2SO4 and 100 µL of supernatant was transferred to a 96-well plate. Absorbance values 
were measured on the Synergy HT plate reader at 450 nm and 540 nm. 
9.5.3. Flow cytometry  
To assess phage binding by flow cytometry, cells were harvested with either trypsin-EDTA 
or cell-dissociation reagent, for clones identified by methods in 9.3.1 or 9.3.2, 
respectively.  
Cells were washed, and resuspended in PBS. Samples were incubated with ~1x108 pfu of 
a single clone in block buffer for 1 hour on ice. Cells were washed and anti-M13 was 
added (1:5000) in block buffer and incubated for 1 hour on ice. Cells were washed and 
Alexa fluor 488 goat anti-mouse secondary antibody (Thermo Fisher Scientific) was added 
in block buffer and incubated for 1 hour on ice. Samples were washed twice and 
transferred to a fresh tube, CD44-APC and EpCAM-PE were added (1:100) in block buffer 
and incubated for 15 minutes. Samples were washed for the final time and resuspended 
in PBS-DAPI (200 ng/mL).  
Double stained (CD44-APC and EpCAM-PE) samples were used to assess the presence of 
the EMT sub-population and control samples were used to determine thresholds for 
positive and negative signals (Table 3). The same antibodies were used in both the Alexa 
fluor 488 positive and negative samples, however, the order in which they were 
incubated with the cells was different. The CD44 and EpCAM antibodies are murine 
antibodies, and as such the Alexa fluor 488 goat anti-mouse will bind to them, which 
would produce a positive signal even in the absence of the anti-M13 which is its target in 
this assay. For the Alexa fluor 488 positive sample, the CD44 and EpCAM antibodies were 
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added first and the Alexa fluor 488 was added subsequently. For the Alexa fluor 488 
negative sample, the 488 was incubated with the cells, which were then washed before 
the other antibodies were added. Antibodies which were added first are denoted by * in 
Table 3. 
Table 3: Antibody staining of control samples for detection of phage binding by flow cytometry. 
Where an X indicates the used of antibody in the staining mix. 
 PHAGE 
ANTI-
M13 
ALEXA 
FLUOR 
488 
CD44-
APC 
EPCAM-
PE 
EPCAM-
APC 
UNSTAINED 
- - - - - - 
SECONDARY ONLY 
- - X - - - 
CD44-APC  
ONLY 
- - - X - - 
EPCAM-PE  
ONLY 
- - - - X - 
EPCAM-APC ONLY 
- - - - - X 
ALEXA FLUOR 488 
POSITIVE  
- - X* X X - 
ALEXA FLUOR 488 
NEGATIVE 
- - X X* X* - 
STANDARD CSC 
STAIN 
- - - X X - 
 
10. Effect of HA glycopolymerson cancer cells  
To investigate the biological properties of the HA glycopolymers described in section 4 
two assays were performed to ensure that the polymers were non-toxic and to see if they 
altered the sphere-forming ability of HNSCC cells.  
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10.1. Live dead assay 
Before cell behaviour assays could be carried out, the LIVE/DEAD™ Viability/Cytotoxicity 
Kit for mammalian cells (Invitrogen), was used to assess cell viability following treatment 
with the synthetic polymers. The two-colour fluorescence assay used Calcein 
acetoxymethyl (AM) to label live cells and Ethidium homodimer-1 (EthD-1) to label dead 
cells. Calcein AM is a non-fluorescent molecule which is cell-permeable, once inside the 
cell hydrolase enzymes are able to convert it to the fluorescent calcein, which has a peak 
excitation of 495 nm and peak emission is at 517 nm. As dead cells are not enzymatically 
active they are not stained green by calcein. Conversely, EthD-1 is not able to cross the 
intact cell membrane, so is excluded from live cells and once it has entered dead cells it 
will bind to DNA which increases fluorescence intensity. EthD-1 has a peak excitation of 
528 nm and peak emission is at 617 nm. 
The kit was used as per manufacturer’s instructions, briefly LuC4 cells were seeded at 
5,000 cells per well into a 96 well plate and cultured in a humidified atmosphere at 37°C, 
5% CO2 for 48 hours. Cells were treated with glycopolymers at a range of concentrations, 
100, 10, 1, 0.1 µg/mL, and incubated for 24 hours. Medium was removed and Live/dead 
stains were added, diluted in PBS and incubated for 1 hour at 37°C. Fluorescence was 
read at ex: 485/20, em: 528/20 and ex: 530/25, em: 590/35 using Synergy HT. The 
number of live and dead cells was calculated as a percentage compared to controls (see 
Table 4) and analysis was carried out using Prism 7 (GraphPad, US). 
Table 4: Live/dead viability/cytotoxicity assay controls. Where an X indicates the cell viability, 
dye, and presence of glycopolymer in each control group. 
 
CELL TYPE CELL STAIN 
 
 
Live Dead Calcein AM EthD-1 Glycopolymer 
LIVE CELL POSITIVE X - X - - 
DEAD CELL NEGATIVE X - - X - 
LIVE CELL NEGATIVE - X X - - 
DEAD CELL POSITIVE - X - X - 
GLYCOPOLYMER CONTROL - - X X X 
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10.2. Sphere assay 
The ability of cells to form spheres in culture has historically been used as an indicator of 
stem-cell potential.230 When cells are seeded at a low density in non-adherent plates, a 
fraction of cells is able to proliferate and form spheres which can grow in suspension, 
thus satisfying the self-renewal component of stem cell requirements.   
10.2.1. Non-adherent plate formation 
Non-adherent plates were prepared by coating with Poly(2-hydroxyethyl methacrylate) 
(polyhema, Sigma Aldrich). A 12 mg/mL solution of polyhema was made up in 95% 
ethanol and 200 µL was transferred to each well of a 24-well plate (Corning). Plates were 
left to dry inside a closed tissue culture hood, with the lid off, overnight. Plates were 
stored at 4 °C until needed. 
10.2.2. Plating cells for spheres  
Cells were isolated as described in section 4, passed through a 100 µm filter to ensure a 
single cell suspension, and counted. Cells were resuspended in medium, as defined in 
section 7, containing 1% methylcellulose (Sigma Aldrich). They were then plated at a 
density of 1000 cells/ well in the polyhema-coated plates and treated with either HA or 
glycopolymers as stated. Plates were incubated at 37 °C, 5% CO2 for two weeks, formation 
of spheres was monitored throughout and images were acquired with the IN Cell Analyzer 
2200 (GE Healthcare, US). Analyses were performed using GE Developer Toolbox 1.9.2, 
ImageJ 1.52a software, and Prism (GraphPad). 
11. Statistical Methods  
Statistical analyses were carried out using GraphPad Prism software version 7.0. Standard 
deviation (SD) is a measure of the variation with in a data set and was used to assess the 
spread of the data about the mean. It was calculated using Equation 7.   
Equation 7: Standard Deviation 
𝑠 =  √
∑ (𝑥𝑖 − 𝑥)2
𝑁
𝑖=1
𝑁 − 1
  
To determine any statistically significant differences present between experimental 
groups Analysis of variance (ANOVA) was used. A one-way ANOVA was used to compare 
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the means of data from experiments investigating one factor, where grouped data were 
collected and the effects of two factors were investigated a two-way ANOVA was used.  
Multiple comparisons testing was carried out following both one- and two-way ANOVA, 
the Tukey-Kramer test was selected to calculate multiplicity adjusted P values as the 
mean of each group was compared to the mean of each of the other groups.   
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SECTION 3: RESULTS AND DISCUSSION 
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Chapter III: Supramolecular Presentation of Hyaluronan onto Model Surfaces for 
Studying the Behaviour of Cancer Stem Cells 
1. Introduction 
The ability to fabricate well-defined substrates to control and investigate cell behaviour 
provides a useful tool for in vitro cell culture. For instance, it is increasingly important for 
the regulated production of in vitro-expanded or differentiated cells for cell-based 
therapies. In this regard, self-assembled monolayers (SAMs) can provide a rapid and 
simple method for fabricating well-ordered surfaces with a wide range of useful 
functionalities.  
SAMs provide a useful platform for high-throughput screening of peptide-cell 
interactions to identify surfaces able to elicit the desired effect on cells in culture.101,201,231 
They have been successfully employed to influence cell adhesion, support proliferation, 
and direct differentiation or even maintain pluripotency of stem cells.194–196,198,199 One 
potential benefit from using SAMs in cell expansion is the elimination of the need for 
animal-derived products to support cell proliferation, which is crucial for the expansion 
of cells which are to be used in cellular therapies.  
The interaction between SAMs and cell culture components, in the form of either cells or 
serum proteins, can be exploited to examine in more detail the role of such proteins in 
cell behaviour. For example, how the conformation of adsorbed fibronectin impacts the 
way in which it interacts with cells, influencing adhesion, focal adhesion formation, cell 
spreading, and differentiation.198,232,233 In addition, the density and spacing of functional 
groups can be controlled234 and the use of micro-contact printing (CP) enables SAMs to 
be formed in discrete patterns, which can be used to further regulate cell adhesion and 
even migration.200,206 
However, the use of SAMs for the non-covalent immobilisation of individual extracellular 
matrix (ECM) components is less frequently used. Hyaluronic acid (HA) is the only non-
sulfated glycosaminoglycan (GAG) which comprises a large part of the ECM of many 
tissues. It is made up of alternating D-glucuronic acid and N-acetyl-D-glucosamine 
monomers, containing hydrophilic and hydrophobic patch domains.61,66 While the 
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hydrophilic carboxyl, hydroxyl and acetamido groups confer high water solubility to HA, 
the hydrophobic regions, created by axial hydrogen atoms, can reversibly interact with 
each other to form a meshwork. In addition, hydrogen bonding between the hydrophilic 
side groups contributes to the porous mesh-like structure which is formed in solution, 
and retains water. Internal swelling pressure is generated on compression of HA networks 
and, when this pressure is released, mutual repulsion between carboxyl groups allows a 
return to its original shape.63 In vivo, this is a key  characteristic which significantly 
contributes to the viscoelastic properties of several tissues, including cartilage235 and the 
vitreous humour.64 
These features make HA a very promising biomaterial for biotechnological and 
biomedical applications. Through chemical crosslinking, robust hydrogels can be created 
whose mechanical characteristics can be precisely tuned by the type and degree of 
crosslinking.236 Additionally, HA can be modified to incorporate signalling molecules 237 
or cell binding peptides238 to stimulate cell adhesion and proliferation, or be used to 
functionalise scaffolds to the same effect239 and to direct cell differentiation.237,240 
In addition to its desirable biophysical characteristics for use in bioengineering, HA itself 
interacts with cells via cell-surface receptors such as CD44 and receptor for hyaluronan-
mediated motility (RHAMM), eliciting a range of cellular responses. HA is also seen to 
accumulate in the tumour microenvironment, and signalling via these receptors, can 
support metastasis, cancer cell proliferation, and multidrug resistance.59,74,217,241,242 
Within head and neck squamous cell carcinoma (HNSCC) there is a sub-population of 
stem-like cells (herein referred to as cancer stem cells or CSCs) with tumour-initiating 
potential and the ability to restore tumour heterogeneity.6 These cells are thought to play 
an important role in tumour progression and are identified predominantly by their higher 
CD44 expression levels.6,15 It has been demonstrated that signalling downstream of HA-
CD44 interactions can regulate stem cell markers and highlights the role of HA in HNSCC 
progression.243,244 
Due to the pivotal role of HA in many cellular processes, numerous strategies have been 
developed to immobilise HA on surfaces, aiming to study its effects in a 2D in vitro 
environment. These approaches often require the chemical modification of native HA by 
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biotinylation,84 conjugation to dopamine,86,87 thiolation,88 azidation,89 or 
functionalisation of surfaces to allow covalent attachment of HA.90–93  
However, such modifications can interfere with the native properties of HA. For example, 
thiolation has been shown to inhibit HA degradation by hyaluronidases,96 and influence 
its conformation once immobilised. Altered presentation of macromolecules has been 
shown to affect cell adhesion and highlights the sensitivity of mammalian cells to their 
culture environment and the importance of creating well-defined surfaces for in vitro 
studies of cell behaviour.97,98 
Herein, we demonstrate a straightforward platform for the immobilisation of HA in its 
native form on a gold surface using a SAM consisting of a thiolated HA-binding peptide.131 
To the best of our knowledge, the supramolecular assembly of HA using HA-binding 
peptides has not yet been exploited to study the effects of HA in vitro. We believe that 
this approach provides important advantages over the previously mentioned 
methodologies. Firstly, it does not require any chemical modification of HA, thus allowing 
a more biomimetic presentation similar to the natural ECM. Secondly, our method is 
simple and rapid, while offering precise control over HA presentation, which is 
advantageous when attempting to control cell behaviour.  
2. Results and Discussion 
2.1. Thiolated HA-binding peptide for and the supramolecular presentation of HA 
In this work, we have taken a 12-amino acid HA-binding peptide identified through phage 
display, named Pep-1, to produce SAMS on gold via peptide thiolation at the N-terminal 
(Figure 17A). Alanine scanning revealed that there are six residues which are required for 
Pep-1-HA binding, these residues are organised in two groups of three at positions 4,5,6 
and 9,10,11.131 Of these amino acids four are non-polar, as such it is hypothesised that 
hydrophobic-hydrophobic interactions between these residues and the hydrophobic 
patches present on HA are responsible for binding.132  
It has been suggested that the free N-terminal in phage-displayed peptides may be 
important for sequence binding function. So it is possible that as our system tethers the 
N-terminal to the Au surface, and the C-terminal of the peptide is free, that binding may 
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be affected. However, we anticipate that the repeating disaccharide structure of HA, 
means that there are not discreet binding sites and Pep-1 is able to interact along the 
length of the molecule. Additionally, immobilisation of Pep-1 via the N-terminal has 
previously been demonstrated to have no obvious effect on HA-binding ability.133 
 
Figure 17: Chemical structure of peptides used: thiolated Pep-1 (A) and acetylated Pep-1 (B) drawn 
in Chemdraw Prime 17.1 
 
This peptide has a distinct sequence which does not contain the consensus domain 
observed in several HA-binding proteins, including CD44 and RHAMM.131 The assessment 
of this peptide’s binding ability to HA-coated beads has revealed a dissociation constant 
(Kd) value of ~ 1.65 µM.131 Studies into the function and effects of Pep-1 have been 
conducted,245 demonstrating its ability to bind HA in solution, immobilised on a surface 
or in complex with cells both in vitro and in tissue sections.132,213 On binding, Pep-1 
influences HA-mediated signalling and has been used as an inhibitor of HA function.134,246 
It has previously been modified and subsequently used to form a peptide layer on human 
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cartilage samples and contact lenses, which sequestered HA, improved water retention 
and resulted in an enhanced surface lubrication.133,247 The covalent bond between thiol 
groups and gold (Au) is well-known and is often used in the formation of SAMs on Au 
substrates. As such, we expect that the thiolated Pep-1 (herein referred to as HS-Pep-1) 
will form a monolayer on Au, which can further immobilise HA in its native form. Figure 
18 illustrates the proposed model for HS-Pep-1 SAM formation (Figure 18B) on an Au 
surface (Figure 18A) and the subsequent immobilisation of HA (Figure 18C) and 
interaction will mammalian cells (Figure 18D). To confirm that the HS-Pep-1 binds to the 
Au substrate, we used both quartz crystal microbalance with dissipation (QCM-D) 
monitoring and water contact angle to monitor changes in the film’s hydrated thickness 
and areal mass density, as well as in the surface hydrophobicity, respectively.  
 
Figure 18: Illustration of the proposed supramolecular immobilisation of HA on surfaces to study 
cell behaviour. Bare gold surface (A), incubated with a solution of HS-Pep-1 to form a SAM (B) 
which can bind HA (C) and in turn can be used to probe HA interactions with cells in culture (D). 
 
Using QCM-D apparatus, a decrease in the resonance frequency, normalised to the 7th 
overtone (n = 7; 35 MHz; Δf7/7), was observed as a function of time following the addition 
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of a 0.01 mM aqueous solution of HS-Pep-1 (-18.7±1.2 Hz). This decrease in the Δf7/7 was 
maintained following washing steps (Figure 19), which reveals the strong interaction of 
the HS-Pep-1 layer with the Au surface. At the same time, a negligible shift in the energy 
dissipation factor was obtained at the 7th overtone (ΔD7 < 0.3×10-6). The very low 
dispersion in the Δfn/n confirms that HS-Pep-1 adsorbs rigidly onto the Au surface (Figure 
19).  
 
Figure 19: Representative QCM-D data for the normalised frequency (Δfn/n) and dissipation (ΔDn) 
shifts obtained as a function of time for the deposition of HS-Pep-1 (1) onto Au-coated quartz 
crystal sensors and intermediate rinsing steps (2). 
Therefore, the adsorbed HS-Pep-1 layer can be considered as a rigid film and, thus, the 
Sauerbrey equation can be used to estimate the areal mass density of the adsorbed HS-
Pep-1 layer (ΔmSauerbrey = 329.6±65.5 ng/cm2). Based on this assumption, the QCM-D data 
and the Sauerbrey relationship were also used to estimate the thickness of the adsorbed 
HS-Pep-1 layer (hSauerbrey = 3.3±0.6 nm). However, as the film is hydrated, one should bear 
in mind that the obtained areal mass density of the film may include the mass of the 
adsorbed layer plus coupled solvent. Therefore, for comparison, the areal mass density 
and hydrodynamic thickness of the adsorbed HS-Pep-1 layer were also estimated using 
the Voigt-based viscoelastic model Table 5. In addition to the observed changes in the 
normalised frequency and energy dissipation shifts, the water contact angle decreased 
from 76.9±6.2° on bare Au, to 66.7±2.7° after incubation with a 1 mM ethanolic solution 
of HS-Pep-1 (Figure 20D, E). This indicates an increase in the hydrophilicity and a change 
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in the surface chemistry of the Au, through HS-Pep-1 deposition. A further decrease in 
the water contact angle to 57.9±4.2° was observed when the surfaces coated with the 
HS-Pep-1 SAM were exposed to an aqueous solution of 1.5 MDa HA (Figure 20D, E), 
indicating that the overall surface became more hydrophilic. This decrease in 
hydrophobicity upon HA binding was expected due to the high number of hydroxyl and 
carboxyl groups present in HA which confer its high water solubility. This value is higher 
than those reported in the literature, where values of 24.8±0.1° and 12.8±0.6° were 
obtained for similar HA-coated surfaces. However, in those cases HA was immobilised by 
co-deposition with poly-dopamine or by covalent attachment to the Au surface, 
respectively.35, 38 Such differences in the immobilisation methods can be proposed as the 
main reason for the discrepancy between these values and the ones obtained in the 
current study reaching values of 354.1±96.6 ng/cm2 (ΔmVoigt) and 3.7±1.0 nm (hVoigt), 
respectively. These values are in the range of those obtained using the Sauerbrey model, 
thus meaning that the obtained areal mass density and thickness are mainly assigned to 
the adsorption of the HS-Pep-1 layer, and the effect of the coupled solvent can be 
considered negligible. 
A further decrease in the Δf7/7, and thus increase in the areal mass density, as well as an 
increase in the ΔD7, was seen after the adsorption of the HA biopolymer (1.5 MDa) onto 
the HS-Pep-1-coated Au surface, reaching values of -9.1±2.7 Hz and (1.8±0.2) ×106, 
respectively (Figure 20A). The overtones become separated after the addition of the HA 
layer, which is a typical behaviour of a soft and hydrated film (Figure 21). This reveals the 
viscoelastic behaviour of the adsorbed HA layer, which is a common characteristic of most 
polymeric systems.248,249 Therefore, the Voigt-based viscoelastic model was used to 
estimate the areal mass change (1154.0±492.1 ng/cm2) and the hydrodynamic thickness 
(10.8±4.8 nm) of the adsorbed 1.5 MDa HA layer. This is within the thicknesses reported 
in the literature, Choi et al.  see a HA layer thickness of between 8.9 and 2.1 nm depending 
on the pH. Their work also suggests that depending on the pH of the HA solution the 
amount of HA deposition can be controlled. 
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Figure 20: HS-Pep-1 attaches to an Au substrate which can then bind HA. Representative QCM-D 
data showing the normalised frequency (Δfn/n) and dissipation (ΔDn) shifts obtained at the 7th 
overtone (n = 7; 35 MHz) as a function of time for the deposition of HA onto HS-Pep-1 (A), Ac-
Pep-1 (B), or PDL (C) modified Au-coated quartz crystal sensors with intermediate rinsing steps. 
Numbers refer to the adsorption of HS-Pep-1, Ac-Pep-1, or PDL (1), 1.5 MDa HA (3), and rinsing 
steps (2 and 4). The addition of a 0.01 mM HS-Pep-1, 0.01 mM Ac-Pep-1, or 0.1 mg/mL PDL in 
150 mM NaCl (1) leads to a decrease in the frequency shift which is maintained upon washing (2). 
The addition of 1.5 MDa HA in 150 mM NaCl (3) to HS-Pep-1 or PDL-coated crystals causes a 
further decrease in frequency shift (A and C). The addition of 1.5 MDa HA in 150 mM NaCl (3) to 
Ac-Pep-1 coated crystals did not alter the frequency. Water contact angle images of the prepared 
surfaces (D) and a graph showing the average contact angles for all surfaces (E). n=3, error = SD, 
****= p<0.0001, ***=p<0.001 compared to bare Au control (one-way ANOVA with Tukey’s 
multiple comparison). 
107 
 
For comparison, when acetylated Pep-1, without the thiol group (herein referred to as 
Ac-Pep-1) was used, a smaller decrease in the Δf7/7 (-10.5 Hz) was seen, which was 
maintained upon washing (Figure 20B). To explain these results, we hypothesise that the 
Ac-Pep-1 was able to interact with the bare Au surface through the positively charged 
arginine residues (i.e. amino groups) at the C-terminal of the peptide. This would also 
explain the lack of adsorption of the negatively charged HA onto the Ac-Pep-1-modified 
Au surface as the amino groups would be inaccessible and the acetyl groups would not 
interact with the HA (Figure 20B). 
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Figure 21:  QCM-D measurement of the normalised frequency (Δfn/n) and dissipation (ΔDn) shifts 
with a range of HA molecular weights. Representative QCM-D data for Δfn/n and ΔDn as a function 
of time for the deposition of HA onto HS-Pep-1- and PDL-modified Au-coated quartz crystal 
sensors and rinsing steps. Numbers refer to the adsorption of (1) HS-Pep-1 (A, C, E) or PDL (B, D, 
F), (2) rinsing step, the adsorption of (3) 20 kDa HA (A, B), 200 kDa (C, D) or 1.5 MDa HA (E, F) and 
a further (4) rinsing step. For both HS-Pep-1 and PDL their addition in an aqueous solution of 150 
mM NaCl leads to a decrease in frequency shift which is maintained on washing. A further 
decrease in frequency shift was seen on addition of each HA molecular weight, which was also 
maintained on washing. 
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Table 5: Average changes in Δf7/7 (Hz) and ΔD7 at the equilibrium, as measured by QCM-
D, and modelled thickness (h, nm) and areal mass density (Δm, ng/cm2), derived using 
the Sauerbrey equation and the Voigt-based viscoelastic model. Values show a decrease 
in frequency and an increase in dissipation when HA solution is incubated with different 
surfaces. All values are the average of at least 3 independent experiments ± SD.* denotes 
experiment with only 2 independent repeats.  
 Δf7/7 (Hz) ΔD7  
(x10-6) 
Voigt 
Thicknes
s, hVoigt 
(nm) 
Voigt Mass 
Density, ΔmVoigt 
(ng/cm2) 
Sauerbrey 
Thickness, 
hSauerbrey 
(nm) 
Sauerbrey Mass 
Density, 
ΔmSauerbrey 
(ng/cm2) 
Adsorption onto Au  
HS-Pep-1 -18.7±1.2 0.3±0.3 3.7±1.0 354.1±96.6 3.3±0.6 329.6±65.5 
PDL -12.4±1.5 0.7±0.3 12.9±3.6 1276.0±366.4 - - 
Adsorption onto HS-Pep-1  
1.5 MDa HA -9.1±2.7 1.8±0.2 10.8±4.8 1154.0±492.1 - - 
200 kDA HA -9.7±2.5 1.4±0.4 10.4±1.4 919.5±329.5 - - 
20 kDa HA -5.5±1.1 0.6±0.2 5.4±1.8 640.0±147.3 - - 
Adsorption onto PDL  
1.5 MDa HA -16.1±0.3 2.4±0.3 12.1±6.6 1342.0±653.7 - - 
200 kDA HA -11.5±1.6 1.5±0.4 3.8±1.5 396.7±166.2 - - 
20 kDa HA* -9.7±0.4 0.5±0.1 1.6±0.4 270.0±99.0 - - 
 
The direct exposure of the Au surface to an aqueous solution of HA, in the absence of a 
HS-Pep-1 SAM, did not result in a change in the contact angle (Figure 20D, E) or deposition 
onto the bare Au surface (Figure 22).  
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Figure 22: Representative QCM-D data for the normalised frequency (Δfn/n) and dissipation (ΔDn) 
shifts as a function of time for the deposition of 200 kDa HA on Au-coated quartz crystal sensors 
and rinsing steps. Numbers refer to the adsorption of (1) HA and (2) rinsing step. The addition of 
HA aqueous solution in 150 mM NaCl leads to a decrease in frequency shift which is reversed on 
washing. This result shows negligible HA adsorption onto the Au-coated quartz crystal. 
Taken together, these results demonstrate that the immobilisation of HS-Pep-1 onto the 
Au surface leads to a rigid film and does not inhibit its ability to bind HA through the 
arginine residues at the C-terminal. Hence, it can be used for the supramolecular 
presentation of HA. This system could be advantageous over other platforms for in vitro 
studies, due to the ease of HS-Pep-1 monolayer formation without loss of HA-binding 
ability. Moreover, it does not require multi-step chemical modification of the surface or 
the chemical modification of HA. The supramolecular immobilisation involves weaker 
attractive forces (electrostatic interactions between negatively charged HA and the 
positively charged HS-Pep-1-modified Au surface), therefore producing a more 
physiologically relevant platform for the investigation of cell behaviours.  
 
2.2. HA immobilisation using HS-Pep-1 and poly-D-lysine model surfaces 
To probe any differences in HA deposition between our system and existing methods, 
poly-lysine was used as a model surface for comparison. Poly-lysine is a positively charged 
hydrophilic polyelectrolyte at a physiological pH (pKa ~10.5218) and is frequently used in 
layer-by-layer assembly studies in combination with oppositely charged HA.250 Poly-lysine 
111 
 
readily adsorbs onto prepared surfaces and due to its positive charge can immobilise HA 
through ionic interactions. As reported in the literature, poly-D-lysine (PDL) has been 
used to minimise any degradation of adsorbed layers by inherent cellular enzyme 
activity.219 
The QCM-D data showed a decrease in the Δf7/7 signal and an increase in ΔD7 when the 
aqueous solution of PDL was introduced into the system, which demonstrates the 
adsorption of PDL onto the bare Au surface (Figure 20C). Again, the rinsing step led to 
negligible changes in both the Δf7/7 and ΔD7 values, thus suggesting the strong 
association of the PDL, as well as the irreversible nature of the adsorption process. A 
further decrease in the Δf7/7 was observed after the addition of an aqueous solution of 
1.5 MDa HA onto the PDL-modified Au surface, indicating HA immobilisation (Figure 20C). 
The comparison of the deposition of HA onto the HS-Pep-1 (Figure 20A) and PDL (C) 
modified Au surfaces reveals a greater decrease in the Δf7/7 signal for the adsorption of 
HA onto the PDL-modified Au surface, -9.1±2.7 Hz compared with -16.1±0.3 Hz, 
respectively. The Voigt-based viscoelastic model was used to determine the areal mass 
density and hydrodynamic thickness of the HA layer adsorbed onto PDL, reaching values 
of 1342.0±653.7 ng/cm2 and 12.1±6.6 nm, respectively (Table 5). 
It should be noted that the SD of the thickness and mass density calculations is not 
insignificant. As such it is important to consider this when drawing conclusions from the 
results, and it indicates that there is variability in the thickness and mass each time the 
films are formed. To provide greater confidence in the reliability of the data, and to get a 
more accurate gauge of the mass and thickness of the deposited HA further repeats 
should be carried out. 
These results indicate that HS-Pep-1 is capable of immobilising HA in a similar manner to 
that of PDL; we believe that using the HS-Pep-1 based system offers a number of 
advantages above those of PDL. Primarily due to the specificity of Pep-1-HA binding, this 
has been demonstrated extensively throughout the literature. Using Pep-1 as a probe for 
detecting HA in tissue samples showed that staining was eradicated if samples were pre-
treated with hyaluronidases.132 Pep-1 was also shown to have significantly higher binding 
to HA-coated beads when compared to chondroitin sulphate-coated beads, in fact the 
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levels of Pep-1 binding to  CS beads was equivalent to binding following enzymatic 
digestion of HA. 131 This level of specificity could contribute to the formation of HA 
surfaces containing fewer contaminants, which in turn could lead to greater consistency 
between experiments. The use of a self-assembling system, driven by the Au-S 
interaction, means that the localisation of peptide, and therefore HA, can easily be 
controlled and surfaces can be patterned using simple contact printing protocols. This 
ability is demonstrated in subsequent experiments detailed in section 2.4. 
The average water contact angle of the PDL-coated Au was 25.4±8.6 which did not 
change significantly on incubation with HA, 21.8±5.8, indicating a highly hydrophilic 
surface (Figure 20D, E). These results demonstrate that the immobilisation of HA by HS-
Pep-1 SAM creates a surface with lower hydrophilicity when compared with its 
immobilisation by PDL. The sequence of HS-Pep-1 (Figure 17B) contains several 
hydrophobic domains, indicating it is less hydrophilic compared to PDL. As such, the lower 
hydrophilicity of the HS-Pep-1-HA surface may be due to incomplete HA coverage of the 
surface, resulting in patches of the surface where the peptide is exposed; we observe 
greater deposition of HA on PDL, which would corroborate this explanation. Conversely, 
regions where the PDL is exposed can contribute to the higher hydrophilicity 
demonstrated by the PDL-HA surface.  
2.2.1. Effect of HA molecular weight on immobilisation 
HA of different molecular weights (MWs) is known to be present throughout biological 
fluids and tissues,251 while exogenous HA has been shown to elicit different effects on cell 
behaviours both in vitro and in vivo. Lower, but not high MWs, can induce maturation of 
dendritic cells and are seen to be immunogenic.252,253 Additionally, oral administration of 
high WM HA can modulate inflammation in mouse models of autoimmune disease.254 
Using QCM-D, we have further analysed the effect of HA molecular weight (20 kDa, 200 
kDa and 1.5 MDa) on its immobilisation by the HS-Pep-1 SAM or PDL (Figure 21). The 
average final mass deposition of HA following washing was not statistically different 
between the three sizes of HA used when immobilised by the HS-Pep-1 SAM. However, 
significantly more 1.5 MDa HA was immobilised by PDL than 20 and 200 kDa HA (Figure 
23A). Using the Voigt-based viscoelastic model to determine the thickness of the HA layer 
formed on the HS-Pep-1 SAM or PDL, no significant difference was observed on HS-Pep-
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1, with the thicknesses ranging from 5.4±1.8 to 10.8±4.8 nm. The 1.5 MDa HA layer on 
PDL was 12.1±6.6 nm, which was significantly thicker than the layers formed by the 20 
and 200 kDa HA (Table 5). 
Furthermore, there was a trend towards a greater mass and, to a lesser extent, thickness 
(Figure 23A and B respectively) with increasing MW of HA. This could be explained by HA 
adsorbing onto the substrates through a similar number of contact points, however 
increased chain length of the higher MW HA would mean a larger amount of HA was 
attached to the surface per binding site. The tethering of high MW HA is likely to result in 
a less condensed conformation of HA would allow for a greater amount of water to be 
held within the HA lattice structure. As a result the mass of the hydrated HA layer on the 
HS-Pep-1 surface would be greater than when a lower MW was used. This model would 
also account for a slightly thicker layer observed with the 1.5 MDa HA. If chains are more 
loosely bound then they may extend out into the surrounding solution and, as mentioned 
previously, retain more water, resulting in both an increased mass and thicker layer.  
In addition to the information on the areal mass density, the QCM-D also allows 
information on the viscoelastic properties of HS-Pep-1-HA and PDL-HA films.255 Figure 
23C shows the mean change in dissipation following the incubation of HS-Pep-1- and PDL-
modified Au surfaces with HA of different molecular weights. The increase in dissipation 
values indicates that the HA-based films are softer than the HS-Pep-1 or PDL layers 
alone.256,257 No statistically significant differences between the ∆D values observed for 
PDL compared to HS-Pep-1 as a means of immobilisation were seen (Figure 23C). 
However, the MW of HA was shown to influence the viscoelastic properties, resulting in 
a more viscoelastic film being formed when a higher MW was used. This is likely due to 
the hydration of the film, where larger HA molecules will be able to incorporate more 
water into the layer. 
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Figure 23: Molecular weight of hyaluronic acid has minimal impact on its deposition on HS-Pep-1 
and PDL coated surfaces. Bar graph showing the average areal mass density (A) and hydrodynamic 
thickness (B) of HA deposited onto either a HS-Pep-1 or PDL surface calculated using the Voigt-
based viscoelastic model. Bar graph showing the change in the dissipation factor at the 7th 
overtone upon HA binding to HS-Pep-1 or PDL surfaces following washing as measured by QCM-
D (C). n=3, error = SD, ****=p<0.0001 ***= p<0.0002, *= p<0.0332 (Two-Way ANOVA, with 
Tukey’s multiple comparisons). 
2.2.2. Topography of HA surfaces 
As a difference in hydrophobicity was observed between the HS-Pep-1-HA and PDL-HA 
surfaces, atomic force microscopy (AFM) was used to assess the topographical features 
of the films. It was seen that the average roughness of the single HS-Pep-1 or PDL layer 
was 4.85±2.16 and 3.77±1.78 nm, respectively (Figure 24B-D).  
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Figure 24: AFM analysis of surfaces. Representative AFM images of bare Au (A), HS-Pep-1 only (B) 
and PDL only (C) in a dried state. Bar graph showing the mean average roughness of bare AU, HS-
Pep-1, PL, HS-Pep-1-HA and PDL-HA surfaces in a dried state (D). n=3, error = SD.  
 
On incubation with 1.5 MDa HA, the average roughness was measured as 4.59±3.12 nm 
for the HS-Pep-1-HA surface and 2.96±1.00 nm for the PDL-HA (Figure 25A-B, E). In both 
cases, the average roughness decreased on addition of HA (Figure 24D).  
Since the intended application of the developed surfaces are cell culture studies and 
these are performed in an aqueous environment, the roughness of HS-Pep-1-HA and PDL-
HA surfaces was also assessed in a hydrated state. No significant change in roughness was 
seen between the dry and hydrated surface when HA was immobilised by PDL (Figure 
25E). A significant increase in average roughness was observed when the HS-Pep-1-HA 
sample was hydrated, from 4.59±3.12 nm to 31.08±36.12 nm. When dry, the polymers 
making up the coating will sit close to the Au surface, however, when hydrated 
untethered sections of HA chains can extend out into the solution from the surface 
resulting in increased roughness.65 
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Figure 25: Immobilisation of HA by PDL and HS-Pep-1 produces substrates with different 
topographies. Representative AFM images of PDL-HA (A, C) and HS-Pep-1-HA (B, D) layers in dried 
(A, B) and hydrated (C, D) states, respectively. Bar graph showing the mean average roughness of 
HS-Pep-1-HA and PDL-HA samples under dry or hydrated conditions (E). n=3, error = SD, * = p < 
0.0332, (one-way ANOVA with Tukey’s multiple comparisons). 
 
The hydrated HS-Pep-1-HA samples were also significantly rougher than the hydrated 
PDL-HA surface (Figure 25C, D and E). The difference in roughness between HA 
immobilisation by PDL and HS-Pep-1 suggests that the mechanism and strength of 
binding is influencing the presentation of HA.  
The strong attractive electrostatic attraction between the positively charged PDL and the 
negatively charged HA chains is distributed evenly along both molecules, creating a 
coating which can uniformly resist the increased forces following swelling resulting in a 
smoother surface. Whereas HS-Pep-1 binding to HA occurs at discrete sites on the HA 
polymer, these individual points of contact may not be strong enough on their own to 
withstand increased forces generated by the HA layer hydration, resulting in more free 
ends or segments of HA which could account for the increased surface roughness 
observed. 
Compared to both PDL and HS-Pep-1-HA in a dried state the standard deviation of the 
average roughness of the hydrated HS-Pep-1-HA surface is large. Having a larger error 
reduces the confidence with which we can draw conclusions from the data; however the 
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statistical analysis conducted corrected for multiple comparisons and takes into account 
the variability of the data. As this large error was only seen with one condition, rather 
than across all experiments, it is possible this variability in data is reflective of the 
variability in the roughness of the hydrated HS-Pep-1-HA surface.  
Combining the QCM mass and thickness data with this apparent increased roughness of 
the 1.5 MDa HA bound by HS-Pep-1 it could be suggested that the HS-Pep-1-HA layers 
form a more dynamic surface. The unbound sections of HA would be free to move in the 
surrounding solution, this movement would not only contribute to the surfaces 
roughness, but could result in a constantly changing topography. If this is the case then 
this state of flux could be expected to have an effect on the reproducibility and 
consistency of the data acquired. Further repeats of these experiments would help 
increase the confidence with which we are able to present these data. 
 
2.3. Culture of LuC4 cells on HS-Pep-1-HA and PDL-HA surfaces  
Current research suggests that while HA surfaces are anti-fouling90 and able to promote 
anchorage-independent cell growth,259 they can also mediate CD44-dependent cell 
adhesion.246 We also wanted to assess if the different surface properties observed by 
contact angle and AFM would have any effect on the cell behaviour. Initially, to assess 
the number of cells adhering to the surface following 6 and 24 hours of incubation, LuC4 
cells were cultured in serum free medium on either tissue culture treated plastic, bare 
Au, HS-Pep-1, PDL, HS-Pep-1-HA, or PDL-HA surfaces. After both 6 and 24 hours of 
culture, no statistically significant differences in cell attachment were seen between any 
of the culture conditions (Figure 26).  
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Figure 26: Supramolecular presentation of HA on surface does not alter the adhesion of LuC4 cells. 
Bar graphs showing the average fold chance in cell number attached to each surface after 6 and 
24 hours. Unsorted parent population of LuC4 (A), two sorted stem cell fractions EMT and CSC 
after 6 (B) and 24 (C) hours. n=3, error = SD. 
 
The assessment of the cells metabolic activity using AlamarBlue indicated that there was 
also no significant effect on metabolism (Figure 27), which suggests that the experimental 
conditions are not having a detrimental effect on normal cell function, measured by their 
redox capacity.   
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Figure 27: Change in metabolic activity following incubation on the different surfaces. Bar graph 
showing the % reduced alamar blue by LuC4 cells following 24 hours of culture on each surface. 
n= 3, error = SD. 
Within the LuC4 cell line, a further subset of the CSCs has been characterised, which 
appear to have undergone epithelial to mesenchymal transition (EMT). These so-called 
EMT cells display a more elongated morphology and express mesenchymal markers.26 
Taking this work into consideration, we hypothesised that the EMT subset of CSCs within 
the LuC4 cell line, which is characterised by high CD44 and low to negative ESA expression 
levels, would preferentially bind to the HS-Pep-1-HA surfaces. Cells were isolated by 
FACS, seeded onto the surfaces and incubated as previously described. Again, after 6 and 
24 hours, no difference was observed between the fold-change in number of cells 
attached compared to the range of surface treatments Figure 26B, C).  
One consideration is that these experiments were performed in the absence of serum; 
cells were serum-starved for these experiments as the undefined, variable nature of FBS 
can result in cells being exposed to different levels of an array of growth factors, 
increasing the potential for variation in results.260 While removal of serum can increase 
experimental reproducibility, the absence of growth factors and proteins present in 
serum can influence cell survival and proliferation. Proteins that promote cell 
attachment, such as fibronectin and collagen are found in serum; as such it would not be 
surprising to see different levels of adhesion in serum-free cultures.261 When these 
components are present they adsorb onto the culture surface and can facilitate cell 
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adhesion and subsequent cell spreading.262 It has been shown that in the absence of 
serum proteins cells do not form classical focal adhesions, and non-canonical signalling 
pathways are activated.263  
The experiments carried out in this work compared cell adhesion on fabricated surfaces 
to adhesion on tissue culture-treated plastic under the same, serum-free, conditions. By 
doing this, any serum-dependent effect on cell adhesion should occur in all conditions. It 
might be of interest to see the effect of a range of serum concentrations on cell adhesion 
when cultured on HA surfaces. 
Initial experiments looking at the effect of serum concentration on LuC4 adhesion to glass 
slides and tissue culture-treated plastic show significantly higher adhesion on glass when 
5% serum is used, while greatest adherence to tissue culture-treated plastic is also seen 
at 5% serum, 0% provides similar results (Figure 28A). However, after 24 hours the 
influence of serum percentage on adhesion seems to be lost (Figure 28B), demonstrating 
that incubation time is also an influencing factor when it comes to cell adhesion. 
 
Figure 28: Effect of serum concentration on cell adhesion. Cells were seeded onto either tissue 
culture-treated plastic or glass slides with media contacting 0, 1, 5, or 10% FCS. After 6 (A) or 24  
(B) hours in culture the number of adhered cells was counted. (n=3), error = SD, **** = p < 0.0001, 
** = p < 0.0021, * = p < 0.0332, (two-way ANOVA with Tukey’s multiple comparisons). 
Differences in cell adhesion to the various surfaces may be diminished following 24 hours 
of culture as a result of the different CD44 expression profile of the LuC4 cell sub 
populations. Within the literature it was reported that glioblastoma multiforme (GBM) 
tumour cells are able to adhere to HA-crosslinked hydrogels following as little as 30 
minutes incubation in serum-free medium, this interaction was shown to be mediated by 
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CD44 as its knockdown eliminated cell binding.264 So if cells are given a longer period of 
time to adhere the distinction between cells which rapidly form attachments and those 
that take much longer to interact with the surface is lost. 
It may seem surprising that enhancement of adhesion was not observed on immobilised-
HA. However, Kim and colleagues did not compare CD44-mediated adhesion on HA to 
other substrates. Additionally, the CD44 isoform expressed may play a role in cellular 
adhesion, HNSCC EMT cells show lower levels of variant isoforms and higher standard 
isoform expression than the bulk population.44 Variant isoform CD44v6 has been shown 
to increase adhesion of prostate cancer cells,265 as this isoform is lower in EMT cells this 
could in part explain why low levels of binding were seen. Further to this, a similar 
subpopulation of HNSCC cells, defined by CD44v3highALDH1high expression, shows 
CD44/HA-dependent enhanced sphere formation.266 Spheres are formed in suspension 
and do not require adhesion to a surface which suggests that HA may promote contact-
independent growth, rather than adhesion in this cell type, which may also apply to 
binding of LuC4 EMT cells to immobilised HA.  
The mechanical properties of a HA surface are also able to modulate cell binding, where 
more binding is seen on stiffer HA hydrogels compared to softer structures.264 This could 
indicate that the HA immobilised by HS-Pep-1 and PDL are similarly stiff as the amount of 
binding on each surface was comparable. 
It has previously been demonstrated that treatment of head and neck cancer cells with 
soluble HA show increased migration.43 Although no effect on cell adhesion was observed 
on the different surfaces, we assessed the HS-Pep-1-HA surfaces ability to alter cancer 
cell migration using a scratch assay. LuC4 cells were seeded onto the surfaces and 
cultured until confluent. Following this, a scratch was made and over the course of 48 
hours the area of the wound was monitored.  
During experimental set up, and creation of the scratch, it is known that cells at the 
wound edge can be damaged and result in the release of signalling molecules from these 
cell which can influence the results.267,268 As such, it is also possible that the underlying 
SAM, and adsorbed HA, are also disturbed on scratch formation. If this is the case, and 
there is no HA in the wound, then the experimental question being asked is different from 
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if the HA coating remains intact. However, provided this is a uniform event across all 
conditions, then a valid comparison can still be made. 
To determine if this is the case further experimental work would be required, 
fluorescently tagged HA could be used to form the coating such that loss of HA could be 
visualised, by the absence of a fluorescent signal. A fluorescent amino acid269 could also 
be incorporated into the HS-Pep-1, provided it does not disrupt the interaction with HA, 
to see the effect of the scratching process on the SAM. Alternatively, or in parallel, AFM 
could be used to identify any changes in topography as a result of the scratch process.  
For all conditions the wound area decreased as it began to close (Figure 29), except for 
the HS-Pep-1 modified Au substrate, which did not support cell growth to confluence. 
Comparing the area of the scratch, as a percentage of its area at time 0, it was seen that 
both HS-Pep-1-HA and PDL-HA conditions showed significantly reduced cell migration. 
This apparent inhibition of migration was also significantly greater when HS-Pep-1 was 
used to immobilise the HA (Figure 29B). 
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Figure 29: Immobilisation of HA by PDL and HS-Pep-1 reduces LuC4 cell migration. Representative 
phase contrast images of the scratch area at 0, 12, 24 and 48 h (A). Bar graph showing the mean 
area of scratch as a % of time 0 (B). (n=3), error = SEM, **** = p < 0.0001, scale bar = 500 µm, 
(two-way ANOVA with Tukey’s multiple comparisons).  
This indicates that immobilised HA can exert a different effect on head and neck cancers 
cells compared to soluble HA and that the method of immobilisation may also influence 
cell behaviour. Several reports suggest that surfaces coated with HA are also able to 
promote the migration of cells. However, this is dependent on cell surface receptors, 
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where the expression of the standard CD44 isoform resulted in increased migration.270 It 
is known that the EMT fraction of HNSCCs downregulate variant isoforms in favour of the 
standard form.44 The lack of increase in migration observed in our system could be 
explained by the low EMT percentage in the LuC4 cell line.26 It has previously been shown 
that when PDL-HA ‘bilayers’ are formed, the PDL is able to diffuse into the HA layer.271,272 
If this is happening in our system, this may contribute to the higher rate of scratch closure 
on the PDL-HA surface over the HS-Pep-1-HA surface.  
2.4. Micro-contact printing of HS-Pep1 and HA patterning 
Patterned surfaces are a useful tool in cell culture and can be used to influence cell 
survival, adhesion, proliferation, migration, and differentiation.205,273 With this in mind, 
PDMS stamps were used to micro-contact print (CP) the HS-Pep-1 onto the bare Au 
substrate. Incubation with Texas Red labelled HA resulted in deposition in distinct foci 
(Figure 30C) or to form a background of HA with patches of bare Au creating a pattern 
(Figure 30D). This demonstrates a simple and rapid method for creating HA patterned 
surfaces with thiolated HA-binding peptide (HS-Pep-1, Figure 30A). Future work to 
investigate the interaction of LuC4 cells with a variety of patterns could provide further 
insights into the role of HA in cancer progression. 
3. Conclusion 
Here we demonstrate the supramolecular immobilisation of unmodified hyaluronan on 
gold surfaces using a thiolated HA-binding peptide. This method produces surfaces which 
are capable of supporting cell growth and, when compared to the immobilisation of HA 
by poly-lysine, have a higher average surface roughness. It is also seen that these surfaces 
reduce migration of head and neck cancer cells, although the mechanism of this was not 
investigated. Finally, this method of immobilisation in combination with µCP provides a 
simple and rapid way of creating HA-patterned surfaces, which could be used to further 
probe the effect of HA on cells in vitro. 
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Figure 30: HS-Pep-1-HA patterning of surfaces using -contact printing. Schematic of PDMS stamp 
(grey) loaded with peptide (purple), which is transferred to the gold surface on contact. The 
islands are then able to immobilise HA (red) (A). Chemical structure of the Texas Red-labelled HA 
(B). Fluorescence images of surfaces patterned with a HS-Pep-1-coated PDMS stamp then 
incubated with Texas Red-labelled 1.5 MDa HA, creating a spot pattern (C) or a ‘negative’ drop 
pattern (D) Scale bar = 200 µm on large image, 100 µm on insert. 
4. Outlook and future work 
The ability to use CP of HS-Pep-1 to control the immobilisation of HA to create patterned 
surfaces has the potential to be used to manipulate cell adhesion and in vitro culture. 
Micro-contact printing to create patterns of immobilised proteins such as fibronectin,205 
myoglobin,274 antibodies, and BSA275 can be used to precisely control culture conditions. 
Within the literature, CP is used to restrict cell adhesion to specific zones and create 
patterns with cultured cells.276 Depending on the size and shape of these regions, CP 
can also be used to encourage cell alignment277 and combining CP of fibronectin with 
temperature-responsive surfaces, to release patterned cell-monolayers which can be 
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stacked or manipulated to form organised 3D structures provides a useful platform for 
the future of tissue engineering. 
Patterned culture of cells has been used to study cell traction forces, which are known to 
influence cell behaviours such as migration and signalling.278 Migration can also be 
studied using CP.279 Altering the spacing of the ECM protein laminin by CP has been 
used to observe the migration capacity of different progeny of adult neuronal stem 
cells.280 Migration of epithelial cells between channels of cell-permissive fibronectin over 
a non-adhesive background resulted in the formation of cell ‘bridges’ suspended above 
the surface, providing an insight into how cell migration may progress during wound 
healing.281 
Depending on how HA-patterned surfaces interact with HNSCC cells, HS-Pep-1 CP and 
HA immobilisation could be applied in similar ways to further study cell migration. 
Combining HS-Pep-1-HA patterns with additional surface modifications could lead to the 
development of more complex systems to immobilise more than one cell type in well-
defined locations.282 The interactions between these cell types and effect of co-culture 
can then be studied. Alternatively, mixtures of SAMs with different functionalities, such 
as cell-binding peptides could be used to determine how co-exposure to extracellular 
cues may stimulate behaviours associated with cancer progression. 
To fully exploit the system developed here, the intended future work would focus on the 
applications of CP. Where the first research question to be investigated would be can 
-contact printed islands of HS-Pep-1-HA surface coatings sequester LuC4 cells in vitro. 
Establishing the stability of these patterns under normal tissue culture conditions would 
also be an important set of experiments, again Texas Red-tagged HA could be used to 
visualise the immobilised HA. It would be of use, for performing co-culture experiments, 
to develop this system to support the culture of two cell types which are grown in 
distinctly separate areas without the need for a physical divide. 
Current work in the Mackenzie lab utilises conditioned medium, which is spent media 
collected from culture flaks which contains the metabolites, extracellular matrix proteins, 
and growth factors excreted by the cultured cells. This is mixed with fresh media and used 
for subsequent cell culture.283 Harvesting the conditioned medium requires 
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centrifugation and filtration steps, which is time consuming, co-culture would remove the 
need for isolating conditioned medium as components secreted by one cell type would 
be able to diffuse and directly act on a second, co-cultured, cell type.  
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Chapter IV - Development and application of a phage display protocol for the selection 
of head and neck cancer cell-binding peptides 
1. Introduction 
Advances in peptide synthesis technology, such as automated peptide synthesis and the 
use of microwaves, have drastically reduced the cost, time and man hours required to 
generate peptides in the lab. This has made the use of synthetic peptides a more 
attractive and accessible option for numerous applications, including therapeutics,284 
regenerative medicine,285 and for biomaterials.286 
1.1. Cell-targeting peptides 
The use of cell-binding peptides in these applications shows promise for improving 
disease treatment, as seen with Glucagon-like peptide-1 receptor agonists (GLP-1RAs), 
5 of which have been approved for the treatment of type two diabetes287 Where the 
sequences of GLP-1RAs are based on the sequence on the native GLP-1 or extendin-1, 
another signalling molecule which binds to the glucagon-like peptide-1 receptor, and is 
able to effect weight-loss in clinical trials.288 Further to this, cell-targeting, or homing 
peptides can be useful tools for targeted therapeutics. Conjugation of cytotoxic drugs to 
such peptides has been shown to allow selective delivery of cargo to target cells and 
improve treatment effectiveness both in vitro and in vivo.181  
Peptides have also been identified which are capable of crossing the cell membrane and 
incorporation of these cell-penetrating peptides (CPPs) can enhance cellular up-take of 
molecules coupled to CPPs.289 Combining cell-penetrating and cell-targeting peptide 
sequences can exploit both their properties to synergistically overcome treatment 
limitations linked to tissue penetration and tissue specificity.163,188   
Within regenerative medicine, incorporation of peptides into 3D-gels and scaffolds can 
provide functionality and improve cell survival, proliferation, and differentiation. Culture 
of endothelial cells on a scaffold containing three peptides derived from ECM 
components, YIGSR, RYVVLPR from laminin 1 and TAGSCLRKFSTM from collagen IV, was 
seen to mimic in vivo conditions more closely than standard culture techniques and 
enhanced endothelial cell function.290 
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1.2. Methods for identification of peptide sequences 
1.2.1. Protein-derived 
Selection of a peptide sequence can be approached in several, ways which will be 
dependent on the intended application. Useful peptides can be identified by digestion of 
natural proteins followed by screening for their desired function, antioxidative peptides 
have been derived from milk proteins in this way.291  
For cell-based applications, such as creating hydrogels or surfaces for cell growth, peptide 
sequences extracted from known functional domains of proteins can be used to promote 
cell adhesion, survival, differentiation, or maintenance of stemness. Knowledge of the 
critical role integrins play in a cells interaction with the ECM and initiation of signal 
transduction makes their ligands, such as laminin,292 collagen,293 and fibronectin,294 prime 
candidates for isolating bioactive sequences. Of the several peptides which are routinely 
used for supporting cell adhesion the three primary motifs, RGD, IKVAV, YIGSR, were 
identified within laminin chains.295 Their incorporation into cell culture substrates has 
been used to support adhesion and proliferation of human neural stem cells and was able 
to direct their differentiation towards a neuronal cell fate observed through increased 
neurite outgrowth.296,297  
Being able to recapitulate the ECM in such a controlled way, without the need for animal 
derived macromolecules, allows the function of individual molecules, or even small 
domains within a molecule, to be probed. In addition, developing in vitro culture systems 
which mimic the in vivo environment more accurately can only lead to a better 
understanding of cell behaviours through minimising artefacts resulting from culture 
conditions. 
1.2.2. Rationally designed 
Identification of biologically relevant peptides can also be achieved through rational 
design. For example, Joshi et al.298 designed a peptide inhibitor of Aminopeptidase N 
(APN), a metalloprotease which is overexpressed in several cancers whose activity has 
been shown to facilitate angiogenesis and cancer metastasis. This was achieved by 
analysis of known substrates and identification of key residues in combination with 
analysis of the APN crystal structure. This strategy for obtaining novel peptides requires 
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a large amount of knowledge of the target molecules structure, function and its natural 
ligands. A similar option which may require less starting information would be rational 
redesign. This approach has been used to generate a peptide with improved binding 
affinity for the target, cysteine-rich intestinal protein 1 (CRIP1), a biomarker for breast 
cancer. Initial peptide binders of CRIP1 were selected by phage display and the sequence 
which had the highest affinity was redesigned using computer modelling.299 This 
redesigned peptide has subsequently been successfully used in an assay, as a capture 
probe, to detect levels of CRIP1 in cancer patient samples, indication the potential to be 
developed as a diagnostic tool.300 
An advantage of using rational design and redesign is the ability to engineer a peptide 
which contains fewer hydrophobic patches, which may lead to aggregation, as well as 
ensuring reasonable water solubility, which is often a limitation of cell-binding peptides. 
Incorporation of non-natural amino acids can help achieve an increased in vivo half-life 
by reducing the action of peptidases. 
1.2.3. Phage-derived  
While using rational design and known target-binding motifs from native proteins to 
identify peptides to generate optimised in vitro culture conditions, tissue scaffolds, and 
targeting molecules has been successful, in most cases prior understanding of the target 
molecule or its natural ligands is required. This can present a problem for cases where 
the exact target molecule is unknown, for example isolation of a peptide which is able to 
home to a specific cell type such as tumour cells.  
Without a candidate receptor, to use as a basis for rational design, phage display offers a 
high-throughput screening platform which does not require any detailed knowledge of 
the target or potential ligand. Random peptide phage display libraries consist of 
genetically modified bacteriophage displaying a random peptide sequence on its surface, 
which is encoded by a fragment of DNA inserted into the phage genome. Large 
commercially available libraries, with a diversity in the order of 109 clones, allows the 
rapid screening of peptides which bind to a target, and, due to the physical linkage 
between genotype and phage phenotype, simultaneous partitioning of encoding DNA. 
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Existing literature demonstrates how phage display can be applied to isolate peptides 
which home specifically to complex targets such as tissues or cells. Peptide phage display 
was used to identify a peptide, HAP-1, that could target synovial cells and, when 
conjugated to an antimicrobial peptide, induce their apoptosis.301 A cell-homing peptide 
for targeting chondrocytes was identified by incubation of a random peptide library with 
ex vivo pieces or cartilage, in order to improve cell specificity, Pi and colleagues302 
employed a round of negative selection against synovial tissue and fluid, to remove clones 
which recognised molecules present in these tissues. Again, the identified peptide 
(chondrocyte-affinity peptide, CAP) was conjugated to polyethylenimine, a nucleotide 
delivery reagent, and CAP was able to increase cartilage-specific delivery of DNA.   
In addition to the use of phage display-discovered peptides for cell-targeting, they are 
also useful reagents for building in vitro cultures systems, to influence and investigate cell 
behaviours. An excellent example of this is screening of peptide libraries to identify 
peptides which can support embryonic stem cell (ESC) proliferation.202 This work by 
Derda et al. elegantly combined the peptides identified through panning on embryonal 
carcinoma cells with an alkane thiol SAM system. Candidate peptides were synthesised 
and coupled, via their C-terminal, to alkane thiols. When incubated with a gold surface, 
the thiol group binds to the gold causing the self-assembly of the alkane thiol-peptides to 
generate a monolayer functionalised with peptide sequences. As mentioned, this surface 
supported ESC proliferation through interactions independent of integrins or 
proteoglycans, again illustrating the power of phage display for selection of peptides 
which can probe the molecular mechanism of cell-environment interactions. 
1.3. Cell-binding peptides in head and neck cancer 
The success of targeting the human epidermal growth factor receptor 2 (HER2), which is 
over-expressed in some breast cancers, highlights the possibility of achieving similar 
targeted therapies against other malignancies.303,304 The complexity of the cell surface 
means that while identification of a target cell population based on phenotypic and 
behavioural characteristics is not always coupled with a single, targetable cell surface 
marker which can be used as a starting point for creating peptide-based targeting 
molecules.  
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The presence of a subpopulation of cancer stem cells (CSCs) within head and neck cancer 
provides an example of this. These cells exhibit elevated tumourgenicity in mouse 
models, therapeutic resistance, the ability to self-renew when compared to the bulk of 
the tumour.6,14 However, their isolation is based on expression of CD44, a single pass 
transmembrane protein, which is found on the surface of almost all cell types.305 Splice 
variants of CD44 show tissue-specific patterns of expression. Thus, targeting isoforms 
which show high expression in tumour cells and have a more restricted expression in 
normal tissues was investigated. The CD44 variant isoform, CD44v6, was identified as a 
target and monoclonal antibodies were raised to target CD44v6-expressing cells and to 
study their distribution.22 While these studies showed a favourable expression pattern of 
CD44v6 significant off-target side effects were seen in phase I trials targeting CD44v6-
expressing cells in HNSCC.306 These off-target effects were observed in the skin, where 
CD44v6 is also expressed, this demonstrated that there is still work to be done defining 
specific markers of HNSCC. 
Added complexity is introduced into mapping markers of HNSCC and their stem cells by 
the presence of a further subset of CSCs. Of these, there is one population which is more 
heavily associated with an aggressive tumour phenotype, with a greater propensity for 
metastasis, therapeutic resistance, and recurrence.31,32 HNSCC cells with 
CD44high/EpCAMlow expression profile are believed to have undergone EMT, induced by 
signals in the tumour microenvironment.26 These cells show altered gene expression, 
markers of epithelial cells, including Calgranulin B and involucrin, are downregulated and 
mesenchymal genes such as Twist, Snail, and Vimentin are upregulated.26 Functional 
assays demonstrate corresponding shift if cell behaviour, where EMT cells have a slower 
growth rate, enhanced migration, and a more elongated morphology. 
It is not uncommon for combinations of markers to be used when defining cell 
populations, as is the case with EMT cells. In addition to a CD44high/EpCAMlow profile 
aldehyde dehydrogenase (ALDH) activity and low epidermal growth factor 
receptor (EGFR) expression are also used as part of a marker panel to isolate HNSCC CSC 
subpopulations.307–309 
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Identification of a molecule which could specifically target one of these subpopulations 
would have important implications for improved isolation of these cells in vitro and 
potential for development of in vivo cell targeting.  
With this in mind, the purpose of the experiments discussed in the following chapter was 
to use phage display to isolate peptide sequences which would selectively bind to a sub 
population of HNSCC cells which are associated with tumour progression, metastasis, 
therapeutic resistance, and recurrence following treatment. Once isolated, the aim 
would be to modify the peptide to include a sulphur moiety so that it can be immobilised 
on an Au surface as a SAM, following the protocol developed in Chapter III. This platform 
could then be used for in vitro cell studies as a tool to further probe cellular 
characteristics. 
 
2. Results  
There are several commercially available random peptide phage display libraries. For this 
work, the Ph.D. - 12 ™ Phage display library was purchased from New England BioLabs 
Inc. The library provides pentavalent display of peptides on the surface of the M13 
filamentous bacteriophage. A Gly-Gly-Gly-Ser linker precedes the 12-amino acid peptide 
which is fused to the N-terminal of the pIII coat protein, thus the N-terminal of the 
peptide is free.  
2.1. Biopanning on LuC4 cells enriches for cell-binding clones 
To establish a suitable protocol for panning, the parent population of LuC4 cells was used. 
Three rounds of positive selection were carried out on LuC4 monolayers. To determine 
the recovery and enrichment for cell-binding clones, the number of input and output 
plaque forming units (pfu) was used as shown in Table 6. An enrichment of cell-binding 
phages was observed with each round or panning. This demonstrates the ability of this 
protocol to select for target-binding clones, which, in this case is a cell monolayer. 
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Table 6: Bacteriophage input and output, values for each round of biopanning on a monolayer of 
unsorted LuC4 cells. 
 
INPUT (PFU) OUTPUT (PFU) 
RECOVERY 
(OUTPUT/INPUT) 
ENRICHMENT 
(PER ROUND) 
ROUND 1 2 x 1011 1 x 107 5 x 10-5 - 
ROUND 2 4 x 1010 1.2 x 106 3 x 10-5 1.67 
ROUND 3 2.2 x 1011 2.7 x 107 1.2 x 10-4 2.45 
 
To further confirm the selection of cell-binding phages, a whole cell ELISA was performed 
to compare the binding capacity of the amplified eluate from each round of panning 
against the wild-type (WT), insert-less phage, and the naïve library. The insertless (WT) 
phages and the naive library had similar levels of binding. The phage pools from the first 
and second rounds of panning showed equivalent binding to both WT and un-panned 
library, while the third round amplified eluate showed a two-fold increase in signal, 
indicating increased binding (Figure 31). Although, as the standard deviation for each 
sample was relatively large, there was no statistically significant increase in binding 
following one or two rounds of biopanning on a LuC4 cell monolayer.  
Taking the increase in recovery ratio and minimal increase in binding, as measured by 
ELISA, together, the results would suggest the phage clones being enriched may not be 
target-specific and may simply be binding the tissue culture plastic.    
To address this issue, modifications were made to the panning procedure. One key 
change was the removal of Tween 20 from the wash buffer during the ELISA. It has been 
demonstrated that inclusion of such non-ionic detergents can increase the non-specific 
binding of M13 phage in a dose-dependent manner that can result in a high background 
signal. The use of Tween in conjunction with a PEG-based purification of amplified phage 
can also contribute to non-specific interactions, PEG molecules associated with the virus 
coat proteins interact with Tween promoting aggregation.310 Additionally cell viability was 
seen to be reduced when Tween was used in panning (Figure 32). 
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Figure 31: Enrichment of phage binding following three rounds of selection. Whole-cell phage 
binding ELISA results of eluted phage after each round of panning on a cell monolayer of unsorted 
LuC4 cells. (n = 3), error = SD, * p= 0.0332, one-way ANOVA with Tukey’s multiple comparisons. 
The two cell populations isolated by FACS, EMT and Epi, were cultured for 24 hours before 
selection for EMT-specific clones was carried out. This was done to give the cells time to 
adhere and to recover from the shear forces exerted during FACS. Additionally, it would 
provide some time for receptors and cell surface proteins, degraded by trypsin during cell 
harvesting, to be synthesised and returned to the cell surface. 
 
Figure 32: FACS plots of LuC4 cells, showing cell shape and complexity, determined by forward 
scatter (FSC) and side scatter (SSC) respectively (A) and viability, where a positive DAPI signal 
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indicated a disrupted cell membrane and poor cell health (B) following washing with wash buffer 
containing 0.01% Tween 20. 
2.2. Biopanning on CD44high/EpCAMlow cell monolayers. 
Sorted cell populations used in subsequent experiments used the gating strategy outlined 
in Figure 33.  
EMT cells tend to make up between 1 and 10% of the LuC4 cell line, for the cell panning 
experiments large numbers of EMT cells are required, where 1x106 cells are used in each 
round of panning. To ensure there were enough cells for each round, cells were sorted in 
advance, frozen down then pooled and cultures for 24 hours as mentioned above. As 
such, the effect of freezing down sorted cells on their marker profile was investigated, to 
assess if this was a viable option for supplying cells for each round of panning. It was seen 
that cells which were sorted, frozen at -80 °C for one month, thawed, and cultured for 48 
hours showed only a slight change in marker profile; 93.8% ± 0.7 of EMT cells and 99.4% 
± 0.3 of CSC cells retained their CD44high/EpCAMlow and CD44high/EpCAMhigh marker 
profile, respectively (Figure 34). These results demonstrate that sorting cells in advance, 
for subsequent use in panning experiments, and storage at -80 °C for a short period of 
time, does not affect the population phenotype in a way that would impact biopanning.  
 
Figure 33: Representative gating strategy for sorted cell populations. Cells were first selected based 
on side and forward scatter (A), then DAPI was used to identify viable cells, those which are DAPI 
negative, (B). Finally CD44 and EpCAM expression was used to select the CD44high/EpCAMlow and 
CD44high/EpCAMhigh populations (C). 
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Figure 34: Analysis of LuC4 marker expression by flow cytometry. Percentage of EMT cells in LuC4 
following 48 hours in culture after storage at -80 °C for 30 days. Unsorted parent population 
shows two distinct sub populations, with approximately 10% of cells falling under the EMT profile 
(A). Cells sorted for CD44high/EpCAMhigh expression prior to culture show less than 1% of the 
population switch to the EMT phenotype (B). Finally, of cells sorted for CD44high/EpCAMlow 
expression prior to culture, 94% retain their EMT phenotype (C). 
The modified protocol was then used, in combination with FACS, to select for phages 
which bind to the EMT sub-fraction of the LuC4 cell line. Following a pre-clearing step to 
deplete the phage library of sequences which had an affinity to the tissue culture plastic, 
one round of positive selection on a monolayer of CD44high/EpCAMhigh was carried out. To 
minimise the number of clones carried through to the next round of panning which are 
binding to general cell surface markers, or molecules expressed by other HNSCC cells, a 
round of negative selection was conducted. The amplified phage pool from the first round 
was incubated with LuC4 Epi (CD44high/EpCAMhigh) cell monolayer prior to a second round 
of positive selection with EMT cells, without an amplification step in-between.  
A final third round of positive selection was conducted and the unamplified eluate was 
titred. Blue plaques were picked and individually amplified, sequencing of phage DNA 
revealed 4 different insert sequences, Table 7, of these three appeared only once while 
the fourth sequence, QVNGLGERSQQM-GGGS was present in 10 of the clones. Analysis 
of these sequences using SAROTUP: Target-Unrelated Peptides Scanners311 revealed that 
there were no known target-unrelated peptide (TUP) motifs within any of the isolated 
peptides. To assess the probability of these sequences being selected due to their binding 
to polystyrene the TUPredict polystyrene surface-binding (PSB) tool, PSBinder, was used. 
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Three of the four sequences were predicted to bind to polystyrene (Table 7), with 
VCSPCGPVPPAK-GGGS being the sequence least likely to bind polystyrene.  
It was interesting to see that both the VCSPCGPVPPAK-GGGS and GNNPLHVHHDKR-GGGS 
peptides had been selected as binders to aggregated monoclonal antibodies.312 Analysis 
of phage binding by Cheung et al. using an ELISA showed VCSPCGPVPPAK-GGGS did not 
show enhanced binging to the target, but GNNPLHVHHDKR-GGGS showed a 7-fold 
increase. The GNNPLHVHHDKR-GGGS was also selected as a Jurkact cell-binder; it showed 
preferential binding for Jurkat cells over MCF-7 and PC3 cells as measured by ELISA. 313 
Table 7: Sequences identified from biopanning on CD44high/EpCAMhigh cells. Including the number 
of times they appeared, the probability and the overall prediction as to whether they will bind to 
polystyrene. 
SEQUENCE APPEARANCES PSBinder PREDICTION 
QVNGLGERSQQM-GGGS x10 0.58 Yes 
GANDGVSLWRNV-GGGS x1 0.86 Yes 
GNNPLHVHHDKR-GGGS x1 0.67 Yes 
VCSPCGPVPPAK-GGGS x1 0.38 No 
 
A whole cell phage ELISA was performed to assess the binding capacity of each clone 
following protocol optimisation. Optimisation experiments used unsorted, parent, LuC4 
cells and compared the effect of cell fixing and blocking buffer components on the ELISA 
signal with WT phage and amplified third sound eluate (Figure 35). Results showed the 
background signal tended to be reduced when wells were blocked with PBS and 3% BSA, 
rather than PBS with 5% milk powder (Marvel, UK). No difference was seen between 
signals produced when using fixed or live cells. As such, samples were blocked with PBS 
3% BSA and live cells were used to keep the conditions as close to those used during 
selection. 
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Figure 35: Comparison of ELISA signal, PFA fixed or live cells were blocked with PBS 5% milk or PBS 
3% BSA prior to incubation with bacteriophage, antibodies, and HRP substrate. No statistically 
significant differences were observed. (n = 3), error = SD, two-way ANOVA with Tukey’s multiple 
comparisons. 
During the ELISA, considerable cell detachment and loss was observed, particularly of the 
EMT cells. This can be explained by the mesenchymal phenotype of these cells, loss of 
EpCAM expression is used to define this cell population so it makes sense that these cells 
are less adherent. EpCAM is a cell-cell adhesion molecule, where EpCAM on once cell will 
bind to EpCAM on adjacent cells,314 in a cell monolayer this interaction is likely to make 
cell attachment more robust and individual cells more resistant to detaching. Whereas 
EMT cells with low or no EpCAM expression do not have this additional adhesion, thus a 
greater proportion of them were lost during the multiple wash steps in the ELISA. 
To reduce the amount of cell-loss seen, plates were coated with poly-D-lysine, a polymer 
which readily adsorbs to tissue culture-treated plastic and has been shown to enhance 
cell adhesion.315 In addition to using PDL-coated plates the cell density was increased 
from 10,000 cells/well to 20,000 cells/well. Results of the optimised ELISA did not 
demonstrate that any of the tested clones were able to preferentially bind to EMT cells; 
however, clones did tend to show increased binding to both cell populations over the no 
cell control. 
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Figure 36: Whole cell phage binding ELISA. Assessment of the binding of peptides isolated 
following three rounds of biopanning on EMT cell monolayers. Clones were incubated with FACS 
populations of EMT and Epi LuC4 CSCs to identify differences in binding. Again, no statistically 
significant differences were seen in ELISA signal between either the peptide sequences or the cell 
types. (n = 3), error = SD, two-way ANOVA with Tukey’s multiple comparisons.  
In order to further assess phage binding, a secondary method, flow cytometry, was used. 
In theory, it is possible for the specific and preferential binding of phages to target cells 
within a mixed population to be detected by flow cytometry. Cells were also stained for 
CD44 and EpCAM alongside phage binding to allow visualisation of the EMT population 
within the sample. Analysis of clones isolated previously was unable to detect any phage 
binding (Figure 37). While the use of flow cytometry has the potential to remove the need 
for cell sorting prior to assessment of binding, it is likely that it would only be possible to 
detect clones with a high binding affinity for the target, due to the physical forces exerted 
on the cells.  
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Figure 37: Phage binding assessment by flow cytometry. Unsorted LuC4 cells were incubated with 
individual phage clones displaying either GNNPLHVHHDKR-GGGS (A), QVNGLGERSQQM-GGGS 
(B), GANDGVSLWRNV-GGGS (C), or VCSPCGPVPPAK-GGGS (D) sequences. Phages were then 
detected by the anti-M13 antibody which is turn was detected by Alexa Fluor 488 goat anti-
mouse. Cells were also stained with APC-conjugated anti-EpCAM antibody. 
2.3. FACS-assisted biopanning with competitive selection  
As panning on a cell monolayer failed to select for cell type-specific binders, a further 
iteration of phage display was used incorporating competitive selection. Taking 
inspiration from Siegel and colleagues, 102 phage display was combined with FACS. Before 
incubation with the naïve library LuC4 cells were sorted based on CD44 and EpCAM 
expression and the Epi (CD44high/EpCAMhigh ) cells were collected, to make up the non-
target cell population. The target EMT (CD44high/EpCAMlow ) cell population was isolated 
from a stably expressing GFP LuC4 cell line. Once isolated these two cell populations were 
mixed and incubated with the phage library in suspension. Target cells and associated 
phage could then be isolated by FACS based on GFP levels alone without further staining, 
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where GFP-positive cells were discarded and only GFP-negative cells were collected. The 
isolated target cells were lysed and a phage titre was carried out as usual. 
The first time this protocol was employed the number of GFP-negative target cells was 
very low, so it was decided that the most appropriate action would be to repeat the 
panning procedure from the beginning, with a higher cell input. Following these 
subsequent three rounds of selection, no enrichment was seen (Table 8). However, 
Sanger sequencing of extracted DNA and analysis of the sequence using CL Sequence 
Viewer 8 (Qiagen, Germany) revealed the following peptide; TLGGLYQFEYAL-GGG, as a 
potential target-specific peptide (Figure 38A) 
Table 8: Bacteriophage input and output, values for each round of FACS-assisted panning on LuC4 
cells in suspension input/output. 
 
INPUT (PFU) OUTPUT (PFU) 
RECOVERY 
(OUTPUT/INPUT) 
ENRICHMENT 
(PER ROUND) 
ROUND 1 2 x 1011 2.7 x 106 1.3 x 10-5 - 
ROUND 2 4.7 x 1012 7.2 x 105 1.5 x 10-7 0.01 
ROUND 3 1.5 x 1012 5 x 104 3.3 x 10-8 0.22 
 
The binding capacity of this phage clone was then assessed using a whole-cell ELISA and 
flow cytometry. The ELISA was carried out on cells in suspension and results show that 
the TLGGLYQFEYAL-GGGS displaying clone has enhanced binding for EMT cells (Figure 
38B). It does, however, show significant binding to epi CSCs compared to the WT phage 
binding which suggests that its binding partner may be expressed, albeit at different 
levels, on both cell populations. Using flow cytometry, 1.99% of the population was 
positive for Alexa Fluor 488; it is not clear if this correlates to target cell binding, as it is 
not a distinct population (Figure 38D). When the CD44/EpCAM profile of the 488+ 
population (Figure 38D) is compared to unsorted LuC4 cells (Figure 38C) the 488+ cells 
have high EpCAM and CD44 expression which suggests that they do not represent the 
EMT population.  
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Figure 38: Assessment of TLGGLYQFEYAL-GGGS binding. Structure of TLGGLYQFEYAL-GGGS 
peptide sequence, identified by FACS-assisted biopanning on LuC4 cells in suspension (A) Sorted 
EMT and Epi LuC4 cells were incubated with the TLGGLYQFEYAL-GGGS displaying phage in 
suspension and the binding was determined by ELISA (B). Unsorted LuC4 cells stained with anti-
CD44 and anti-EpCAM show the typical FACS plot (C). Unsorted LuC4 cells incubated with the 
TLGGLYQFEYAL-GGGS clone followed by anti-M13 and Alexa Fluor 488 goat anti-mouse to detect 
phage binding, the gate on the left captures cell which have a negative to low level of 488 staining, 
86% of the population, the gate on the right captures the cells with the highest 488 signal (D). 
CD44 and EpCAM expression profile of the 1.99% Alexa Fluor positive LuC4 cells from the right 
had gate in the previous plot (E). (n = 3), error = SD, one-way ANOVA with Tukey’s multiple 
comparisons. 
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3. Discussion 
While panning on EMT cell monolayers failed to select clones showing significantly 
enhanced binding to the target cell type, the use of FACS assisted panning to isolate 
target cell-associated phage clones from a cell mixture in suspension did identify a 
candidate which warrants further investigation.  
On embarking on this research there was no existing phage display facility or established 
protocol in place in our laboratory. As such, it is not surprising that initially experimental 
progress was slow as a large amount of time was dedicated to optimisation of bacterial 
culture, phage panning, and titring. By the end of the work the protocols employed were 
successfully yielding peptide sequences which demonstrated binding, of varying degrees, 
to cell targets. It would not be unreasonable to expect that subsequent experiments 
would build on the existing results to produce more robust results, as is typical as a 
method becomes more routine and standardised. 
Lack of clear binding by flow cytometry may be due to the detection method, rather than 
an absence of binding or lack of specificity, which was seen by ELISA. The anti-M13-HRP 
conjugated antibody has not been validated for use in flow cytometry so may not be 
suitable. As a result, detection of binding by flow cytometry is reliant on 3 interactions, 
between the phage and the cell, the anti-M13 and the phage, and between the secondary 
antibody and the anti-M13, whereas the staining of CD44 and EpCAM only requires 
binding between the fluorophore-conjugated antibody and the receptor. Use of a directly 
conjugated anti-M13 antibody in future work may make detection of phage-cell 
complexes possible. 
Phage display is a theoretically simple, high-throughput method for screening protein-
protein interactions and while there are thousands of papers which have succeeded in 
selecting target-binging peptides or antibodies there are a number of limitations which it 
is important to consider.  
Firstly, the commercially available peptide library from New England BioLabs, which was 
used in this work, provides a complexity of ~ 109 clones. However, in the case of the 12-
mer library, this does not come close to covering all 4 x 1015 possible combinations of 
amino acids. This means that it is possible that the binding sequence or motif for any 
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given target will not be represented in the library. However, commercial libraries do 
provide an excellent screening tool that does not require researchers to construct their 
own random libraries, which can be a laborious and time consuming process,108 thus 
making phage display a much more accessible platform. 
A second important consideration is target specificity. As seen with the sequences 
identified by panning on EMT cell monolayers, it is possible for peptides to be selected as 
binders for more than one target in entirely independent experiments. This can have 
implications for downstream applications, such as cell-targeting, if the peptide turns out 
not to be as specific as initially thought. In the case of the GNNPLHVHHDKR-GGGS 
peptide, two of the experiments it was isolated in were conducted on live cells. It is 
conceivable that the target molecule it is binding to is present on both cell types. In the 
subsequent assessment of phage binding, we were unable to confirm preferential binding 
to the target, but an increase in binding to LuC4 cells was seen. This would support the 
notion that GNNPLHVHHDKR-GGGS binds to a ubiquitous cell surface molecule. While the 
identified general cell-binding peptide may have a number of useful experimental 
applications, we sought to identify a peptide which would allow specific targeting of a 
subset of LuC4 cells. As such, further work needs to be done, in similar experiments, 
Cheung et al.312 were able to show an enrichment of binding to their target Jurkat cells 
when compared to two unrelated cell lines. Additionally, when incorporated into a fusion 
protein with interferon-α (IFNα), it could enhance the effects of IFNα treatment in vitro.  
It has been demonstrated that in the absence of positive selection some phage clones 
have a growth advantage, leading to their over representation within the pool of 
phage.148 Selection of the GNNPLHVHHDKR-GGGS peptide in our study, but lack of 
positive ELISA signal, could be a result of an increased replicative advantage, thus 
enhancing its frequency within the pool, and a panning strategy employed to isolate EMT 
specific binders was not stringent enough. As such, only a weak interaction between the 
peptide and cells would be sufficient to carry the GNNPLHVHHDKR-GGGS peptide 
through to the final round of panning. Additionally, this sequence, along with 
QVNGLGERSQQM-GGGS and GANDGVSLWRNV-GGGS, was predicted to bind to 
polystyrene which suggest that it may have been selected through non-specific 
interactions. The final sequence, VCSPCGPVPPAK-GGGS, was also identified by another 
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group, but failed to show target specificity in an ELISA.312 Because we also selected this 
sequence, but were unable to see a positive signal by ELISA, suggests that this clone may 
also have a replicative advantage, especially as it was not predicted to bind to 
polystyrene. 
The method of panning can have a large impact on the phage clones eluted and therefore 
carried into the next round. By conducting panning on cells in suspension, binding sites 
which may be occluded when cells are adhered to a surface will be revealed and can 
increase the number of potential binding sites. The used of FACS to isolate cell-associated 
phages also provided a more stringent method, seen by a reduced rate of phage recovery 
compared to panning on a monolayer of EMT cells (Table 7 and Table 8), which in theory 
would facilitate selection of clones with the highest affinity. However, a lack of 
enrichment suggests that there is still work needed to optimise the outcomes. The 
decrease in phage recovery after each subsequent round of panning could be a result of 
an overly stringent method, or the phage input being too high, where selective clones 
only make up a very small percentage of the pool and due to a replicative disadvantage 
are not proportionally represented following amplification. In this case, further rounds of 
panning may be required to see phage enrichment. 
4. Future work 
Cell-binding peptides identified by phage display have been applied to a range of 
applications, including enhanced drug-delivery,16 optimisation of cell culture,101 and 
imaging.178 Once the protocol for panning HNSCC cells in suspension has been optimised, 
to isolate target-cell/phage complexes using FACS, and a peptide which specifically binds 
to the EMT subpopulation has been identified, there are three main avenues of further 
research; in vitro studies, development of translational applications, and identification of 
the cell-surface binding partner.   
As reported in chapter III, modification of peptides with a thiol group can be used to 
display these peptides as a self-assembled monolayer. Using a similar strategy, EMT cell-
binding peptides could be used to create surfaces which would interact selectively with 
this subpopulation. Aside from investigation how culture on a peptide SAM would 
influence cell behaviour, these surfaces could also be used for a very crude purification 
of the EMT population from an unsorted cell suspension. There are several commercially 
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available kits for the separation of cells from a heterogeneous population; the majority 
of these kits use magnetically labelled antibodies which bind to a marker of the cell type 
of interest on the cell surface. Cell populations are incubated with these antibodies and 
then the mixture is passed through a column loaded, into a magnetic block, and cells 
which have been labelled are immobilised by the magnetic field.316,317 There are three 
main commercially available options, Dynabeads™,318 MACS™ technologies,316 and 
EasySep™319. Identified peptides could be used as a direct alternative to antibodies in 
these technologies by conjugation to magnetic beads. An example of a similar strategy 
from the literature demonstrates it is possible to use phage display to identify a protein-
binding peptide, which when conjugated to magnetic beads can be used to extract its 
protein target from a solution containing multiple proteins.320 NHS-activated magnetic 
beads can be purchased which would make the conjugation step a straightforward 
process, by incubating the peptide and beads at room temperature for 4-6 hours in an 
appropriate buffer. 
Crude enrichment of target cells would be a useful tool before further isolation by FACS 
to maximise the yield of target cells. FACS is an accurate tool for isolating highly defined 
cell populations. However, it requires expensive reagents, fluorophore conjugated 
antibodies, and can be time consuming. In the case of EMT cells within HNSCC cell lines, 
they represent only a small percentage of the total population, which requires a large 
number of cells to be sorted to isolate enough EMT cells for downstream applications. 
Enrichment of EMT cells prior to sorting would reduce the amount of time and cells 
needing to be sorted. 
It would also be of interest to develop the peptide for use as a reagent for flow cytometry, 
by conjugation to a fluorophore. This has the potential to provide a single marker for the 
identification of the EMT population, which could be used in conjunction with the 2-
marker expression profile currently used. The fluorophore conjugated peptide could also 
be used for immunohistochemistry to identify EMT cells in patient samples. 
More translational applications, subject to successes in the use of an EMT cell-binding 
peptide to enrich target cells in vitro, would be to utilise the peptide to detect circulating 
tumour cells (CTCs), or as a cell-homing peptide for targeted cancer treatment.  
148 
 
Currently, EpCAM is routinely used as a marker to detect CTCs out of HNSCC patient blood 
samples.321 However, CTCs which have downregulated EpCAM, such as cells that have 
undergone EMT, will not be detected. A peptide able to bind such a population of cells 
would fill a current gap in CTC detection. The ability to bind peptides to a gold surface 
through the inclusion of a thiol could also be exploited to functionalise a gold-coated 
medical wire for the in vivo capture of CTCs.322,323 
The development of targeted therapeutics offers the potential for improved treatment 
of malignancies, while reducing the impact on normal healthy cells. As off target effects 
seen with intra-venous administration of anticancer can be limiting factors in cancer 
treatments and can impact patient quality of life, reduction of these by using targeted 
treatments is an attractive option.324 Conjugation of peptides which home to specific 
cancer cells have shown successes in reducing tumour growth325 and increasing cell 
death.326 Development of peptides, found by phage display, to specifically target the EMT 
subpopulation has the potential to improve treatment and reduce recurrence of the 
disease. Nanoparticle functionalisation has been shown to improve drug delivery to 
target cells with limited accumulation in healthy tissues.327 Peptides discovered by phage 
display have also been used to target both nanoparticles and drug compounds to the 
tumour site,163 highlighting the potential for a similar result to be achieved in HNC 
through selective delivery. 
For all these applications, generation of a secondary phage sub-library could be used to 
enhance the affinity with which selected peptides bind to the EMT cells. The DNA 
encoding the selected peptide can be mutated to construct a library based around the 
original sequence, which can then be panned against EMT cells to select for the best 
binder.108,328 
Finally, another interesting future project would be to determine the cell-surface binding 
partner of selected peptides. This could be achieved through co-immunoprecipitation 
experiments, where synthesised peptides can be conjugated to biotin, magnetic beads, 
or a thiol-containing molecule that then enables immobilisation of the peptide by 
streptavidin, a magnet, or a gold surface, respectively. Peptides can then be incubated 
with cell lysates, to allow them to bind to their binding partner, and immobilised resulting 
in the co precipitation of any molecules that have been bound. A Western blot can then 
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be done by running precipitated complexes on an electrophoresis gel, to separate 
proteins present based on size. Once the protein is transferred to a membrane, this can 
be probed with the peptide displayed as a fusion on the M13 phage, which in turn can be 
detected using the ant-M13 HRP-conjugated antibody. Once the approximate molecular 
weight, and location of the band on the gel, which belongs to the potential binding 
partner has been determined, the experiment can be repeated. This time the gel is 
stained with Coomassie brilliant blue to visualise the bands, and the one containing the 
potential binding partner can be cut out and analysed by mass spectroscopy. Any 
returned sequences from this analysis can be BLAST searched to see if they correspond 
to known cell proteins.329,330 
To summarise the discussion of future works, I believe that from the current data the key 
areas moving forward are as follows: 
I. To repeat the FACS-assisted panning procedure, taking on board all the tweaks to 
methodology identified during the previous rounds, such as ensuring the number 
of cells used is sufficiently high to allow isolation of target cells at the final sorting 
step. Replication of the panning process will aim to identify additional sequences 
which can be tested for binding, and hopefully the re-identification of the 
TLGGLYQFEYAL-GGGS peptide. 
II. Continuation of TLGGLYQFEYAL-GGGS binding assessment. Establishing the 
peptides binding capacity will inform subsequent uses as either a detection probe, 
or in the SAM platform developed in Chapter III. 
III. Modification of TLGGLYQFEYAL-GGGS, or newly identified EMT cell-binding 
peptides, to use to form SAM surfaces which can be tested for their suitability for 
in vitro cell culture.  
5. Conclusion 
Overall, this work has established a protocol for panning on live HNSCC cells in suspension 
which dilutes the target cell time with an equal number, or excess, of non-target cells to 
select for clones that selectively bind to target cells. Using a cell line which has a stably-
expressing GFP line has enabled the separation of target from non-target cells by FACS 
without the need for additional staining. This method is capable of selecting for peptides 
150 
 
which preferentially bind to the target cell type. However, results could be improved by 
additional optimisation and peptides with enhanced binding could be generated by 
constructing a focused library based on the TLGGLYQFEYAL-GGGS sequence. 
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Chapter V - Hyaluronic acid-inspired glycomonomers and their application to cell 
culture as potential mimics of hyaluronic acid 
1. Introduction 
The use of hyaluronic acid (HA) in the medical field is far reaching. It is employed in, but 
not limited, plastic surgeries as a dermal filler,331 the clinic for the treatment of 
arthritis,332 biomaterials applications as a hydrogel scaffold,236  in vitro studies to 
influence cell function,74 and drug delivery.333  
In mammals, HA is synthesised by three enzymes belonging to the HA synthase family, 
HAS1, HAS2, and HAS3.334 HAS enzymes are membrane bound, and each contain 7 
membrane domains, and polymerise alternating molecules of uridine-diphosphate-D-
glucuronic acid (UDP-GlcA) and uridine diphosphate-N-Acetyl-D-glucosamine (UDP-
GlcNAc) at the intracellular surface to form HA chains, which can then be translocated to 
the extracellular space through the HAS complex.334 Each of these enzymes are capable 
of synthesising HA, but they have been shown to have different properties. HAS2 is 
embryonic lethal in mouse models, HAS2-/- knock out mice were seen to exhibit significant 
cardiac defects at embryonic day 9.5,335 whereas knockdown of HAS1 and HAS3 does not 
result in any gross abnormalities.336,337 In addition to differing roles in embryogenesis, the 
HAS isoforms show differential levels of enzymatic activity. HAS1 exhibits the highest Km 
for UDP-GlcA and UDP-GlcNAc which correlates with the smaller HA coat generated when 
COS-1 cells were transfected with HAS1 cDNA when compared to HAS2 and HAS3, with 
HAS3 having the highest rate of activity.338 The average molecular weight of the HA 
synthesised by each of the enzymes is also different, with HAS2 producing higher 
molecular weight HA, in the region of 2 x 106 Da.338  
Current methods for production of the large quantities of HA needed for use in disease 
treatment, translational and basic science, involves either isolation from animal sources, 
bacterial synthesis, or cell-free systems, each of which comes with its own benefits and 
drawbacks. 
Extraction from animal tissues, predominantly from bovine vitreous and rooster comb, 
was the primary method used to obtain HA on an industrial scale.339 This protocol 
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produces polydisperse high molecular weight HA, which presents several limitations. 
During the extraction process, tissues are homogenised which causes release of 
hyaluronidases from within cells. This, coupled with the harsh extraction conditions, can 
result in the degradation of HA, thus contributing to the wide range of molecular weights 
generated. While rooster comb and bovine vitreous have high HA expression levels when 
compared with other animal tissues, the yield produced is still very low.340  
Through bacterial fermentation, HA can be produced with a higher yield of approximately 
6-7 g/L. Increased viscosity of the bacterial culture broth, caused by the secretion of HA, 
results in poor mixing and oxygenation which, in turn, limits the amount of HA that can 
be synthesised and isolated from each batch.341 Using bacteria to synthesise HA allows a 
level of control over the molecular weight range of the HA produced and greater 
oxygenation of cultures leads to the production of HA with a greater molecular weight. 
The availability of the precursor sugars UDP-GlcA and UDP-GlcNAc also influences HA 
MW. By keeping the ratio of hyaluronan synthase to monomers below 2, the size of HA 
polymers can be maximised.342 
Both bacterial synthesis and extraction from animal tissues carry the risk of the HA 
product being contaminated by amino acids, DNA, or viruses with purification techniques 
providing a costly solution. Contamination with bacterial or animal products is of 
particular importance when HA is to be used as a therapeutic agent. As a result, 
production of HA using cell-free systems has been developed by Jing and DeAngelis.,343 
They were able to engineer a soluble HAS protein which retained its glycosyltransferase 
activity. Using this method, it is possible to synthesise HA molecules with a much 
narrower distribution of MWs and, by controlling the availability of the UDP-sugars to 
each enzyme, the MW of HA generated can be regulated. For example, having a large 
number of enzyme molecules, but restricted sugar availability, will result in smaller chains 
being synthesised as the limited sugars will be distributed across all of the HAS units,344 
demonstrating how important the molar ratio of enzyme to substrate is. Using this 
method affords greater control over the HA produced, without the risk of animal product 
contamination, but the yield still remains low.345 
One alternative to overcome the challenges of HA synthesis is to develop synthetic 
mimics, using a polymer backbone functionalised with the HA (GlcA and GlcNAc) sugars. 
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Similar strategies to synthesise glycopolymers inspired by natural carbohydrates have 
been used and shown to have a degree of biological activity.346,347 The ability to synthesise 
bioinspired mimics has helped advance the study and understanding of signal 
transduction downstream of glycan-receptor interaction at the cell surface. 348 
Chemical synthesis of HA glycopolymers has been attempted using HA-derived dimers of 
GlcA and GlcNAc. The disacchride was coupled to a polymerisable chemical group via a 
linker to form a glycomonomer. Once polymerised, the polynorbornene acts as a 
backbone to display the HA fragments, and it is suggested to act to inhibit native 
saccharide-protein interactions.349 Additionally, by using this method of synthesis the 
glycopolymers formed showed a low level of polydispersity, demonstrating the ability of 
chemical synthesis to produce glycopolymers of a uniform size. A similar study used 
heparan sulfate saccharides on a bottleneck polymer backbone to inhibit the activity of 
the heparan sulfate-cleaving enzyme heparanase.350 
The literature demonstrates that there is still a requirement for animal product-free 
synthesis of uniformly high molecular weight HA on an industrial scale to meet the 
commercial demand in a market. It is anticipated that the HA market will reach a value of 
$7.25 billion by 2023,351 While the replacement of HA by biomimetic glycopolymers in 
cosmetics and therapeutics may not happen in the near future, their use as probes to 
perform in vitro studies may be a closer eventuality. 
In addition to the removal of the risk of animal product contamination, other potential 
benefits of synthetic HA analogues include enhanced control over MW and increased 
uniformity, and the possibility for pre- and post–synthesis functionalization. Greater 
control over HA MW is of particular interest due to the size-dependent effects of HA in 
cells signalling which is also implicated in disease.79,80 The different effects of HA based 
on its MW highlights the importance of having control over the size of HA chains used in 
in vitro studies aimed at elucidating the function of HA.  
The work developed by a colleague in the lab, Mr. Dominic Collis elegantly demonstrates 
the chemical synthesis of a number of glycopolymers comprising of the two HA 
monosaccharides. 221 Four of these glycopolymers were selected for investigating their 
potential effects on cells in vitro. The chosen glycopolymers included two homopolymers, 
consisting of either GlcA or GlcNAc glycomonomers, a statistical copolymer, and an 
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alternating copolymer (Figure 39). All four glycopolymers were formed by 
polymersisation of the poly(4-vinylbenzyl chloride) backbone and subsequent addition of 
the two sugars using ‘click’ chemistry.352 
 
Figure 39: Chemical structure of glycopolymers, PVB-GlcNAc (A) and PVB-GlcA (B) homopolymers, 
PVB-GlcA-co-VB-GlcNAc (C) and PVB-GlcNAc-alt-PMI-GlcA (D) copolymers, with the repeating HA 
disaccharide (E). 
2. Results 
2.1. Cytotoxicity assessment of glycopolymers  
Before performing cell studies to investigate the effect of the glycopolymers on cell 
behaviours and their ability to mimic natural HA, it was necessary to ensure that they 
were not cytotoxic. LuC4 cells were seeded onto 96-well plates and, following 48 hours 
incubation, treated with 100 µg/ml, 10 µg/ml, 1 µg/ml, or 0.1 µg/ml of each glycopolymer 
for 24 hours. The viability of cells was determined using the Live/dead® 
viability/cytotoxicity kit, this kit was selected in place of simply counting cells as, when 
counting cells, it can be difficult to determine which cells on the surface are alive and 
which are dead, the live/dead assay identifies live cells by their intracellular esterase 
activity. It also provides information on the proportion of dead cells, which is useful 
information to have when investigating the effect of treatment on cell lines. A final reason 
155 
 
for the use of a fluorescence assay is that it provides a less labour intensive method for 
collecting data. 
Fluorescence intensity was measured at emission 528/20 nm with excitation 485/20 nm 
and emission: 590/35 nm with excitation 530/25nm, respectively. To calculate the 
percentage of live and dead cells in each well, the following equations supplied by the 
manufacturer were used: 
Equation 8: Percentage of live cells 
% 𝐿𝑖𝑣𝑒 𝑐𝑒𝑙𝑙𝑠 =  
𝐹(530)𝑆𝑎𝑚𝑝𝑙𝑒 − 𝐹(530)𝑚𝑖𝑛
𝐹(530)𝑚𝑎𝑥 − 𝐹(530)𝑚𝑖𝑛
 𝑥 100% 
 
Equation 9: Percentage of dead cells 
% 𝐷𝑒𝑎𝑑 𝑐𝑒𝑙𝑙𝑠 =  
𝐹(645)𝑆𝑎𝑚𝑝𝑙𝑒 − 𝐹(645)𝑚𝑖𝑛
𝐹(645)𝑚𝑎𝑥 − 𝐹(645)𝑚𝑖𝑛
 𝑥 100% 
 
Where F(530)sample is the fluorescence signal of the sample at 530 nm, F(530)min is the 
fluorescence signal at 530 nm of methanol-fixed cells stained with EthD-1, F(530)max is the 
fluorescence signal at 530 nm of untreated cells stained with calcein, F(645)sample is the 
fluorescence signal of the sample at 645 nm, F(645)min is the fluorescence signal at 645 
nm of methanol-fixed cells stained with calcein, and F(645)max is the fluorescence reading 
at 645 nm of dead cells stained with EthD-1. 
Treatment of LuC4 cells with the alternating copolymer and GlcNAc homopolymer had 
little effect on the proportion of live cells. However an increase in the number of dead 
cells for both treatments was seen to increase to around 20%. Treatment with the GlcA 
homopolymer showed a trend for reduced viability in a dose-dependent manner; a 
similar trend was not seen with the percentage of dead cells. Treatment of cells with the 
statistical copolymer resulted in the lowest level of cell viability of around 60%, while cell 
death was around 30%. 
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There was no significant difference in cell viability or amount of cell death between any 
of the four glycopolymer treatments. As such, it was concluded that the HA-based 
glycopolymers are not significantly cytotoxic. 
2.2. Effect of HA-based glycopolymers on sphere formation 
The LuC4 cell line used in this work, and in previous experimental chapters, is an 
immortalised head and neck cancer cell line which contains a subpopulation of cells which 
exhibit a higher level of CD44 expression. These cells possess stem cell-like properties and 
are thought to contribute significantly to high rates of secondary tumours and recurrence 
seen in HNSCC patients.15,353 A role for CD44/HA induced signalling in the progression of 
cancer has been established and suggests the importance of this interaction in cell 
motility, therapeutic resistance, and maintenance of stem cell properties.354 Specifically, 
within HNSCC, treatment of cells with HA, through supplementation of cell culture 
medium, has been shown influence cancer stem cell behaviour. A FACS sorted 
subpopulation of HNSCC cells, with high CD44 isoform v3 and ALDH1 levels (CD44v3high/ 
ALDH1high), treated with HA showed an increase in both the number and size of spheres 
formed in a sphere assay.244 
 
 
 
Figure 40: Effect of glycopolymers on cell viability, following treatment with HA-based 
glycopolymers viability was assessed using the Live/Dead viability/cytotoxicity kit. Bar graph 
shows the average percentage of live (A) and dead (B) LuC4 cells. (n=3), error bars represent 
standard deviation, two-way ANOVA with Tukey’s multiple comparisons. 
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A similar subpopulation of HNSCC cells, with CSC properties, identified by 
CD44high/EpCAMlow expression profile exists within the LuC4 cell line.49 Although ALDH1 
profile is not used to select for this cell population, it has been shown that at least a 
fraction of these cells possess ALDH1 enzyme activity and have the capacity to form 
spheres in vitro.26,49  
As the HA-based glycopolymers did not show cell toxicity we wanted to see if they were 
able to influence LuC4 CSC properties in a similar way to HA. To asses this a sphere assay 
was carried out using this CD44high/EpCAMlow (EMT) subpopulation of cells. Poly(2-
hydroxyethyl methacrylate)-coated plates were used to seed sorted EMT cells in full 
culture medium supplemented with 1% methylcellulose and 50 µg/ml final concentration 
of HA or glycopolymer. 
Work carried out in the Azevedo laboratory has utilised peptide synthesis to generate 
small peptides which mimic the natural HA binding motif found in CD44, as well as the 
more widely expressed link domain sequence, which also binds HA. Surface plasmon 
resonance was subsequently employed to demonstrate that there are varying degrees of 
interaction between the synthetic glycopolymers and HA binding sequences. 221 As such 
we hypothesise that these glycopolymers may be able to alter cell behaviour in a similar 
way to how HA has been shown to in the literature. 
Initially, after 14 days in culture, imaging revealed no real sphere formation under any of 
the treatment conditions. In some wells, one or two small groups of cells were seen which 
could represent the early stages of sphere formation (Figure 41).  
 
 
 
158 
 
 
Figure 41: Formation of small cell clusters by sphere assay. Representative image of tissue culture 
plate wells and LuC4 cells following treatment with 1.5 MDa HA for 14 days (A), and an enlarged 
image of the selected area (B). Scale bars represent 1 mm and 250 µm, respectively. 
Spheres were allowed to form for a further week, to take the total period of time in 
culture to 21 days. At this time point, an increase in the number of groups of cells was 
seen, and they tended to be of a larger size (Figure 42). However, the cells within these 
groups were not highly compacted, and distinct cells could be seen. The morphology of 
these pre-spheres suggests that a greater period of incubation and treatment would be 
required to see the formation of fully matured and compacted spheres.  
 
Figure 42: Effect of glycopolymers on LuC4 cell sphere forming ability compared to natural HA. 
Representative images of LuC4 cells following 21 days in culture under non-adherent conditions. 
Cells were treated with glycopolymers (top row) or HA with various MW (bottom row), as 
indicated, with a final concentration of 50 µg/mL. Scale bar represents 250 µm. 
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As the MW of HA has repeatedly been shown to influence its effects both in vivo and in 
vitro, three different molecular weights of HA were used to treat cells with sphere 
forming potential, 20 kDA, 200 kDa, and 1.5 MDa. Over the course of the 21 days 
treatment, HA molecular weight did not appear to have a substantial effect on the 
number of spheres formed. However, a greater average number of ‘pre-spheres’ was 
observed when cells were treated with higher HA MW, 200 kDa and 1.5 MDa (Figure 43). 
 
Figure 43: Formation of 'pre-spheres' following treatment with HA. LuC4 cells were cultured under 
non-adherent conditions and treated with 50 µg/mL HA with a MW of 20 kDa, 200 kDa, or 1.5 
MDa. After 21 days the number of ‘pre-spheres’ were counted. n=3.  
3. Discussion 
The preliminary experiments presented here demonstrate that treatment of LuC4 cells 
with HA-based glycopolymers did not affect their viability. Of all the glycopolymers, the 
statistical copolymer showed the lowest level of cell viability. It was interesting to see that 
although there was a reduction in cell viability, and an increase in cell death, these values 
were similar across the range of concentrations used, suggesting that this effect was 
dose-independent.  
To investigate the ability of these glycopolymers to mimic some of the biological functions 
of HA in the context of head and neck cancer stem cells, a sphere assay was performed. 
This assay is commonly used to assess the stem-ness of population of cells through 
determining their ability to form spheres and proliferate in suspension. From this 
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information, it is possible to calculate the frequency with which stem cells and their 
progenitors exist in the population of cells being studied.355  
The clusters of cells that were seen where cells were treated with HA, either with a MW 
of 200 kDa or 1.5 MDa, and glycopolymers, looked like they could be at the beginning 
stages of sphere formation. However, it is likely to be misleading to categorise them as 
spheres in this assay.355 Mature spheres contain compacted cells with a regular 
morphology and can have a diameter ranging from around 50-250 µm, while the groups 
of cells observed in this work were much less condensed and were of a more irregular 
shape and size. This should be kept in mind throughout the discussion of the trends 
observed. 
As mentioned, existing literature demonstrated the ability of HA treatment to increase 
sphere formation.244 However, our results were unable to replicate this convincingly. 
There a several potential explanations for this. Primarily, it is likely that the duration of 
the experiment was not sufficiently long to allow maturation of spheres. While sphere 
formation can be seen in as little as a few days in the case of some cancer cells,356,357 
other cells take much longer before mature spheres are observed. It is possible that the 
cell aggregates seen are simply due to cell clumping, but a well-established protocol was 
followed which included passing cells through a strainer to ensure single cell suspension. 
Additionally, cells were seeded in medium containing 1% methylcellulose, which 
increases the viscosity of the medium and reduces the amount of cell movement thereby 
minimising single cells drifting into each other. LuC4 cells have previously been shown to 
form spheres after 2 weeks of culture,49 but a higher starting cell density was used, plating 
twice as many cells per well. This could explain the difference in sphere formation, as it 
is well established that starting cell concentration can influence the rate of sphere 
formation.230 
A trend for increased ‘pre-spheres’ was seen for the treatment of LuC4 cells with 200 kDa 
or 1.5 MDa, but not 20 kDa HA (Figure 43). This observation could be indicative of another 
example of the importance of MW on the effects of HA. To the best of my knowledge the 
effects of HA molecular weight on sphere formation of CSCs has not been directly 
compared. Treatment of cells with 500 kDa HA resulted in the upregulation of stem cell 
genes mediated through interaction with CD44,358 which supports the idea that high MW 
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HA is involved in stem cell signalling and promotion of sphere formation previously 
documented.244 
Little evidence of the beginnings of sphere formation was observed when cells were 
treated with the four HA-based glycopolymers, indicating that these glycopolymers are 
unable to mimic the in vitro effects of HA. There are a number of possible reasons why 
this may be the case. Aside from the polymer backbone, which is more rigid and may have 
interfered with cell-binding and subsequent signalling, one key difference between the 
alternating copolymer and natural HA is the absence of a glycosidic bond. This may be 
important for maintaining the correct conformation of the two monosaccharides for 
interacting with cell surface receptors to induce signalling. Unpublished data collected by 
other members of our lab demonstrates that alternating glycopolymer-binding to Pep-1, 
a HA-binding peptide, is minimal which would also suggest that such glycopolymers in 
their current format are not yet able to mimic HA binding. It should also be noted that 
the MW of the glycopolymers is approximately 20 kDa, and when cells were treated with 
20 kDa HA minimal effects on pre-sphere number were seen (Figure 43). As such, the lack 
of effect of the glycopolymers may also be a result of their low MW. 
4. Conclusions and outlook   
This work demonstrates that HA-based polymers can be used as probes to investigate the 
behaviour of cancer cells without causing a significant reduction of cell viability, although 
no effect on sphere formation was seen. Further work to determine the optimal 
conditions and duration of the sphere assay would be required before any firm 
conclusions can be drawn from this work.  
An important consideration moving forward would be to investigate how glycopolymers 
are processed by cells. In vivo, HA is degraded by hyaluronidases, of which there are six 
in humans.63 Their expression and action has been shown to influence cell behaviour. For 
example, HA fragments produced by the enzymatic action of hyaluronidases can induce 
activation of metalloproteinases or initiate inflammation.359,360 Within the literature, 
glycopolymers have been used to inhibit the function of glycosidases, suggesting that 
they are resistant to degradation themselves.350 It would be important to investigate the 
potential inhibitory effects of HA-based glycopolymers on the ability of hyaluronidases, 
such as HYAL1, to degrade natural HA. It would be expected that these glycopolymers are 
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not susceptible to degradation as they lack a glycosidic bond.  It is possible that even if 
glycopolymers alone are not able to influence cell behaviour in the same way as HA, they 
could still be employed to reduce HA fragmentation by hyaluronidases and act as enzyme 
inhibitors. 
  
163 
 
 
 
 
 
 
 
 
SECTION 4 - CONCLUSIONS 
  
164 
 
Chapter VI – Conclusions and Future work 
This final section of the thesis aims to summarise the work carried out and draw together 
the key conclusions, with a focus on how this work can be built on through future 
research. 
The work set out in this thesis applies chemical modification of a peptide to create a 
reagent for forming SAMs that can be used to immobilise a component of the EMC, and 
subsequently be used for cell culture. A high throughput protocol for selecting candidate 
peptides for use in this is also established which will inevitably lead to the creation of 
novel surfaces for probing cell behaviours in vitro. Parallel work began to investigate the 
use of synthetic, HA-based, glycopolymers to manipulate cell properties in vitro utilised. 
With a view to develop a peptide based system that could immobilise these 
glycopolymers and reduce the need for cell derived products in cell culture systems.  
The extracellular environment has a critical role in the regulation of cell behaviour; 
interactions between the extracellular matrix (ECM) and the cell are responsible for 
modulation of cell migration, survival, and differentiation. In disease, changes in the 
localised environment, such as joint tissue in arthritis or the tumour microenvironment, 
are often evident and have been shown to be responsible for dysregulation of normal cell 
function. In the case of head and neck cancer (HNC), ECM glycosaminoglycan hyaluronic 
acid (HA) plays an important role in influencing cell properties. It has been shown to 
increase the migratory capacity of cells, to upregulate putative stem cell markers, and to 
enhance behaviour associated with stemness, including contact-independent growth and 
recapitulate heterogeneity from a single cell. 
Immobilisation of HA on surfaces to study its effects on cancer stem cells (CSCs) in vitro 
would be a useful tool. However, the majority of work in the literature utilises chemically 
modified or cross-linked HA which can interfere with the native characteristics of HA, 
such as its enzymatic degradation by hyaluronidases. Here, immobilisation of native HA 
was achieved using self-assembled monolayers (SAMs) of HA-binding peptide, Pep-1, 
modified to contain a thiol group at its N-terminal. Characterisation of the peptide-HA 
surface revealed a substrate with distinct properties when compared to HA 
immobilisation by electrostatic forces with poly-ᴅ-lysine. Preparation of these HA 
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surfaces for tissue culture altered cell migration, but further work to fully establish and 
exploit HA-cell interactions is required. 
The system developed to successfully form peptide SAMs on gold surfaces, using 
thiolated Pep-1 as a starting point, can easily be applied to a different set of research 
questions by immobilising a different peptide. Identification of a potential peptide was 
achieved through combining fluorescence activated cell sorting (FACS), GFP cell lines, and 
phage display. FACS-isolated CD44high/EpCAMlow cells were used as target cells for three 
rounds of biopanning to select binding peptides from the commercially available New 
England BioLabs random peptide library. Sequencing the genome of the isolated 
bacteriophage revealed a 12 amino acid peptide with the sequence TLGGLYQFEYAL. This 
peptide was seen to have enhanced binding to CD44high/EpCAMlow cells compared to 
CD44high/EpCAMhigh cells by phage-binding ELISA. 
We anticipate that inclusion of a cysteine at the C-terminal will allow the peptide to form 
a SAM on gold; if this is the case; future research can focus on elucidating potential effects 
of this peptide in vitro and the molecular mechanisms through which the signalling is 
transduced. There is also scope for develop the peptide-SAM for crude isolation and 
enrichment of target cells from heterogeneous populations prior to more precise 
selection techniques, such as FACS. 
Research presented in the third chapter started to investigate the ability of HA-based 
glycopolymers to mimic the biological function of HA. However, additional work is 
required to fully assess their potential as synthetic HA substitutes or as molecular tools 
for studying HA’s multiple functions. 
Over all, the work presented in this thesis has contributed to the development of a 
peptide-based self-assembly system for the immobilisation of individual components of 
the ECM and the study of specific cell-ECM interactions in vitro. It has also demonstrated 
the use of phage display for the identification of cell-binding peptide. This peptide has 
the potential to be modified to incorporate a thiol group and applied to the above self-
assembly system.  
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